<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">74272</article-id><article-id pub-id-type="doi">10.7554/eLife.74272</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Robust T cell activation requires an eIF3-driven burst in T cell receptor translation</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-255579"><name><surname>De Silva</surname><given-names>Dasmanthie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6824-0850</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-255580"><name><surname>Ferguson</surname><given-names>Lucas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-255581"><name><surname>Chin</surname><given-names>Grant H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-255582"><name><surname>Smith</surname><given-names>Benjamin E</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-255583"><name><surname>Apathy</surname><given-names>Ryan A</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-255584"><name><surname>Roth</surname><given-names>Theodore L</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-255585"><name><surname>Blaeschke</surname><given-names>Franziska</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-255586"><name><surname>Kudla</surname><given-names>Marek</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-255587"><name><surname>Marson</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-17742"><name><surname>Ingolia</surname><given-names>Nicholas T</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3395-1545</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-4624"><name><surname>Cate</surname><given-names>Jamie HD</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5965-7902</contrib-id><email>j-h-doudna-cate@berkeley.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Molecular and Cell Biology, University of California-Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>The J. David Gladstone Institutes</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>School of Optometry, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Microbiology and Immunology, University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Gladstone-UCSF Institute of Genomic Immunology</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Diabetes Center, University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Chan Zuckerberg Biohub</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Department of Medicine, University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>Parker Institute for Cancer Immunotherapy</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution>Innovative Genomics Institute, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution>California Institute for Quantitative Biosciences, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution>Department of Chemistry, University of California-Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff13"><label>13</label><institution>Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Malissen</surname><given-names>Bernard</given-names></name><role>Reviewing Editor</role><aff><institution>Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université</institution><country>France</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution>Institute of Industrial Science, The University of Tokyo</institution><country>Japan</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>31</day><month>12</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e74272</elocation-id><history><date date-type="received" iso-8601-date="2021-09-28"><day>28</day><month>09</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-12-30"><day>30</day><month>12</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-10-04"><day>04</day><month>10</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.10.04.463005"/></event></pub-history><permissions><copyright-statement>© 2021, De Silva et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>De Silva et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-74272-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-74272-figures-v2.pdf"/><abstract><p>Activation of T cells requires a rapid surge in cellular protein synthesis. However, the role of translation initiation in the early induction of specific genes remains unclear. Here, we show human translation initiation factor eIF3 interacts with select immune system related mRNAs including those encoding the T cell receptor (TCR) subunits TCRA and TCRB. Binding of eIF3 to the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-untranslated regions (3’-UTRs) depends on CD28 coreceptor signaling and regulates a burst in TCR translation required for robust T cell activation. Use of the <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTRs to control expression of an anti-CD19 chimeric antigen receptor (CAR) improves the ability of CAR-T cells to kill tumor cells in vitro. These results identify a new mechanism of eIF3-mediated translation control that can aid T cell engineering for immunotherapy applications.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>eIF3</kwd><kwd>protein synthesis</kwd><kwd>T cell receptor</kwd><kwd>CD28</kwd><kwd>chimeric antigen receptor</kwd><kwd>cellular immunotherapy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01-GM065050</award-id><principal-award-recipient><name><surname>De Silva</surname><given-names>Dasmanthie</given-names></name><name><surname>Chin</surname><given-names>Grant H</given-names></name><name><surname>Cate</surname><given-names>Jamie HD</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Tang Prize for Biopharmaceutical Science</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Cate</surname><given-names>Jamie HD</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001021</institution-id><institution>Damon Runyon Cancer Research Foundation</institution></institution-wrap></funding-source><award-id>DRR#37-15</award-id><principal-award-recipient><name><surname>Ingolia</surname><given-names>Nicholas T</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DP2 CA195768</award-id><principal-award-recipient><name><surname>Ferguson</surname><given-names>Lucas</given-names></name><name><surname>Kudla</surname><given-names>Marek</given-names></name><name><surname>Ingolia</surname><given-names>Nicholas T</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30EY003176</award-id><principal-award-recipient><name><surname>Smith</surname><given-names>Benjamin E</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>S10 OD018174</award-id><principal-award-recipient><name><surname>De Silva</surname><given-names>Dasmanthie</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009417</institution-id><institution>Care-for-Rare Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Blaeschke</surname><given-names>Franziska</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>German Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Blaeschke</surname><given-names>Franziska</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000861</institution-id><institution>Burroughs Wellcome Fund</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Marson</surname><given-names>Alexander</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000884</institution-id><institution>Cancer Research Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Marson</surname><given-names>Alexander</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution>Chan Zuckerberg Initiative</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Apathy</surname><given-names>Ryan A</given-names></name><name><surname>Roth</surname><given-names>Theodore L</given-names></name><name><surname>Marson</surname><given-names>Alexander</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100014220</institution-id><institution>Innovative Genomics Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Apathy</surname><given-names>Ryan A</given-names></name><name><surname>Roth</surname><given-names>Theodore L</given-names></name><name><surname>Marson</surname><given-names>Alexander</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100014547</institution-id><institution>Parker Institute for Cancer Immunotherapy</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Marson</surname><given-names>Alexander</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Binding of the translation initiation factor eIF3 to the messenger RNAs encoding the T cell receptor subunits alpha and beta is required to drive a short burst in their translation and promote a strong T cell response.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Translation initiation serves as a key gatekeeper of protein synthesis in eukaryotes and requires the action of eukaryotic initiation factor 3 (eIF3) (<xref ref-type="bibr" rid="bib39">Hernández et al., 2020</xref>; <xref ref-type="bibr" rid="bib72">Pelletier and Sonenberg, 2019</xref>). In humans, eIF3 is a 13-subunit protein complex that coordinates the cellular machinery in positioning ribosomes at the mRNA start codon. Several lines of evidence indicate eIF3 also serves specialized roles in cellular translation, by recognizing specific RNA structures in the 5’-untranslated regions (5’-UTRs) of target mRNAs (<xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>), binding the 7-methyl-guanosine (m<sup>7</sup>G) cap (<xref ref-type="bibr" rid="bib53">Lamper et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Lee et al., 2016</xref>) or through interactions with <italic>N</italic>-6-methyl-adenosine (m<sup>6</sup>A) post-transcriptional modifications in mRNAs (<xref ref-type="bibr" rid="bib61">Meyer et al., 2015</xref>). Binding to these <italic>cis</italic>-regulatory elements in mRNA can lead to translation activation or repression, depending on the RNA sequence and structural context (<xref ref-type="bibr" rid="bib23">de la Parra et al., 2018</xref>; <xref ref-type="bibr" rid="bib55">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>; <xref ref-type="bibr" rid="bib61">Meyer et al., 2015</xref>). These non-canonical functions for eIF3 can aid cell proliferation (<xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>), or allow cells to rapidly adapt to stresses such as heat shock (<xref ref-type="bibr" rid="bib61">Meyer et al., 2015</xref>). In the immune system, T cell activation requires a rapid increase in protein synthesis within the first few hours that also involves eIF3 (<xref ref-type="bibr" rid="bib2">Ahern et al., 1974</xref>; <xref ref-type="bibr" rid="bib48">Kleijn and Proud, 2002</xref>; <xref ref-type="bibr" rid="bib64">Miyamoto et al., 2005</xref>; <xref ref-type="bibr" rid="bib74">Ricciardi et al., 2018</xref>). However, whether eIF3 serves a general or more specific role in T cell activation is unknown.</p><p>Translation in non-activated lymphocytes is limited by the availability of translation initiation factors (<xref ref-type="bibr" rid="bib2">Ahern et al., 1974</xref>; <xref ref-type="bibr" rid="bib58">Mao et al., 1992</xref>; <xref ref-type="bibr" rid="bib94">Wolf et al., 2020</xref>). The mRNAs for several translation initiation factors, including those for many eIF3 subunits, are repressed in resting T cells and are rapidly translated within hours of activation (<xref ref-type="bibr" rid="bib94">Wolf et al., 2020</xref>). Additionally, nearly inactive eIF3 in quiescent T cells is activated to form translation initiation complexes in the first few hours after stimulation (<xref ref-type="bibr" rid="bib64">Miyamoto et al., 2005</xref>). Activation of eIF3 coincides with the recruitment of subunit eIF3j to eIF3 and translation initiation complexes (<xref ref-type="bibr" rid="bib64">Miyamoto et al., 2005</xref>). Post-translational modifications are also thought to contribute to the early increase in translation, for example activation of the guanine nucleotide exchange factor eIF2B (<xref ref-type="bibr" rid="bib48">Kleijn and Proud, 2002</xref>). By contrast, the level of the canonical mRNA cap-binding complex eIF4F–composed of translation initiation factors eIF4E, eIF4G, and eIF4A–increases much later after T cell activation (<xref ref-type="bibr" rid="bib58">Mao et al., 1992</xref>).</p><p>Recent studies have identified translational control of specific transcripts required for the rewiring of metabolism needed for effector T cell function. Translation of these specific transcripts involved in glycolysis and fatty acid synthesis occurs within 1–3 days of T cell activation (<xref ref-type="bibr" rid="bib74">Ricciardi et al., 2018</xref>), and depends on the activity of eIF4F. Hundreds of other mRNAs translationally repressed in resting T cells are rapidly translated within hours after activation, including those encoding key transcription factors and ribosomal proteins, in addition to the translation initiation factors noted above (<xref ref-type="bibr" rid="bib94">Wolf et al., 2020</xref>). Most of these mRNAs are sensitive to mTOR inhibition, highlighting the importance of eIF4F for the translation of these specific transcripts. However, a small subset of mRNAs evade mTOR inhibition by an unknown mechanism (<xref ref-type="bibr" rid="bib94">Wolf et al., 2020</xref>). Whether eIF3 selectively regulates these or other mRNAs early in T cell activation is not known.</p><p>In the adaptive immune system, T cells are activated when a foreign antigen is recognized by the T cell receptor (TCR). However, robust T cell activation requires a second signal generated by interactions between the T cell and antigen presenting cell mediated by the co-receptor CD28 (<xref ref-type="bibr" rid="bib26">Esensten et al., 2016</xref>). This two-signal mechanism enables T cells to adopt a fully active state and avoid becoming unresponsive (<xref ref-type="bibr" rid="bib15">Chen and Flies, 2013</xref>). The process of T cell activation can be mimicked in vitro using antibodies targeting both the TCR and CD28 (anti-CD3 and anti-CD28 antibodies, respectively) (<xref ref-type="bibr" rid="bib37">Harding et al., 1992</xref>), which has greatly aided the dissection of molecular mechanisms underlying T cell activation.</p><p>Insights from these studies have also inspired efforts to engineer T cells for immunotherapy applications such as treating cancers (<xref ref-type="bibr" rid="bib15">Chen and Flies, 2013</xref>). T cells can be engineered to express chimeric antigen receptors (CARs) that specifically target antigens on the surface of cancer cells, and signal through protein elements derived from both the TCR and CD28 or other co-stimulatory receptors (<xref ref-type="bibr" rid="bib15">Chen and Flies, 2013</xref>; <xref ref-type="bibr" rid="bib31">Globerson Levin et al., 2021</xref>). The most successful of these CAR T cells have been used to treat CD19-positive B cell malignancies, with dramatic results (<xref ref-type="bibr" rid="bib29">Friedman et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">Kalos et al., 2011</xref>; <xref ref-type="bibr" rid="bib51">Kochenderfer et al., 2013</xref>; <xref ref-type="bibr" rid="bib73">Qin et al., 2020</xref>; <xref ref-type="bibr" rid="bib91">Wang et al., 2020</xref>). However, CAR T cells still have a number of drawbacks, including toxicity to the patient, CAR T cell exhaustion, limited persistence and poor efficacy in solid tumors. These problems highlight the need for a deeper understanding of T cell activation and how it can be controlled in CAR T cells (<xref ref-type="bibr" rid="bib31">Globerson Levin et al., 2021</xref>; <xref ref-type="bibr" rid="bib92">Watanabe et al., 2018</xref>).</p><p>Here, we identified mRNAs that specifically bind eIF3 in activated T cells, including many encoding proteins involved in immune cell function such as the TCR. We mapped the eIF3-dependent <italic>cis</italic>-regulatory elements in the mRNAs encoding the TCR alpha and beta subunits (TCRA and TCRB, respectively), finding the 3’-untranslated regions (3’-UTRs) of these mRNAs control a rapid burst in TCRA and TCRB translation that depends on CD28 coreceptor signaling. Finally, we use this information to engineer T cells expressing chimeric antigen receptors to modulate the dynamics of CAR expression and improve the ability of CAR T cells to kill tumor cells in vitro.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>A specific suite of RNAs interact with eIF3 in activated Jurkat cells</title><p>To delineate how eIF3 contributes to T cell activation, we first identified RNAs that directly interact with eIF3 in Jurkat cells activated for 5 hours with phorbol 12-myristate 13-acetate and ionomycin (PMA + I), using photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) (<xref ref-type="bibr" rid="bib34">Hafner et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Mukherjee et al., 2019</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). In the Jurkat PAR-CLIP experiments, RNA crosslinked to eight of the 13 eIF3 subunits, as identified by mass spectrometry: subunits EIF3A, EIF3B, EIF3D, and EIF3G as previously seen in HEK293T cells (<xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>), as well as subunits EIF3C, EIF3E, EIF3F, and EIF3L (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–1B</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Consistent with its role in T cell activation, eIF3 crosslinked to a substantially larger number of mRNAs (~75 x more) in activated Jurkat cells compared to control non-activated cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C–1D</xref> and <xref ref-type="supplementary-material" rid="supp2 supp3">Supplementary files 2 and 3</xref>). Notably, in activated Jurkat cells eIF3 interacted with mRNAs enriched for those encoding proteins central to immune cell function, in contrast to those previously identified in HEK293T cells (<xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>; <xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). The extent of eIF3 crosslinking in activated Jurkat cells does not correlate with mRNA abundance based on transcription profiling carried out in parallel (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref> and <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). This suggests the enrichment of immune system related mRNAs reflects the involvement of eIF3 in specific regulation of T cell activation.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>eIF3 interacts with specific mRNAs related to immune function in activated Jurkat cells.</title><p>(<bold>A</bold>) Schematic of the PAR-CLIP experiment in Jurkat cells, showing steps through cell harvesting. (<bold>B</bold>) Phosphorimage of SDS polyacrylamide gel resolving 5′ <sup>32</sup>P-labeled RNAs crosslinked to eIF3 subunits in activated and non-activated Jurkat cells, from one of two biological replicates. (<bold>C</bold>) Pathway enrichment categories determined using the STRING Database for both biological replicates of the EIF3A/C/B PAR-CLIP libraries (mRNAs with ≥ 100 reads). Number of genes in each pathway whose mRNAs crosslinked to eIF3 is shown next to each bar. Note that the categories reported by the STRING Database are not disjoint sets. (<bold>D</bold>) Varied mRNA crosslinking patterns to eIF3 in activated Jurkat cells. Cumulative plot showing mRNA crosslinking in sample EIF3A/C/B to predominantly the 5’-UTR (n = 396, 414 mRNAs in replicates 1 and 2, respectively), and across the entire length of some mRNAs (‘pan-mRNAs’, n = 634, 621 mRNAs). The 5’-UTR, CDS, and 3’-UTR regions are shown normalized by length. (<bold>E</bold>) Crosslinking of the eIF3 subunits as indicated across the entire <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs, in activated and non-activated Jurkat cells. 5’-UTR, coding sequence (CDS), and 3’-UTR elements (below) along with the variable (<bold>V</bold>), joining (<bold>J</bold>) and constant (<bold>C</bold>) regions (above) for the mapped TCR genes in Jurkat cells are shown. The blue and red vertical lines in the plotted reads indicate the amount of T-C transitions vs other mutations, respectively for a particular nucleotide. The <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs are present in both non-activated and activated Jurkat cells (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). (<bold>F</bold>) FISH analysis of <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs (yellow and magenta, respectively) and P bodies (top) marked by the location of DCP1 (cyan) and stress granules (bottom) marked by the location of G3BP1 (cyan), in activated Jurkat cells. Graphs to the right of the images indicate Pearson’s correlation coefficients (PCCs) of <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs localizing with each other or with P bodies or stress granules. TetraSpeck microsphere beads were used as a positive control for colocalization. Labels on the x axis are, B: TetraSpeck microsphere beads, C: activated Jurkat cells. (n = 5, p &lt; 0.008, for PCC values of cells relative to bead colocalization, across all the channels tested, using the Wilcoxon rank-sum test). Images are representative of one experiment of the five independent experiments in the graphs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>eIF3 PAR-CLIP experiments in activated and non-activated Jurkat cells.</title><p>(<bold>A</bold>) Composition of eIF3 in I + PMA activated and non-activated Jurkat cells after anti-EIF3B immunoprecipitation (IP), identified by mass spectrometry. Shown is an SDS polyacrylamide gel stained with Coomassie Brilliant Blue. (<bold>B</bold>) Composition of eIF3 in activated Jurkat cells determined by western blot after anti-EIF3B IP. IN: input; FT: flow-through from anti-EIF3B IP beads; ELU: elution of eIF3 from anti-EIF3B IP beads. Anti-EIF4G1 and anti-RPS19 western blots confirm the stringency of bead wash steps (<xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>). (<bold>C</bold>) (Top) The length distribution of PAR-CLIP clusters mapped to RNAs crosslinked to eIF3 in the EIF3A/C/B samples, from activated (red) and non-activated (gray) Jurkat cells. (Bottom) The frequency distribution of the number of eIF3 PAR-CLIP clusters mapped to RNAs in the EIF3A/C/B samples, from activated (red) and non-activated (gray) Jurkat cells. In all panels, the distributions are the average of both biological replicates. RNA PAR-CLIP properties observed in the EIF3A/C/B sample are representative of those seen in PAR-CLIP sequence reads of RNAs crosslinked to other eIF3 subunits. (<bold>D</bold>) Categories of RNA crosslinked to eIF3, defined by clusters and divided into RNA categories, in I + PMA activated Jurkat cells and non-activated Jurkat cells (grey). In all panels, RNA categories include: 5’-UTR, 5’-UTR of mRNA; 3’-UTR, 3’-UTR of mRNA; CDS, protein coding region of mRNA; Start codon, beginning of mRNA CDS; Stop codon, stop codon region of mRNA; Intron, regions of pre-mRNA; Other, other classes of RNA; No annotation, reads that map to the human genome but that have no annotation assigned. A given mRNA may give rise to clusters in different mRNA categories. Panels <bold>C</bold> and <bold>D</bold> show representative results from one of two biological replicates. (<bold>E</bold>) Venn diagram of genes identified by eIF3 PAR-CLIP in activated Jurkat cells from two biological replicates, compared with the eIF3 PAR-CLIP mRNAs previously identified in HEK293T cells. The same number of mRNAs from the Jurkat cell PAR-CLIP libraries, ranked by total reads mapped to a given gene, are compared to the number of mRNAs identified in the HEK293T PAR-CLIP experiments. (<bold>F</bold>) Scatterplot of TPM of mRNAs expressed in activated Jurkat cells (most abundant isoform, see Methods) versus mRNAs identified by PAR-CLIP as crosslinked to eIF3 in the EIF3A/C/B samples, with ≥100 total read counts. n = 1029 and 1035 for PAR-CLIP hit genes plotted for replicates 1 and 2, respectively. The R-squared goodness of fit to a linear equation is shown. (<bold>G</bold>) mRNAs sorted by increasing value of the ratio of normalized 5’-UTR reads to normalized 3’-UTR reads in the EIF3A/C/B samples. Values of the ratio of 5’-UTR/3’-UTR normalized reads &gt;200 have been truncated to a value of 200 in the plot (asterisk). The arrow indicates the threshold used to create cumulative plots shown in <xref ref-type="fig" rid="fig1">Figure 1D</xref>. (<bold>H</bold>) Examples of eIF3 crosslinking to histone mRNAs <italic>HIST1H2AI</italic> and <italic>HIST1H3H</italic> in activated Jurkat cells are shown. Transcription start sites were determined from the FANTOM5 Database (<xref ref-type="bibr" rid="bib68">Noguchi et al., 2017</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>The <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs do not colocalize with P bodies and stress granules in activated T cells.</title><p>(<bold>A</bold>) (right panel) Single optical section of TetraSpeck microspheres (0.1 µm) adjacent to a Jurkat cell probed for P bodies. Scatter plots of pixel intensities in different emission channels are shown: channel 1, 670 nm; channel 2, 570 nm; channel 3, 488 nm. (left panel) Single optical section of a Jurkat cell probed for <italic>TCRA</italic> mRNA (channel 1), <italic>TCRB</italic> mRNA (channel 2), and DCP1 to mark P bodies (channel 3). (middle panels) Scatter plots showing: channel 1 vs. channel 2, channel 1 vs. channel 3, and channel 2 vs. channel 3. (<bold>B</bold>) (right panel) Single optical section and scatter plots for TetraSpeck microspheres as in <bold>A</bold>, but adjacent to a Jurkat cell probed for stress granules. (left panel) Single plane image of a Jurkat cell probed for <italic>TCRA</italic> mRNA (channel 1), <italic>TCRB</italic> mRNA (channel 2), and G3BP1 to mark stress granules (channel 3). (middle panels) Scatter plots as in <bold>A</bold>. Images of each cell are representative of those used in the analysis in <xref ref-type="fig" rid="fig1">Figure 1F</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig1-figsupp2-v2.tif"/></fig></fig-group><p>In activated Jurkat cells, eIF3 showed a multitude of crosslinking patterns on different mRNAs (<xref ref-type="fig" rid="fig1">Figure 1D–E</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D, G and H</xref>), consistent with varied roles for eIF3 in T cell activation and function. Many of the mRNAs have a single PAR-CLIP site in the 5’-UTR as observed in HEK293T cells (<xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>; <xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>, <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). However, eIF3 crosslinked to some mRNAs across the entire length of the transcript, from the beginning of the 5’-UTR through the 3’-UTR (<xref ref-type="fig" rid="fig1">Figure 1E</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref>). This ‘pan-mRNA’ pattern of eIF3 crosslinking–which includes polyadenylated mRNAs as well as histone mRNAs–has not been observed before. Interestingly, a number of these mRNAs encode proteins important for T cell activation, including both the alpha and beta subunits of the T cell receptor (TCR), subunits TCRA and TCRB (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>).</p></sec><sec id="s2-2"><title><italic>TCRA</italic> and <italic>TCRB</italic> mRNAs do not colocalize with P bodies or stress granules in activated Jurkat cells</title><p>Crosslinking in PAR-CLIP experiments requires direct interaction between the RNA and protein of interest (<xref ref-type="bibr" rid="bib5">Ascano et al., 2012</xref>). Thus, the pan-mRNA pattern of crosslinking between eIF3 and certain mRNAs suggests formation of ribonucleoprotein complexes (RNPs) highly enriched in eIF3. Notably, the pan-mRNA crosslinking pattern in the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs occurs in activated but not in non-activated Jurkat cells (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), suggesting eIF3 may contribute to increased translation of these mRNAs rather than their repression. We therefore examined <italic>TCRA</italic> and <italic>TCRB</italic> mRNA localization in activated Jurkat cells, to determine whether they colocalized with repressive environments such as P bodies or stress granules (<xref ref-type="bibr" rid="bib85">Tauber et al., 2020</xref>). Since Jurkat cells have a defined TCR, we designed fluorescence in situ hybridization (FISH) probes across the entire <italic>TCRA</italic> and <italic>TCRB</italic> transcripts to examine their localization. Interestingly, the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs did not co-localize with either P bodies or stress granules, or with each other in Jurkat cells activated with anti-CD3/anti-CD28 antibodies, which induce both TCR and CD28 coreceptor signaling required for robust T cell activation (<xref ref-type="bibr" rid="bib37">Harding et al., 1992</xref>; <xref ref-type="fig" rid="fig1">Figure 1F</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A and B</xref>). These results suggest that the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs are not translationally repressed but are possibly activated by eIF3 binding.</p></sec><sec id="s2-3"><title>Pan-mRNAs remain bound to eIF3 in translating ribosomes</title><p>The pan-mRNA crosslinking pattern suggests that eIF3 remains bound to the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs while they are actively translated. To capture <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs in translating ribosomes and examine their interactions with eIF3, we analyzed polysomes in Jurkat cells activated with anti-CD3/anti-CD28 antibodies (<xref ref-type="fig" rid="fig2">Figure 2A</xref>; <xref ref-type="bibr" rid="bib37">Harding et al., 1992</xref>). The cells were first treated with protein-protein crosslinker dithiobis(succinimidyl propionate) (DSP) before isolating polysomes on sucrose gradients (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). We then incubated the cell lysates with RNase H and DNA oligonucleotides designed to cleave the mRNAs specifically between the 5’-UTR, coding sequence (CDS), and 3’-UTR (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). This protocol efficiently cleaved the mRNAs and prevented the released 5’-UTR and 3’-UTR elements from entering polysomes (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B–1E</xref>). It also allowed us to detect eIF3 interactions with the mRNA CDS regions independent of eIF3 interactions with the UTR sequences identified in the PAR-CLIP analysis. We detected mRNAs interacting with eIF3 in the polysomes by performing anti-EIF3B immunoprecipitations followed by qRT-PCR (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We compared both <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs to another pan-crosslinked mRNA, <italic>DUSP2</italic>, and to two mRNAs that crosslinked to eIF3 only through their 5’-UTRs (<italic>EGR1</italic>, <italic>TRIM28</italic>). Using primers to the CDS regions of the mRNAs, we found that eIF3 only immunoprecipitated the pan-crosslinked mRNAs (<italic>TCRA</italic>, <italic>TCRB</italic>, <italic>DUSP2</italic>) from polysomes, but not mRNAs that only crosslinked to eIF3 through their 5’-UTRs (<italic>EGR1</italic>, <italic>TRIM28</italic>) (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). Importantly, all these mRNAs are present in translating ribosomes and can be immunoprecipitated with eIF3 when the mRNAs are left intact (RNase H treatment without DNA oligos) (<xref ref-type="fig" rid="fig2">Figure 2E</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>eIF3 remains bound to the coding sequences (CDS) of pan-mRNAs independent of their 5’-UTR and 3’-UTR elements in actively translating ribosomes.</title><p>(<bold>A</bold>) Schematic outlining the RNase H-based assay of eIF3 interactions with mRNAs in polysomes. DSP refers to the dithiobis (succinimidyl propionate) crosslinking agent. Oligos, DNA oligos designed for RNase H-mediated targeting and cleavage of specific mRNAs. (<bold>B</bold>) Strategy for detecting mRNA fragments released by RNase H digestion. Red arrows denote DNA oligos for RNase H-mediated targeting of mRNAs. RT-qPCR primers (black) were used to detect the CDS regions of the mRNAs. (<bold>C</bold>) Amount of eIF3-bound mRNA co-immunoprecipitated by an anti-EIF3B antibody (<xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>), from polysome fractions of Jurkat cells treated with RNase H and oligos targeting the CDS-UTR junctions (red arrows diagrammed in panel <bold>B</bold>). (<bold>D</bold>) Amount of eIF3-bound mRNA co-immunoprecipitated with IgG beads, from polysome fractions of Jurkat cell lysate treated with RNase H and oligos targeting the CDS-UTR junctions. (<bold>E</bold>) Amount of eIF3-bound mRNA co-immunoprecipitated by the anti-EIF3B antibody, from polysome fractions of Jurkat cell lysate treated only with RNase H. (<bold>F</bold>) Amount of eIF3-bound mRNA co-immunoprecipitated by an anti-EIF3B antibody, from polysome fractions of primary human T cells treated with RNase H and oligos targeting the CDS-UTR junctions (red arrows diagrammed in panel <bold>B</bold>). (<bold>G</bold>) Amount of eIF3-bound mRNA co-immunoprecipitated with IgG beads, from polysome fractions of primary human T cell lysate treated with RNase H and oligos targeting the CDS-UTR junctions. (<bold>H</bold>) Amount of eIF3-bound mRNA co-immunoprecipitated by the anti-EIF3B antibody, from polysome fractions of primary human T cell lysate treated only with RNase H. In panels C–H, the percentage is relative to the amount of total mRNA present in the polysome fraction prior to immunoprecipitation. All the immunoprecipitation experiments in panels <bold>C–H</bold> were carried out in biological duplicate with one technical triplicate shown (n = 3, with mean and standard deviations shown). The primary human T cell experiment was done using two donors.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>The <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs remain bound to elongating ribosomes via eIF3 in activated T cells.</title><p>(<bold>A</bold>) Sucrose gradient fractionation of polysomes from crosslinked Jurkat cells. Cell lysates treated with RNase H, as indicated, were fractionated on 10–50% sucrose gradients. Shown is the absorbance at 254 nm, for one of two biological replicates. (<bold>B</bold>) Strategy for detecting mRNA cleavage by RNase H digestion. RT-qPCR primers were designed to span the mRNA digestion sites. (<bold>C</bold>) Strategy for detecting 5’-UTR or 3’-UTR mRNA fragments released by RNase H digestion. RT-qPCR primers were designed within the 5’-UTR or 3’-UTR regions. (<bold>D</bold>) Fraction of intact mRNA segments remaining after RNase H treatment of DSP-crosslinked cell lysates from Jurkat cells, in the presence or absence of mRNA-specific DNA oligos for the indicated mRNAs. The mRNAs were detected using RT-qPCR oligos as illustrated in panel <bold>B</bold>. (<bold>E</bold>) Amount of eIF3-bound 5’-UTR and 3’-UTR regions of the mRNA co-immunoprecipitated by anti-EIF3B antibody, from polysome fractions of lysate from Jurkat cells treated with RNase H, either in the absence (left) or presence (right) of mRNA-targeting DNA oligos. Percentage is relative to the amount of total mRNA present in the polysome fraction prior to immunoprecipitation. Primers to the mRNA 5’-UTR and 3’-UTR regions, as indicated in panel <bold>C</bold>, were used for quantification. (<bold>F</bold>) Sucrose gradient fractionation of polysomes from crosslinked primary human T cells. (<bold>G</bold>) Fraction of intact mRNA segments remaining after RNase H treatment of DSP-crosslinked cell lysates from primary T cells, in the presence or absence of mRNA-specific DNA oligos for the indicated mRNAs. The mRNAs were detected using RT-qPCR oligos as illustrated in panel <bold>B</bold>. (<bold>H</bold>) Amount of eIF3-bound 5’-UTR and 3’-UTR regions of the mRNA co-immunoprecipitated by anti-EIF3B antibody, from polysome fractions of lysate from primary human T cells treated with RNase H, either in the absence (left) or presence (right) of mRNA-targeting DNA oligos. Percentage is relative to mRNA present in the polysome fraction prior to immunoprecipitation. Primers to the mRNA 5’-UTR and 3’-UTR regions, as indicated in panel <bold>C</bold>, were used for quantification. All experiments were carried out in biological duplicate with one technical triplicate shown (n = 3, with mean and standard deviations shown). All the primary human T cell experiments were performed using samples from two donors and data from one representative donor are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig2-figsupp1-v2.tif"/></fig></fig-group><p>We also tested whether these mRNAs interact with eIF3 similarly in primary human T cells during activation. We could not examine <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs in primary human T cells, as these mRNAs do not have a unique sequence in the 5’-UTR or variable region of the CDS to which we could design DNA oligonucleotides as described above. Therefore, we tested the distribution of <italic>DUSP2</italic>, <italic>EGR1,</italic> and <italic>TRIM28</italic> mRNAs in primary human T cells activated with anti-CD3/anti-CD28 antibodies (<xref ref-type="bibr" rid="bib37">Harding et al., 1992</xref>). As observed in Jurkat cells, <italic>DUSP2</italic> mRNA remained bound to eIF3 through its CDS region in polysomes whereas the <italic>EGR1</italic> and <italic>TRIM28</italic> mRNAs did not remain bound (<xref ref-type="fig" rid="fig2">Figure 2F–H</xref>). We also confirmed that the 5’-UTR and 3’-UTR elements of these mRNAs are efficiently cleaved and did not enter polysomes (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F–1H</xref>). Taken together, these results indicate that, in activated T cells, eIF3 remains bound to the coding sequences (CDS) of the pan-mRNAs <italic>TCRA</italic>, <italic>TCRB,</italic> and <italic>DUSP2</italic> in polysomes independent of their 5’-UTR and 3’-UTR elements. These results further support the model that the pan-mRNA crosslinking pattern of <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs reflects eIF3 binding to these mRNAs during translation elongation.</p></sec><sec id="s2-4"><title>eIF3 interacts with the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTRs and controls a burst in translation during T cell activation</title><p>Although crosslinking of eIF3 to the CDS regions of the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs (<xref ref-type="fig" rid="fig1">Figure 1E</xref>) indicates eIF3 remains bound to them during translation elongation (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), we wondered whether the 5’-UTRs and 3’-UTRs might play a role in recruiting these mRNAs to translating ribosomes. The <italic>TCRA</italic> and <italic>TCRB</italic> genes encode a different, often short 5’-UTR for each variable region of the mature locus (<xref ref-type="bibr" rid="bib70">Omer et al., 2021</xref>; <xref ref-type="bibr" rid="bib78">Scaviner and Lefranc, 2000</xref>), suggesting the 5’-UTR is unlikely to harbor eIF3-dependent regulatory elements. We therefore focused on the roles of the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs. We constructed nanoluciferase reporters fused to the WT <italic>TCRA</italic> or <italic>TCRB</italic> mRNA 3’-UTR sequence, to 3’-UTRs with the eIF3 PAR-CLIP site deleted (<italic>ΔPAR</italic>) or to 3’-UTRs with the reversed sequence of the eIF3 PAR-CLIP site (R*<italic>PAR</italic>, i.e. 5’–3’ sequence reversed to 3’–5’ direction to maintain the length of the 3’-UTR) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We then stably expressed these mRNAs in primary human T cells using lentiviral transduction and activated these T cells using anti-CD3/anti-CD28 antibodies. T cells expressing the reporters with the WT <italic>TCRA</italic> or <italic>TCRB</italic> mRNA 3’-UTR sequences produced substantially higher luminescence that peaked 1 hr after activation, while cells expressing nanoluciferase from reporters with a deletion or reversal of the eIF3 PAR-CLIP site sequence showed no apparent burst in translation (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The <italic>TCRA</italic> Δ<italic>PAR</italic> or R*<italic>PAR</italic> or <italic>TCRB</italic> Δ<italic>PAR</italic> or R*<italic>PAR</italic> mutations, however, did not cause significant defects in the nanoluciferase mRNA levels when compared to reporters with the corresponding WT 3’-UTR sequences (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). This suggests the burst in nanoluciferase expression observed with the WT <italic>TCRA</italic> or <italic>TCRB</italic> mRNA 3’-UTR sequences is regulated posttranscriptionally. Immunoprecipitation of eIF3 followed by qRT-PCR quantification of nanoluciferase mRNA showed that less nanoluciferase mRNA bound to eIF3 when the 3’-UTR PAR-CLIP site was either deleted or reversed, compared to nanoluciferase mRNAs carrying the WT <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTR (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>). Interestingly, although the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTR elements that crosslinked to eIF3 do not share any conserved sequences or RNA structural elements (<xref ref-type="bibr" rid="bib96">Xu and Mathews, 2016</xref>), the above results support the idea that eIF3 binding to specific sequences or structures within the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs controls a burst in translation after T cell activation.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Interaction of eIF3 with <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTR elements mediates a burst in TCR translation in primary human T cells.</title><p>(<bold>A</bold>) Schematic of nanoluciferase reporters stably expressed in primary human T cells. The reporters carry the <italic>HBB</italic> 5’-UTR and WT, <italic>ΔPAR</italic> or R*<italic>PAR</italic> 3’-UTRs. WT, intact 3’-UTR from either <italic>TCRA</italic> or <italic>TCRB</italic> mRNA; <italic>ΔPAR</italic>, 3’-UTR of <italic>TCRA</italic> or <italic>TCRB</italic> with the eIF3 PAR-CLIP site deleted; R*<italic>PAR</italic>, reversed PAR-CLIP sequence in the 3’-UTR of <italic>TCRA</italic> or <italic>TCRB</italic> mRNA. (<bold>B</bold>) Luciferase activity in anti-CD3/anti-CD28 activated T cells stably expressing nanoluciferase constructs described in <bold>A</bold>, relative to non-activated controls (ACT/NoACT). (<bold>C</bold>) Changes in nanoluciferase mRNA levels in <bold>B</bold>, as determined by qRT-PCR. (<bold>D</bold>) Schematic of immunoprecipitation of eIF3 using an anti-EIF3B antibody (<xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>), followed by qRT-PCR to quantify the amount of nanoluciferase mRNA bound to eIF3. (<bold>E</bold>) Immunoprecipitation as shown in <bold>D</bold> showing the amount of nanoluciferase mRNA bound to eIF3 in T cells stably transduced with either <italic>TCRA</italic> (left) or <italic>TCRB</italic> (right) WT, <italic>ΔPAR</italic> or R*<italic>PAR</italic> 3’-UTRs after activation with anti-CD3/anti-CD28 antibodies for 1 hr. The percent mRNA bound to anti-EIF3B beads is calculated relative to total mRNA isolated from the cells. (<bold>F</bold>) Schematic of nanoluciferase reporters stably expressed in primary human T cells. Nanoluciferase reporters carry the <italic>HBB</italic> 5’-UTR and WT, Δ<italic>PAR,</italic> R*<italic>PAR</italic> of the <italic>TCRA</italic> 3’-UTR, or Δ<italic>PAR</italic> of the <italic>TCRA</italic> 3’-UTR replaced with either a <italic>JUN</italic> 5’-UTR hairpin or hepatitis C viral (HCV) internal ribosome entry site (domain IIIabc). (<bold>G</bold>) Luciferase activity in anti-CD3/anti-CD28 activated T cells stably expressing nanoluciferase constructs described in <bold>F</bold>, relative to non-activated controls. (<bold>H</bold>) Changes in nanoluciferase mRNA levels in <bold>G</bold>, as determined by qRT-PCR. (<bold>I</bold>) Immunoprecipitation as shown in <bold>D</bold> to quantify the amount of nanoluciferase mRNA bound to eIF3 in T cells stably expressing nanoluciferase constructs in <bold>F</bold> after activation with anti-CD3/anti-CD28 antibodies for 0.5, 1, 3, and 5 hr. The percent mRNA bound to anti-EIF3B beads is calculated relative to total mRNA isolated from the cells. All experiments were carried out in triplicate (three separate wells per condition), with mean and standard deviations shown. All the primary human T cell experiments were performed using two donors and data from one representative donor is shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig3-v2.tif"/></fig><p>We next tested whether the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs serve to initially recruit eIF3 to the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs, as eIF3 does not remain stably bound to these 3’-UTRs in translating ribosomes (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2G</xref>). We made nanoluciferase reporters in which we replaced the eIF3 PAR-CLIP site in the <italic>TCRA</italic> 3’-UTR with sequences from the hepatitis C viral internal ribosome entry site (HCV IRES domain IIIabc) or the <italic>JUN</italic> mRNA 5’-UTR, each previously shown to bind directly to eIF3 (<xref ref-type="bibr" rid="bib47">Kieft et al., 2001</xref>; <xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>; <xref ref-type="fig" rid="fig3">Figure 3F</xref>). We stably transduced these constructs into primary T cells and measured nanoluciferase activity after activating the cells with anti-CD3/anti-CD28 antibodies. By contrast to the <italic>TCRA</italic> Δ<italic>PAR</italic> 3’-UTR, the HCV IRES IIIabc and <italic>JUN</italic> sequences increased nanoluciferase translation (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). This was true despite the fact that there was less of an increase in mRNA abundance for the HCV IRES IIIabc and <italic>JUN</italic> constructs compared to the <italic>TCRA</italic> Δ<italic>PAR</italic> 3’-UTR (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). The HCV IRES IIIabc and <italic>JUN</italic> sequences also rescued eIF3 binding to the reporter mRNAs (<xref ref-type="fig" rid="fig3">Figure 3I</xref>) upon T cell activation. These results are consistent with the engineered 3’-UTRs recruiting eIF3 to the mRNA. However, the dynamics of translation activation induced by the 3’-UTRs harboring the HCV IRES or <italic>JUN</italic> sequences did not recapitulate the effects of the WT <italic>TCRA</italic> 3’-UTR. Both engineered 3’-UTRs increased nanoluciferase levels within 30 min of activation, in contrast to the WT <italic>TCRA</italic> 3’-UTR (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). Furthermore, neither engineered 3’-UTR led to a marked decrease of nanoluciferase levels after the 1 hr peak in luminescence seen with the WT <italic>TCRA</italic> 3’-UTR (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). Taken together, the nanoluciferase reporter experiments reveal the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTRs are necessary and sufficient to drive a burst in translation after T cell activation. They also suggest these 3’-UTR elements recruit eIF3 to the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs to drive a burst in translation of the TCR alpha and beta subunits.</p></sec><sec id="s2-5"><title>The <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTRs control a burst in translation in a CD28-dependent manner</title><p>Robust T cell activation after antigen recognition generally requires signaling both through the TCR and through the costimulatory receptor CD28, which interacts with proteins CD80 and CD86 on the surface of antigen presenting cells (<xref ref-type="bibr" rid="bib1">Adams et al., 2016</xref>). However, since T cell activation in some cases does not require the TCR (<xref ref-type="bibr" rid="bib8">Beyersdorf et al., 2005</xref>; <xref ref-type="bibr" rid="bib82">Siefken et al., 1998</xref>), we also tested whether the burst in translation controlled by the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTRs could be induced by activation of either the TCR or CD28 individually (<xref ref-type="fig" rid="fig4">Figure 4</xref>). We found anti-CD28 stimulation alone was sufficient to cause a transient burst in translation in the nanoluciferase reporters with the WT <italic>TCRA</italic> or <italic>TCRB</italic> mRNA 3’-UTRs, whereas anti-CD3 stimulation caused a continuous increase in reporter protein expression (<xref ref-type="fig" rid="fig4">Figure 4B–D</xref>). Interestingly, the burst in translation required the reporters to be membrane tethered via a N-terminal transmembrane helix (from CD3zeta) that is co-translationally inserted into the membrane (<xref ref-type="bibr" rid="bib14">Call and Wucherpfennig, 2005</xref>; <xref ref-type="fig" rid="fig4">Figure 4A–D</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–1C</xref>), consistent with the fact that CD28 signaling involves multiple membrane-associated events (<xref ref-type="bibr" rid="bib10">Boomer and Green, 2010</xref>). Moreover, the reporters with <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> 3’-UTRs failed to show a burst in expression even when the reporter proteins were tethered to the membrane (<xref ref-type="fig" rid="fig4">Figure 4A–D</xref>), supporting the role for eIF3 in the translational burst. Taken together, these results support the model that the CD28 costimulatory pathway drives an early burst in TCR translation after T cell activation, mediated by eIF3 binding to the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The burst in nanoluciferase reporter translation requires membrane-proximal CD28 signaling.</title><p>(<bold>A</bold>) Schematic of the membrane-tethered nanoluciferase reporters stably expressed in primary human T cells. (Top) Wild-type CD3-zeta protein with asterisk indicating two amino acids mutated in the transmembrane region to prevent association with the TCR (<xref ref-type="bibr" rid="bib24">Dong et al., 2019</xref>) (EX: extracellular, TM: transmembrane). (Bottom) Schematic of the nanoluciferase reporters. Nanoluciferase is fused C-terminal to the extracellular and transmembrane segments of CD3-zeta, mutated to prevent TCR association. The reporters carry the <italic>HBB</italic> 5’-UTR and <italic>TCRA, TCRB</italic>, <italic>TCRA</italic> Δ<italic>PAR,</italic> or <italic>TCRB</italic> Δ<italic>PAR</italic> 3’-UTR. (<bold>B</bold>) Luciferase activity in primary human T cells stably expressing membrane-tethered reporters described in <bold>A</bold> stimulated with anti-CD3/anti-CD28 antibodies, relative to non-activated controls (ACT/NoACT). (<bold>C</bold>) Luciferase activity in primary human T cells stably expressing membrane-tethered reporters described in <bold>A</bold>, and activated only with anti-CD28 antibodies, relative to non-activated controls. (<bold>D</bold>) Luciferase activity in primary human T cells stably expressing membrane-tethered reporters described in <bold>A</bold>, and activated only with anti-CD3 antibodies, relative to non-activated controls. (<bold>E</bold>) Luciferase activity in primary human T cells stably expressing membrane-tethered reporter with WT <italic>TCRA</italic> 3’-UTR described in <bold>A</bold> inhibited with either AZD5363 (AZD) to inhibit AKT activity or Torin 1 to inhibit mTOR before activating with anti-CD3/anti-CD28 antibodies, relative to non-activated controls. In panels A–E, all experiments were carried out in triplicate (three separate wells per condition), with mean and standard deviations shown. (<bold>F</bold>) Western blot carried out to measure AKT activity in the presence of AZD5363 (AZD) using an anti-Phospho-GSK-3β antibody or mTOR activity in the presence of Torin 1 using an anti-Phospho-4EBP1 antibody, for the samples in <bold>E</bold>. HSP90 was used as a loading control. All the primary human T cell experiments were performed using two donors and data from one representative donor is shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Nanoluciferase reporter expression in activated T cells.</title><p>(<bold>A</bold>) Schematic of nanoluciferase reporters without a transmembrane helix (not membrane tethered) stably expressed in primary human T cells. The reporters carry the <italic>HBB</italic> 5’-UTR and <italic>TCRA, TCRB, TCRA</italic> Δ<italic>PAR,</italic> or <italic>TCRB</italic> Δ<italic>PAR</italic> 3’-UTR. (<bold>B</bold>) Luciferase activity in T cells stably expressing reporters described in <bold>A</bold> stimulated only with anti-CD28 antibodies, relative to non-activated controls (n = 3, with mean and standard deviations shown). (<bold>C</bold>) Luciferase activity in primary human T cells stably expressing reporters described in <bold>A</bold> stimulated only with anti-CD3 antibodies, relative to non-activated controls (n = 3, with mean and standard deviations shown). (<bold>D</bold>) Luciferase activity in primary human T cells stably expressing membrane-tethered reporter (described in the schematic above) with WT <italic>TCRA</italic> 3’-UTR inhibited with either AZD5363 (AZD) to inhibit AKT activity or Torin 1 to inhibit mTOR before activating with anti-CD3/anti-CD28 antibodies, relative to non-activated controls. In panels <bold>B–D</bold>, all experiments were carried out in triplicate (three separate wells per condition), with mean and standard deviations shown. (<bold>E</bold>) Western blot carried out to measure AKT activity in the presence of AZD5363 (AZD) using an anti-Phospho-GSK-3β antibody or mTOR activity in the presence of Torin 1 using an anti-Phospho-4EBP1 antibody for the samples in <bold>D</bold>. HSP90 was used as a loading control. All the primary human T cell experiments were performed using samples from two donors and data from one representative donor are shown here. The data from the other donor are presented in <xref ref-type="fig" rid="fig4">Figure 4F</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig4-figsupp1-v2.tif"/></fig></fig-group><p>As noted above, CD28 signaling involves multiple membrane-associated events leading to activation of various kinases, including AKT and mTOR (<xref ref-type="bibr" rid="bib10">Boomer and Green, 2010</xref>; <xref ref-type="bibr" rid="bib65">Mondino and Mueller, 2007</xref>; <xref ref-type="bibr" rid="bib77">Rudd et al., 2009</xref>). We therefore tested whether these kinases are responsible for the signaling downstream of CD28 that leads to eIF3-mediated dynamic regulation of reporter expression, by using inhibitors of the kinases AKT (<xref ref-type="bibr" rid="bib16">Choi et al., 2016</xref>; <xref ref-type="bibr" rid="bib95">Wu et al., 2020</xref>) and mTOR (<xref ref-type="bibr" rid="bib86">Thoreen et al., 2009</xref>). In T cells expressing the membrane-tethered nanoluciferase reporter mRNA with the WT <italic>TCRA</italic> 3’-UTR (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), treatment with the mTOR inhibitor Torin 1 had no effect on the rapid increase in reporter expression as seen with the DMSO control. However, the burst in nanoluciferase expression was blocked when AKT kinase activity was inhibited with AZD5363 (AZD) (<xref ref-type="fig" rid="fig4">Figure 4E–F</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D–1E</xref>). Altogether, these data indicate that the transient burst in TCR expression likely requires specific interactions between eIF3 and the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs and also membrane-proximal CD28 signaling. Furthermore, these results support a model in which T cell activation requires CD28 costimulation to elicit an initial positive signal involving AKT kinase activity, which is later repressed by a negative feedback loop also mediated by CD28 signaling and cis-regulatory elements in the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTRs.</p></sec><sec id="s2-6"><title>eIF3 interactions with the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTRs regulate a burst in TCR translation important for T cell activation</title><p>Given that the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTRs are necessary and sufficient to drive a burst in translation after T cell activation, we examined their effects on the endogenous levels of the TCR. We analyzed the expression of TCR protein levels using western blots probed with an anti-TCRA antibody, since the formation of an intact TCR is required to stabilize both the TCRA and TCRB subunits (<xref ref-type="bibr" rid="bib52">Koning et al., 1988</xref>; <xref ref-type="bibr" rid="bib69">Ohashi et al., 1985</xref>). As seen with the nanoluciferase reporters, TCRA levels rose and peaked approximately one hour after T cell activation with anti-CD3/anti-CD28 antibodies (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Furthermore, the early burst in TCRA translation is dependent on CD28 but not on TCR signaling (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), also as observed with membrane-tethered reporters (<xref ref-type="fig" rid="fig4">Figure 4</xref>). To more directly assess the role of the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTRs, we used CRISPR-Cas9 genome editing to delete the eIF3 PAR-CLIP sites in either the <italic>TCRA</italic> or <italic>TCRB</italic> mRNA 3’-UTRs in primary T cells from two healthy human donors (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). PCR analysis showed successful deletion of the eIF3 PAR-CLIP site in the <italic>TCRA</italic> 3’-UTR or in the <italic>TCRB</italic> 3’-UTR (<italic>TCRA</italic> Δ<italic>PAR</italic> or <italic>TCRB</italic> Δ<italic>PAR</italic>, respectively) in 43–49% of the alleles (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). A scrambled sgRNA (SC), which does not target any site in the human genome was used as a control. We first measured the total endogenous TCRA protein levels by western blot in <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTR edited cells versus control cells at different time points after activating with anti-CD3/anti-CD28 antibodies (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). The SC control cells – which should behave as wild-type T cells – exhibited a substantial burst in TCRA protein levels immediately after activation (~1 hr). By contrast, TCRA protein levels were nearly absent or clearly reduced at early time points after activation in both <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> cell populations (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Only at later time points did TCRA levels in the <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> cell populations begin to increase. These results share the same pattern of expression seen with the nanoluciferase reporters described above (<xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>eIF3 binding to the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTR elements is required for a rapid burst in TCR translation and robust activation of primary human T cells.</title><p>(<bold>A</bold>) Western blots of TCRA protein levels in T cells as a function of time after different modes of activation. HSP90 was used as a loading control. (<bold>B</bold>) Western blots measuring TCRA protein levels as a function of time after anti-CD3/anti-CD28 activation. Cell lines used are labeled on the left: <italic>TCRA</italic> Δ<italic>PAR</italic>, <italic>TCRB</italic> Δ<italic>PAR</italic>, and SC (scrambled gRNA). HSP90 was used as a loading control. Schematics of <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs with and without eIF3 PAR-CLIP sites are shown above. SC control cells have the WT 3’-UTRs for <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs. (<bold>C</bold>) The number of T cells with one or more TCR clusters measured by anti-TCRA/anti-TCRB protein staining and epifluorescence microscopy as a function of time after anti-CD3/anti-CD28 activation. A total of 100 cells from each donor were imaged for <italic>TCRA</italic> Δ<italic>PAR</italic> (n = 2 donors, stained with anti-TCRA antibody), <italic>TCRB</italic> Δ<italic>PAR</italic> (n = 2 donors, stained with anti-TCRB antibody), and SC cell lines (n = 2 donors, each stained separately with anti-TCRA and anti-TCRB antibodies). Values are mean ± standard deviation. (<bold>D</bold>) Flow cytometric analysis measuring T cell activation markers CD69 (early activation marker) and CD25 (mid-activation marker), quantifying the mean percent of CD4+ T cells that are CD69+ CD25+. (<bold>E</bold>) Flow cytometric analysis of CD8+ T cells, quantifying the mean percent of CD8+ T cells that are CD69+ CD25+. Cells sorted as shown in <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>. (<bold>F</bold>) Quantification of IL2 secreted from SC, <italic>TCRA</italic> Δ<italic>PAR, TCRB</italic> Δ<italic>PAR,</italic> and Δ<italic>TCR</italic> cell populations at different time points after stimulation with anti-CD3/anti-CD28 antibodies, as determined by ELISA. (<bold>G</bold>) Quantification IFNγ secreted from the cells in <bold>F</bold>, as determined by ELISA. In panels <bold>D–G</bold>, all experiments were carried out in triplicate (three separate wells per condition), with mean and standard deviations shown. Representative results from one donor are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Generation and analysis of <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> primary human T cells.</title><p>(<bold>A</bold>) CRISPR/Cas9 RNP-mediated genome editing at the <italic>TCRA</italic> and <italic>TCRB</italic> genomic loci in primary human T cells. Location of gRNA sites targeting the <italic>TCRA</italic> 3’-UTR, to generate <italic>TCRA</italic> Δ<italic>PAR</italic> cells is highlighted in red. In <italic>TCRA</italic>, gRNA1 and gRNA2 target hg38 genomic locations chr14:22,551,700 and chr14:22,552,073, respectively. Location of gRNA sites targeting the <italic>TCRB</italic> 3’-UTR, to generate <italic>TCRB</italic> Δ<italic>PAR</italic> cells is highlighted in blue. In <italic>TCRB</italic>, gRNA1 and gRNA2 target hg38 genomic locations chr7:142,802,561 and chr7:142,802,695, respectively. (<bold>B</bold>) Top gel: Analysis of <italic>TCRA</italic> 3’-UTR PAR-CLIP site deletion efficiency. Total genomic DNA extracted from WT, <italic>TCRA</italic> Δ<italic>PAR, TCRB</italic> Δ<italic>PAR</italic> (here serving as a negative control), scrambled gRNA nucleofected (S) and non-nucleofected (N) cells was analyzed by PCR to measure the editing efficiency. <italic>TCRA</italic> Δ<italic>PAR</italic> cells produced a 1283 bp PCR product compared to 1676 bp in S, N or <italic>TCRB</italic> Δ<italic>PAR</italic> cells (See panel<bold> A</bold>). Bottom gel: Analysis of <italic>TCRB</italic> 3’-UTR PAR-CLIP site deletion efficiency. Total genomic DNA extracted from WT, <italic>TCRA</italic> Δ<italic>PAR</italic> (here serving as a negative control)<italic>, TCRB</italic> Δ<italic>PAR</italic>, scrambled gRNA nucleofected (S) and non-nucleofected (N) cells were analyzed by PCR to measure the editing efficiency. <italic>TCRB</italic> Δ<italic>PAR</italic> cells produced a 1022 bp PCR product compared to 1190 bp in S, N or <italic>TCRA</italic> Δ<italic>PAR</italic> cells (See panel<bold> A</bold>). The percentage of alleles with PAR-CLIP site deletion, quantified by imageJ. (<bold>C</bold>) Representative immunofluorescence images used to count TCR clusters in WT, <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> primary human T cells. The white arrows indicate the cells that were scored as having TCR clusters. (<bold>D</bold>) Percentage of cells expressing TCR on the cell surface of activated T cells measured by flow cytometric analysis. TCR expressing cells in the cell populations tested: <italic>N</italic>, Non-nucleofected cells; SC, Scrambled gRNA; <italic>1gA</italic>, <italic>TCRA</italic> gRNA 1; <italic>2gA</italic>, <italic>TCRA</italic> gRNA 2; <italic>1 + 2</italic> gA, <italic>TCRA</italic> gRNA 1 + 2 (i.e. <italic>TCRA</italic> Δ<italic>PAR</italic>); <italic>1</italic> gB, <italic>TCRB</italic> gRNA 1; <italic>2</italic> gB, <italic>TCRB</italic> gRNA 2; <italic>1 + 2</italic> gB, <italic>TCRB</italic> gRNA 1 + 2 (i.e. <italic>TCRB</italic> Δ<italic>PAR</italic>); Δ<italic>TCR</italic>, TCR gRNA targeting the CDS of <italic>TCRA</italic>. (n = 3 replicates from three separate wells, with mean and standard deviation shown.) (<bold>E</bold>) Representative density plots showing the percentage of TCR on the cell surface in activated T cells. The cell lines shown are: SC, <italic>TCRA</italic> Δ<italic>PAR</italic>, <italic>TCRB</italic> Δ<italic>PAR</italic>, Δ<italic>TCR</italic> (negative control). In panels <bold>D</bold> and <bold>E</bold>, representative results from one of two donors are shown. (<bold>F</bold>) Gating strategy for flow cytometric analysis of CD69 and CD25 levels. Primary human T cells were gated to isolate lymphocytes, followed by isolation of single cells, then live cells. Next, cells were gated to separate CD4+ and CD8+ cells expressing T cell activation markers CD69 and CD25. The gates for CD69+ and CD25+ cells were set based on CD69 and CD25 levels in the Δ<italic>TCR</italic> T cells. Shown is the workflow of the FACS gating, with an example of T cells activated with anti-CD3/anti-CD28 antibodies for 8 hr.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Effects of <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> mutations on different steps of CD8+ T cell activation.</title><p>Representative density plots showing the percentage of CD8+ T cells expressing CD69 (early activation marker), CD25 (mid-activation marker) or CD69 and CD25 after activation with anti-CD3/anti-CD28 antibodies at different time points, analyzed by flow cytometry. The plots represent one of the two donors. The cell lines shown are SC, <italic>TCRA</italic> Δ<italic>PAR</italic>, <italic>TCRB</italic> Δ<italic>PAR,</italic> and Δ<italic>TCR</italic> (negative control). The gating for CD69+ and CD25+ cells was set based on CD69 and CD25 levels in Δ<italic>TCR</italic> T cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Effects of <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> mutations on different steps of CD4+ T cell activation.</title><p>Representative density plots showing the percentage of CD4+ T cells expressing CD69 (early activation marker), CD25 (mid-activation marker) or CD69 and CD25 after activation with anti-CD3/anti-CD28 antibodies at different time points, analyzed by flow cytometry. The plots represent one of the two donors. The cell lines shown are SC, <italic>TCRA</italic> Δ<italic>PAR</italic>, <italic>TCRB</italic> Δ<italic>PAR,</italic> and Δ<italic>TCR</italic> (negative control). The gating for CD69+ and CD25+ cells was set based on CD69 and CD25 levels in Δ<italic>TCR</italic> T cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig5-figsupp3-v2.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>Effects of <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> mutations on different steps of T cell activation.</title><p>(<bold>A and B</bold>) Flow cytometric analysis quantifying the mean percent of <bold>A</bold>, CD8+ T and <bold>B</bold>, CD4+ T cells that are only CD69+. (<bold>C and D</bold>) Flow cytometric analysis quantifying the mean percent of <bold>C</bold>, CD8+ T and <bold>D</bold>, CD4+ T cells that are CD69+ CD25+. (<bold>E and F</bold>) Quantification of <bold>E</bold>, secreted IL-2 and <bold>F</bold>, secreted IFNγ, for all cell populations tested, as determined by ELISA. The cell populations tested: N, Non-nucleofected cells; SC, Scrambled gRNA; <italic>1gA</italic>, <italic>TCRA</italic> gRNA 1; <italic>2gA</italic>, <italic>TCRA</italic> gRNA 2; <italic>1 + 2</italic> gA, <italic>TCRA</italic> gRNA 1 + 2 (i.e. <italic>TCRA</italic> Δ<italic>PAR</italic>); <italic>1</italic> gB, <italic>TCRB</italic> gRNA 1; <italic>2</italic> gB, <italic>TCRB</italic> gRNA 2; <italic>1 + 2</italic> gB, <italic>TCRB</italic> gRNA 1 + 2 (i.e. <italic>TCRB</italic> Δ<italic>PAR</italic>); <italic>ΔTCR</italic> gRNA targeting the CDS of <italic>TCRA</italic>. All experiments were carried out in triplicate (three separate wells per condition), with mean and standard deviations shown. Representative results from one donor are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig5-figsupp4-v2.tif"/></fig><fig id="fig5s5" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 5.</label><caption><title>eIF3 binding to the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTR elements in Jurkat cells.</title><p>(<bold>A</bold>) Western blots of TCRA protein levels as a function of time after anti-CD3/anti-CD28 activation. Cell lines used: WT Jurkat cells, <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic>, Jurkat cells in which the eIF3 PAR-CLIP sites in the 3’-UTRs of the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs, respectively, have been deleted. Schematics of <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs with and without eIF3 PAR-CLIP sites are shown above. HSP90 was used as a loading control. Western blots are representative of two biological replicates. (<bold>B</bold>) <italic>TCRA</italic> and <italic>TCRB</italic> mRNA levels in WT Jurkat cells, or Jurkat cells with the <italic>TCRA</italic> eIF3 3’-UTR PAR-CLIP site deleted, as determined by qRT-PCR at different time points after anti-CD3/anti-CD28 activation. (<bold>C</bold>) <italic>TCRA</italic> and <italic>TCRB</italic> mRNA levels in WT Jurkat cells, or Jurkat cells with the <italic>TCRB</italic> eIF3 3’-UTR PAR-CLIP site deleted, as determined by qRT-PCR at different time points after anti-CD3/anti-CD28 activation. (<bold>D</bold>) Schematic of immunoprecipitation of eIF3 using an anti-EIF3B antibody, followed by qRT-PCR to quantify the amount of nanoluciferase mRNA bound to eIF3. (<bold>E</bold>) Immunoprecipitation of eIF3 as shown in <bold>D</bold> to quantify the amount of <italic>TCRA</italic> or <italic>TCRB</italic> mRNA bound to eIF3 in Jurkat cells after activation with anti-CD3/anti-CD28 antibodies for 5 hours (left) and 8 hr (right). The percent mRNA bound to anti-EIF3B beads is calculated relative to total mRNA isolated from the cells. In panels <bold>B–E</bold>, all experiments were carried out in triplicate (three separate wells per condition), with mean and standard deviations shown. Representative results from one of two biological replicates are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig5-figsupp5-v2.tif"/></fig></fig-group><p>We next asked whether the burst in TCR expression driven by the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs affected downstream steps in T cell activation. During TCR-dependent T cell activation, membrane proteins on the cell surface reorganize at the interface between the T cell and antigen-presenting cell (APC) to form an immunological synapse (<xref ref-type="bibr" rid="bib41">Huppa and Davis, 2003</xref>). TCR cluster formation is a central aspect of immune synapse formation (<xref ref-type="bibr" rid="bib19">Cochran et al., 2001</xref>). Therefore, we tested whether TCR cluster formation is affected by reduced TCR protein levels in <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> T cells at early time points after activation. We used the same cell populations as those used for the western blots above (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), to correlate the TCRA protein levels observed in the western blots with TCR clustering. We performed immunofluorescence on SC, <italic>TCRA ΔPAR</italic> and <italic>TCRB ΔPAR</italic> T cell populations using anti-TCRA and anti-TCRB antibodies to detect the TCR. Both <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> cells had fewer cells forming TCR clusters, especially at the early time point compared to SC control cells when activated with anti-CD3/anti-CD28 (<xref ref-type="fig" rid="fig5">Figure 5C</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). Consistent with the TCRA expression levels observed in western blots and the rate of TCR clustering (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>), both <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> cells expressed lower amounts of cell surface TCR compared to SC control cells or cells edited with a single gRNA when tested by flow cytometric analysis after PMA + I activation (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D and E</xref>).</p><p>To test whether the defect in TCR clustering in the <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> cell populations reflects a general deficiency in T cell activation, we measured the T cell activation markers CD69 and CD25 (subunit IL2RA of the IL2 receptor) on the cell surface by flow cytometry (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplements 2</xref>–<xref ref-type="fig" rid="fig5s4">4</xref> ). Fewer cells in the <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> CD8+ and CD4+ primary T cell populations expressed CD69 at early time points after activation (5–8 hr) (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4A and B</xref>) and fewer expressed both CD69 and CD25 at later time points after activation, compared to SC control cells (<xref ref-type="fig" rid="fig5">Figure 5D–E</xref> and <xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4C and D</xref>). We also found the <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> T cell populations secreted lower amounts of the stimulatory cytokines IL2 (<xref ref-type="fig" rid="fig5">Figure 5F</xref> and <xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4E</xref>) and IFNγ (<xref ref-type="fig" rid="fig5">Figure 5G</xref> and <xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4F</xref>), compared to the SC control cells. Taken together, the <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> primary T cell populations exhibited multiple early and late T cell activation defects. These results support the model that after T cell activation, eIF3 binding to the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTRs drives an early burst in TCR translation that is required for many subsequent steps in T cell activation.</p><p>To obtain additional mechanistic understanding of eIF3-mediated regulation of TCR translation we generated clonal <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> Jurkat cells using the CRISPR-Cas9 genome editing strategy developed for primary T cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>, <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). We first measured total TCR levels using western blots and an anti-TCRA antibody as described above (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), at different time points after activation with anti-CD3/anti-CD28 antibodies. WT Jurkat cells showed a TCR translational burst that peaked 5–8 hr after activation (<xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5A</xref>). By contrast, both <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> Jurkat cell populations expressed lower levels of the TCR proteins compared to WT cells, and failed to show a burst in TCR expression at early time points after activation (<xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5A</xref>). Importantly, <italic>TCRA</italic> and <italic>TCRB</italic> mRNA levels were unaffected or even increased in the <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> Jurkat cells (<xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5B and C</xref>), similar to our observations with nanoluciferase reporters in primary T cells (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). This is consistent with TCR expression levels being regulated post-transcriptionally by eIF3 interactions with the <italic>TCRA</italic> or <italic>TCRB</italic> mRNA 3’-UTR elements. We then tested whether deleting eIF3 binding sites in both <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTRs affected their interaction with eIF3. In both <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> cells, eIF3 bound to significantly lower amounts of the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs compared to WT cells at both the 5 hr and 8 hr time points after anti-CD3/anti-CD28 activation (<xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5D and E</xref>). This indicates deleting the eIF3 PAR-CLIP sites in the 3’-UTR disrupts eIF3 interactions with the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs substantially. Together with the nanoluciferase reporter experiments in primary T cells (<xref ref-type="fig" rid="fig3">Figure 3</xref>), these results support the model that eIF3 binding to the 3’-UTR elements of the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs mediates the rapid burst in TCR translation after T cell activation.</p></sec><sec id="s2-7"><title>The <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTRs enhance anti-CD19 CAR T cell function</title><p>T cells engineered to express chimeric antigen receptors (CARs) for cancer immunotherapy now in use clinically employ artificial 3’-UTRs in the CAR-encoding mRNA, a woodchuck hepatitis viral posttranscriptional regulatory element (<italic>WPRE</italic>) (<xref ref-type="bibr" rid="bib63">Milone et al., 2009</xref>), or a retroviral 3’-long terminal repeat (<italic>3’-LTR</italic>) (<xref ref-type="bibr" rid="bib49">Kochenderfer et al., 2009</xref>). However, it is not known whether these 3’-UTR elements provide optimal CAR expression or CAR T cell function. To test whether these 3’-UTRs induce a transient burst in translation as observed with the WT <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTRs, we fused the <italic>WPRE</italic> and <italic>3’-LTR</italic> 3’-UTR sequences to nanoluciferase reporters and expressed these in primary T cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). In contrast to the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs (<xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>), the <italic>WPRE</italic> and <italic>3’-LTR</italic> 3’-UTR elements failed to induce the early burst in nanoluciferase expression (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). These data suggest that fusing the <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTR sequences to engineered CAR open reading frames could be used to obtain more physiological expression dynamics seen for the endogenous TCR.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>The <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTR elements enhance CAR T cell function.</title><p>(<bold>A</bold>) (Top) Schematic of membrane-tethered nanoluciferase reporters stably expressed in primary human T cells. The reporters have the <italic>HBB</italic> 5’-UTR and either the <italic>TCRA</italic> 3’-UTR, the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (<italic>WPRE</italic>) or the gammaretroviral 3’-Long Terminal Repeat (<italic>3’-LTR</italic>) as 3’-UTR. (Bottom) Luciferase activity in primary human T cells stably expressing membrane-tethered nanoluciferase reporters described above and activated with anti-CD3/anti-CD28 antibodies, relative to non-activated cells. Representative results from one of two donors are shown (n = 3 separate wells, with mean and standard deviations shown). (<bold>B</bold>) Schematics of FMC63-BBZ CAR cDNA sequence fused 5’ of the <italic>WPRE, 3’-LTR, TCRA</italic> 3’-UTR or <italic>TCRB</italic> 3’-UTR. The membrane-tethered nanoluciferase reporter with <italic>TCRA</italic> 3’-UTR was used as a control for the effects of lentiviral expression. (<bold>C</bold>) Timeline of CAR T cell generation from primary human T cells and the experiments performed. (<bold>D</bold>) Western blots measuring FMC63-BBZ CAR protein levels as a function of time after incubation with NALM6 cells. CAR T cells expressing the constructs in <bold>B</bold> are labeled: Control<italic>, WPRE, 3’-LTR, TCRA</italic> and <italic>TCRB</italic> 3’-UTR. HSP90 was used as a loading control (n = 2 donors). (<bold>E</bold>) Schematic describing the cytotoxicity assay used to detect live tumor cells after incubation with FMC63-BBZ CAR cells using flow cytometric analysis. (<bold>F</bold>) Top panels show cytotoxic activity of FMC63-BBZ CARs fused to various 3’-UTRs described in <bold>B</bold> after incubating with NALM6 cells for 24 and 48 hr. Bottom panels show CAR T cells present in the experiments at the different time points, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. (<bold>G</bold>) Top panels show cytotoxic activity of FMC63-BBZ CARs fused to various 3’-UTRs described in <bold>B</bold> after incubating with Jeko 1 cells for 24 and 48 hr. Bottom panels show CAR T cells present in the experiments at the different time points, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. In panels <bold>F</bold> and <bold>G</bold>, representative results for one of two donors are shown for T cells propagated in 50 U/mL IL2 (n = 3 separate wells, with mean and standard deviations shown).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Effects of the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTR elements on CAR T cell function.</title><p>(<bold>A</bold>) Western blots measuring TCRA protein levels as a function of time in FMC63-BBZ CAR T cells after incubation with NALM6 tumor cells. Cell lines used are labeled: Control<italic>, WPRE, 3’-LTR, TCRA,</italic> and <italic>TCRB</italic> 3’-UTR diagrammed in <xref ref-type="fig" rid="fig6">Figure 6B</xref>. HSP90 was used as a loading control. (<bold>B</bold>) Gating strategy for flow cytometric analysis to detect live tumor cells after incubation with CAR T cells. This includes: (1) both CAR T and tumor cell gating, (2) isolating single cells, (3) isolating live cells based on propidium iodide staining and (4) separating cell trace violet (CTV) stained vs non-stained cells to isolate live tumor cells. (<bold>C</bold>) Left panel shows cytotoxic activity of FMC63-BBZ CARs fused to various 3’-UTRs described in <xref ref-type="fig" rid="fig6">Figure 6B</xref> after incubating with NALM6 tumor cells for 72 hr. Right panel shows CAR T cells present in the experiments at 72 hr, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. (<bold>D</bold>) Left panel shows cytotoxic activity of FMC63-BBZ CARs fused to various 3’-UTRs described in <xref ref-type="fig" rid="fig6">Figure 6B</xref> after incubating with Jeko 1 tumor cells for 72 hr. Right panel shows CAR T cells present in the experiments at 72 hr, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. Results in panels <bold>C</bold> and <bold>D</bold> for one of two donors are shown (n = 3 separate wells, with mean and standard deviations shown).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Effects of the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTR elements on CAR T cell function, donor 2.</title><p>(<bold>A</bold>) Top panels, cytotoxic activity of FMC63-BBZ CARs fused to various 3’-UTRs described in <xref ref-type="fig" rid="fig6">Figure 6B</xref> after incubating with NALM6 cells for 24, 48, and 72 hr. Bottom panels, CAR T cells present in the experiments at the different time points, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. (<bold>B</bold>) Top panels, cytotoxic activity of FMC63-BBZ CARs fused to various 3’-UTRs described in <xref ref-type="fig" rid="fig6">Figure 6B</xref> after incubating with Jeko 1 cells for 24, 48, and 72 hr. Bottom panels, CAR T cells present in the experiments at the different time points, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. These are results for the second of the two donors with T cells propagated in 50 U/mL IL2 (n = 3 separate wells, with mean and standard deviations shown).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig6-figsupp2-v2.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Anti-CD19 CAR T cell killing assays for T cells propagated in 500 U/mL IL2, donor 1.</title><p>(<bold>A</bold>) Top panels, cytotoxic activity of FMC63-BBZ CARs fused to various 3’-UTRs described in <xref ref-type="fig" rid="fig6">Figure 6B</xref> after incubating with NALM6 cells for 24, 48, and 72 hr. Bottom panels, CAR T cells present in the experiments at the different time points, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. (<bold>B</bold>) Top panels, cytotoxic activity of FMC63-BBZ CARs fused to various 3’-UTRs described in <xref ref-type="fig" rid="fig6">Figure 6B</xref> after incubating with Jeko 1 cells for 24, 48, and 72 hr. Bottom panels, CAR T cells present in the experiments at the different time points, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. These are results for one of two donors with T cells propagated in 500 U/mL IL2 (n = 3 separate wells, with mean and standard deviations shown).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig6-figsupp3-v2.tif"/></fig><fig id="fig6s4" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 4.</label><caption><title>Anti-CD19 CAR T cell killing assays for T cells propagated in 500 U/mL IL2, donor 2.</title><p>(<bold>A</bold>) Top panels, cytotoxic activity of FMC63-BBZ CARs fused to various 3’-UTRs described in <xref ref-type="fig" rid="fig6">Figure 6B</xref> after incubating with NALM6 cells for 24, 48, and 72 hr. Bottom panels, CAR T cells present in the experiments at the different time points, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. (<bold>B</bold>) Top panels, cytotoxic activity of FMC63-BBZ CARs fused to various 3’-UTRs described in <xref ref-type="fig" rid="fig6">Figure 6B</xref> after incubating with Jeko 1 cells for 24, 48, and 72 hr. Bottom panels, CAR T cells present in the experiments at the different time points, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. These are results for the second of two donors with T cells propagated in 500 U/mL IL2 (n = 3 separate wells, with mean and standard deviations shown). Cells expressing the anti-CD19 CAR using the <italic>TCRA</italic> 3’-UTR were lost due to a failed transduction.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig6-figsupp4-v2.tif"/></fig><fig id="fig6s5" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 5.</label><caption><title>Effects of the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTR elements on CAR T cell function, in cells with TCR expression knocked out.</title><p>(<bold>A</bold>) Timeline of CAR T cell generation from primary human T cells and the experiments performed. (<bold>B</bold>) Expression levels of the TCR in CAR T cells after editing of the <italic>TCRA</italic> CDS (see Methods). (<bold>C</bold>) Top panels, cytotoxic activity of FMC63-BBZ CARs fused to various 3’-UTRs described in <xref ref-type="fig" rid="fig6">Figure 6B</xref> after incubating with NALM6 cells for 24, 48, and 72 hr. Bottom panels, CAR T cells present in the experiments at the different time points, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. (<bold>D</bold>) Top panels, cytotoxic activity of FMC63-BBZ CARs fused to various 3’-UTRs described in <xref ref-type="fig" rid="fig6">Figure 6B</xref> after incubating with Jeko 1 cells for 24, 48, and 72 hr. Bottom panels, CAR T cells present in the experiments at the different time points, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. These are results for one donor with T cells propagated in 50 U/mL IL2 (n = 3 separate wells, with mean and standard deviations shown).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig6-figsupp5-v2.tif"/></fig><fig id="fig6s6" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 6.</label><caption><title>Effects of the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTR elements on CAR T cell function for T cells expressing an FMC63-28Z CAR.</title><p>(<bold>A</bold>) Schematic of FMC63-28Z CAR cDNA sequence fused 5’ of the <italic>WPRE, 3’-LTR, TCRA</italic> 3’-UTR or <italic>TCRB</italic> 3’-UTR. The membrane-tethered nanoluciferase reporter with <italic>TCRA</italic> 3’-UTR was used as a control for the effects of lentiviral expression. (<bold>B</bold>) Top panels, cytotoxic activity of FMC63-28Z CARs fused to various 3’-UTRs described in panel <bold>A</bold> after incubating with NALM6 cells for 24, 48, and 72 hr. Bottom panels, CAR T cells present in the experiments at the different time points, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. (<bold>C</bold>) Top panels. cytotoxic activity of FMC63-28Z CARs fused to various 3’-UTRs described in panel <bold>A</bold> after incubating with Jeko 1 cells for 24, 48, and 72 hr. Bottom panels, CAR T cells present in the experiments at the different time points, normalized to the <italic>WPRE</italic> CAR T cells at a 1:1 ratio with target tumor cells. These are results from one donor with T cells propagated in 500 U/mL IL2 (n = 3 separate wells, with mean and standard deviations shown).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig6-figsupp6-v2.tif"/></fig></fig-group><p>We therefore engineered primary human T cells to express an anti-CD19 CAR currently in use clinically to treat B cell lymphomas (<xref ref-type="bibr" rid="bib45">Kalos et al., 2011</xref>; <xref ref-type="bibr" rid="bib63">Milone et al., 2009</xref>; <xref ref-type="bibr" rid="bib44">June et al., 2014</xref>). We used lentiviral transduction to express the anti-CD19 CAR from mRNAs with either <italic>WPRE</italic>, <italic>3’-LTR</italic>, <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTRs to make anti-CD19 CAR T cells (<xref ref-type="fig" rid="fig6">Figure 6B and C</xref>). We then stimulated these CAR T cells by incubating them with CD19-expressing leukemia cells (NALM6) and measured the CAR expression by western blot analysis at different time points. Interestingly, the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs induced a burst in anti-CD19 CAR protein levels within 5 hr of NALM6 cell addition, whereas the <italic>WPRE</italic> and <italic>3’-LTR</italic> sequences delayed the burst in CAR expression to ~24 hr (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). In these CAR T cells, TCR expression also followed the burst in CAR expression, and was dependent on the presence of the CAR in addition to the NALM6 cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>).</p><p>Lastly, we tested whether the timing of CAR protein expression correlates with the killing capacity of these CAR T cells. Using in vitro cytotoxicity assays (<xref ref-type="fig" rid="fig6">Figure 6E</xref>), CAR T cells expressing the CAR using either the <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTR showed more robust killing of two tumor cell lines compared to CARs using either the <italic>WPRE</italic> or <italic>3’-LTR</italic> 3’-UTRs. This was true for CAR T cells propagated using two different concentrations of IL2 in the media (50 U/mL or 500 U/mL) (<xref ref-type="fig" rid="fig6">Figure 6F–G</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B–1D</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>, and <xref ref-type="fig" rid="fig6s3">Figure 6—figure supplements 3</xref> and <xref ref-type="fig" rid="fig6s4">4</xref>). Interestingly, CAR T cells expressing the CAR using either the <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTR generally propagated more robustly in the presence of the target tumor cells regardless of condition (<xref ref-type="fig" rid="fig6">Figure 6F–G</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B–1D</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>, and <xref ref-type="fig" rid="fig6s3">Figure 6—figure supplements 3</xref> and <xref ref-type="fig" rid="fig6s4">4</xref>). We also tested CAR T cells in which TCR expression was knocked out (<xref ref-type="fig" rid="fig6s5">Figure 6—figure supplement 5A and B</xref>). As observed above, these CAR T cells expressing the CAR using either the <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTR also showed more robust killing and propagated more robustly in the presence of target tumor cells (<xref ref-type="fig" rid="fig6s5">Figure 6—figure supplement 5C and D</xref>).</p><p>We also tested a separate anti-CD19 CAR used in the clinic that uses a CD28-derived signaling domain (<xref ref-type="fig" rid="fig6s6">Figure 6—figure supplement 6A</xref>; <xref ref-type="bibr" rid="bib50">Kochenderfer et al., 2010</xref>; <xref ref-type="bibr" rid="bib49">Kochenderfer et al., 2009</xref>) rather than the 4-1BB derived signaling domain tested above (<xref ref-type="fig" rid="fig6">Figure 6B</xref>; <xref ref-type="bibr" rid="bib45">Kalos et al., 2011</xref>; <xref ref-type="bibr" rid="bib63">Milone et al., 2009</xref>; <xref ref-type="bibr" rid="bib44">June et al., 2014</xref>). As observed for the 4-1BB domain-containing CAR, the CD28 domain-containing CAR also exhibited more potent killing and CAR T cells propagated more robustly in the presence of target tumor cells when the CAR expression was driven by the <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTRs (<xref ref-type="fig" rid="fig6s6">Figure 6—figure supplement 6B and C</xref>). Taken together, these results are consistent with the importance of an early burst of CAR translation for optimal CAR T cell function. These results also support the idea that using the native <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTRs for CAR expression can be used to improve CAR T cell function.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The eIF3 PAR-CLIP experiment we present here provides a snapshot of eIF3-RNA interactions that occur at the time TCR translation is most sensitive to eIF3 regulation (5 hr in Jurkat cells, <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A</xref>). At this point in time, eIF3 crosslinks to multiple mRNAs encoding proteins involved in immune cell function (<xref ref-type="supplementary-material" rid="supp2 supp3">Supplementary files 2 and 3</xref>). Interestingly, the patterns of eIF3 crosslinking, which for a number of mRNAs include interactions with the protein coding sequence and 3’-UTR (<xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G and H</xref>), suggest an active role for eIF3 in promoting translation of these mRNAs. In support of this model, the two examples of pan-mRNAs we examined here (<italic>TCRA</italic> and <italic>TCRB</italic>) do not colocalize with P bodies or stress granules (<xref ref-type="fig" rid="fig1">Figure 1F</xref>) and binding to eIF3 includes the mRNA coding sequence on translating ribosomes (<xref ref-type="fig" rid="fig2">Figure 2</xref>). However, this eIF3-mediated translation activation is transient, lasting only 1–2 hr in primary T cells (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Importantly, the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTR elements are necessary and sufficient to control this burst in translation (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Recent evidence suggests that eIF3 can remain associated with translating ribosomes (<xref ref-type="bibr" rid="bib9">Bohlen et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Lin et al., 2020</xref>; <xref ref-type="bibr" rid="bib90">Wagner et al., 2020</xref>), a phenomenon that seems to be enhanced for the pan-mRNAs identified here. It is possible that the 5’-UTRs and 3’-UTRs of some mRNAs are in close proximity, that is on the membrane of the endoplasmic reticulum (<xref ref-type="bibr" rid="bib17">Christensen et al., 1987</xref>; <xref ref-type="bibr" rid="bib18">Christensen and Bourne, 1999</xref>), and eIF3 binding to the 3’-UTR could directly influence the efficiency of translation initiation from the 5’-UTR. Additional layers of translation regulation also contribute to T cell function (<xref ref-type="bibr" rid="bib84">Tan et al., 2017</xref>), particularly with respect to mTOR signaling (<xref ref-type="bibr" rid="bib64">Miyamoto et al., 2005</xref>; <xref ref-type="bibr" rid="bib67">Myers et al., 2019</xref>) and carbon metabolism (<xref ref-type="bibr" rid="bib57">Manfrini et al., 2017</xref>; <xref ref-type="bibr" rid="bib74">Ricciardi et al., 2018</xref>). The present PAR-CLIP experiments should help to elucidate additional roles for eIF3-mediated translation regulation and to map the system-wide role of translation regulation in T cell activation.</p><p>Recent experiments indicate that T cells must cross a threshold of T cell receptor signaling to commit to activation and proliferation (<xref ref-type="bibr" rid="bib7">Au-Yeung et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Au-Yeung et al., 2014</xref>), setting up a ‘digital’ response to antigen recognition (<xref ref-type="bibr" rid="bib3">Allison et al., 2016</xref>; <xref ref-type="bibr" rid="bib7">Au-Yeung et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Au-Yeung et al., 2014</xref>; <xref ref-type="bibr" rid="bib75">Richard et al., 2018</xref>). The response threshold involves integration of intensity and duration of TCR signaling (<xref ref-type="bibr" rid="bib7">Au-Yeung et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Au-Yeung et al., 2014</xref>; <xref ref-type="bibr" rid="bib75">Richard et al., 2018</xref>), and spans a wide range of TCR antigen affinity (<xref ref-type="bibr" rid="bib3">Allison et al., 2016</xref>; <xref ref-type="bibr" rid="bib7">Au-Yeung et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Au-Yeung et al., 2014</xref>; <xref ref-type="bibr" rid="bib75">Richard et al., 2018</xref>). Notably, T cell commitment to clonal expansion and differentiation can occur within as little as 1–2 hr of TCR stimulation for effector CD4+ and naive CD8+ T cells (<xref ref-type="bibr" rid="bib42">Iezzi et al., 1998</xref>; <xref ref-type="bibr" rid="bib88">van Stipdonk et al., 2001</xref>). Remarkably, this time period spans the burst in TCR protein synthesis mediated by eIF3 interactions with the <italic>TCRA</italic> and <italic>TCRB</italic> mRNA 3’-UTR elements (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Naive CD4+ T cells require a longer duration of TCR signaling of ~20 hr (<xref ref-type="bibr" rid="bib42">Iezzi et al., 1998</xref>; <xref ref-type="bibr" rid="bib79">Schrum et al., 2005</xref>). Our observation of the burst in TCRA translation (and by implication TCRB translation) (<xref ref-type="bibr" rid="bib52">Koning et al., 1988</xref>; <xref ref-type="bibr" rid="bib69">Ohashi et al., 1985</xref>) in the first 1–2 hr of stimulation also correlates with multiple downstream events required for T cell activation and function. For example, loss of the burst in TCR protein synthesis delayed formation of TCR clusters (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), suggesting that surface expression of the TCR (<xref ref-type="bibr" rid="bib19">Cochran et al., 2001</xref>; <xref ref-type="bibr" rid="bib41">Huppa and Davis, 2003</xref>) is also impacted by the dynamics of TCRA and TCRB translation. Although we were not able to distinguish levels of TCR translation in isolated CD8+ and CD4+ T cells (<xref ref-type="fig" rid="fig5">Figure 5</xref>), subsequent events in T cell activation including CD69 and CD25 expression, and IL2 and IFNγ secretion, were equally affected in CD8+ and CD4+ cells in which the <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTR PAR-CLIP sites were deleted (<xref ref-type="fig" rid="fig5">Figure 5C–F</xref>). In an immune response, CD28 engagement serves as the second signal required for T cell activation (<xref ref-type="bibr" rid="bib37">Harding et al., 1992</xref>; <xref ref-type="bibr" rid="bib38">Harding and Allison, 1993</xref>) and affects the first minutes of TCR-mediated signaling (<xref ref-type="bibr" rid="bib33">Green et al., 2000</xref>; <xref ref-type="bibr" rid="bib32">Green et al., 1994</xref>; <xref ref-type="bibr" rid="bib62">Michel et al., 2001</xref>; <xref ref-type="bibr" rid="bib81">Shahinian et al., 1993</xref>; <xref ref-type="bibr" rid="bib87">Tuosto and Acuto, 1998</xref>). Here, we show CD28-mediated signaling is also needed for the burst of TCR translation on the hour timescale in primary T cells (<xref ref-type="bibr" rid="bib12">Buckler et al., 2006</xref>; <xref ref-type="fig" rid="fig4">Figure 4</xref>). Taken together, our results indicate that eIF3 controls <italic>TCRA</italic> and <italic>TCRB</italic> mRNA translation during the first critical hours after antigen recognition that leads to subsequent T cell commitment to proliferation and differentiation (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><p>We found the CD28-dependent burst in TCR translation requires cotranslational membrane targeting, consistent with the fact that CD28-mediated signaling occurs at the plasma membrane (<xref ref-type="bibr" rid="bib10">Boomer and Green, 2010</xref>) and the fact that both the TCRA and TCRB subunits are integral membrane proteins. We also observed additional immune-related mRNAs in the PAR-CLIP experiment that encode membrane proteins or secreted proteins (i.e. B2M, CD28, CD3D, HLA-E, and LAT in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>, and TAP1 and TAP2 in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>) which may be particularly sensitive to CD28 signaling. The requirement for CD28 in PD-1 mediated inhibition of T cell activation (<xref ref-type="bibr" rid="bib40">Hui et al., 2017</xref>; <xref ref-type="bibr" rid="bib46">Kamphorst et al., 2017</xref>) also suggests eIF3-mediated control of TCR expression may affect PD-1 checkpoint blockade-based cancer immunotherapy (<xref ref-type="bibr" rid="bib43">Jiang et al., 2019</xref>). It will be interesting to determine if there is a connection between PD1-mediated inhibition of the T-cell response and eIF3 binding to the 3’-UTRs of the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs. It will also be important to map the CD28-downstream signaling pathway to understand both the increase and subsequent decrease in TCR translation that occur during the translation burst. We found that AKT influences the rapid rise in translation (<xref ref-type="fig" rid="fig4">Figure 4E–F</xref>), but other kinases such as Tec-kinases (<xref ref-type="bibr" rid="bib4">Andreotti et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Gallagher et al., 2021</xref>; <xref ref-type="bibr" rid="bib36">Hallumi et al., 2021</xref>) could also impact the translation burst.</p><p>Cell immunotherapies targeting various cancers have made great strides, due to the engineering of chimeric antigen receptors that couple antigen recognition to intracellular signaling domains that activate cytotoxic T cells. However, CAR T cells often fail to eradicate cancers due to loss of activity over time, for example T cell exhaustion (<xref ref-type="bibr" rid="bib31">Globerson Levin et al., 2021</xref>; <xref ref-type="bibr" rid="bib92">Watanabe et al., 2018</xref>). Our results using nanoluciferase reporters indicated that eIF3-responsive mRNA 3’-UTR elements could be used to improve chimeric antigen receptor expression and CAR T cell responsiveness (<xref ref-type="bibr" rid="bib27">Eyquem et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Globerson Levin et al., 2021</xref>; <xref ref-type="bibr" rid="bib92">Watanabe et al., 2018</xref>). We used this information to improve the ability of CAR T cells to kill tumor cells in vitro. With a clinically validated anti-CD19 CAR, we found that using the <italic>TCRA</italic> or <italic>TCRB</italic> mRNA 3’-UTRs dramatically shortened the lag time before the burst in CAR protein expression upon exposure to tumor cells (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). This short lag time correlated with improved tumor cell killing in cytotoxicity assays (<xref ref-type="fig" rid="fig6">Figure 6F and G</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplements 1</xref>–<xref ref-type="fig" rid="fig6s6">6</xref>). Interestingly, using the <italic>TCRA</italic> or <italic>TCRB</italic> mRNA 3’-UTRs for CAR expression also improved CAR T cell propagation in the presence of target tumor cells (<xref ref-type="fig" rid="fig6">Figure 6F and G</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplements 1</xref>–<xref ref-type="fig" rid="fig6s6">6</xref>). Future experiments will be needed to determine the physiological basis for improved propagation of these CAR T cells in the presence of target tumor cells, and to address whether the timing of the CAR translational burst affects CAR T cell exhaustion.</p><p>There are fundamental differences between TCRs and CARs used in the clinic that may not be addressed using the modular nature of the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs. For example, CARs generally have a weaker affinity for their target ligand compared to TCRs for antigens presented on the cell surface (<xref ref-type="bibr" rid="bib92">Watanabe et al., 2018</xref>). Furthermore, CARs do not elicit immune synapses as observed for TCRs (<xref ref-type="bibr" rid="bib25">Dong et al., 2020</xref>). Here, we observed the burst in CAR protein expression using the <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTRs was still not as rapid as that of the endogenous TCR in T cells stimulated by anti-CD3/anti-CD28 antibodies (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). This could be due to multiple factors, including CAR affinity for the CD19 antigen or the activity of the 4-1BB costimulatory domain used in the present CAR (<xref ref-type="bibr" rid="bib45">Kalos et al., 2011</xref>; <xref ref-type="bibr" rid="bib63">Milone et al., 2009</xref>; <xref ref-type="bibr" rid="bib44">June et al., 2014</xref>) instead of the CD28 signaling domain (<xref ref-type="bibr" rid="bib49">Kochenderfer et al., 2009</xref>). It is also possible that the 3’-UTRs of the endogenous TCR subunits, which were left intact in most of the present cytotoxicity assays, and which also responded to CAR signaling (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>), titrated cellular factors required for even shorter response times. T cell engineering to knock out the endogenous TCR 3’-UTRs or improved CAR design may shorten the lag before the burst in CAR expression and further improve CAR T cell function. Taken together, our experiments delineate the central role of eIF3 in T cell activation and highlight the importance of understanding translation regulation in immune cells to open new avenues for engineering improved cell therapies (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Model for robust T cell activation and improved CAR T cell function mediated by eIF3 interactions with the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs.</title><p>Left, a T cell activated upon antigen recognition by the TCR and CD28 costimulatory signal leads to recruitment of the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs to translating ribosomes due to eIF3 binding to the mRNA 3’-UTRs. This results in a short burst in TCRA and TCRB translation followed by a robust increase in T cell function as measured by CD69 and CD25 expression and cytokine release. Right, activation of CAR T cells expressing CAR mRNAs with the <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTRs leads to a burst in CAR translation and improved tumor cell killing.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-fig7-v2.tif"/></fig></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Jurkat cell culture</title><p>Human Jurkat Clone E6-1 (ATCC TIB-152) was purchased from American Type Culture Collection (ATCC). Cells were routinely tested for mycoplasma contamination at the UC Berkeley Cell Culture Facility. Cells were maintained in RPMI 1640 Medium (ATCC modification) with 10% FBS (VWR Life Science Seradigm) and 0.01% Penicillin-Streptomycin (10,000 U/mL) (ThermoFisher). The cells were maintained between 1 x 10<sup>5</sup> cells ml<sup>–1</sup> to 8 × 10<sup>5</sup> cells ml<sup>–1</sup>. When cells were stimulated, they were always maintained at 8 × 10<sup>5</sup> cells ml<sup>–1</sup>.</p></sec><sec id="s4-2"><title>Jurkat cell stimulation</title><p>The Jurkat cells used for the PAR-CLIP experiment were stimulated with 1 X Cell Stimulation Cocktail, containing phorbol 12-myristate 13-acetate (PMA) and ionomycin (ThermoFisher, Cat. #: 00-4970-93) to ensure a large proportion of the cells were activated. Unless otherwise stated, all other experiments involving activated Jurkat cells used anti-CD3/anti-CD28 antibodies (Tonbo) for stimulation. Flat bottom plates were coated with anti-CD3 antibody at a 10 μg/mL concentration, and anti-CD28 antibody was added to the cell culture media at a concentration of 5 µg/mL.</p></sec><sec id="s4-3"><title>Isolation of human primary T cells</title><p>Primary human T cells were isolated from healthy human donors from leukoreduction chambers after Trima Apheresis (Vitalant, formerly Blood Centers of the Pacific). Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples by Ficoll centrifugation using SepMate tubes (STEMCELL) per manufacturer’s instructions. T cells were isolated from PBMCs from all cell sources by magnetic negative selection using an EasySep Human T Cell Isolation Kit (STEMCELL), per manufacturer’s instructions. Unless otherwise noted, isolated T cells were stimulated with anti-CD3/anti-CD28 antibodies (Tonbo) as described above and used immediately.</p></sec><sec id="s4-4"><title>Primary human T cell culture</title><p>Bulk T cells were cultured in XVivo15 medium (Lonza) with 5% fetal bovine serum (FBS), 50 μM 2-mercaptoethanol (Sigma), and 10 μM <italic>N</italic>-acetyl-cystine (Sigma) or ImmunoCult-XF T Cell Expansion Medium (StemCell). Immediately after isolation, T cells were either frozen or stimulated for 2 days with anti-human CD3/CD28 magnetic Dynabeads (ThermoFisher) at a bead to cell concentration of 1:1, along with cytokine IL-2 (UCSF Pharmacy). For T cells cultured after electroporation, the media was supplemented with IL-2 at 500 U/mL. Throughout the culture period T cells were maintained at an approximate density of 1 million cells per mL of media. Every 2–3 days after electroporation, additional media was added, along with fresh IL-2 at 500 U/mL concentration, and the cells were transferred to larger culture flasks as necessary to maintain a density of 1 million cells per mL. For all the other times T cells were maintained at 50 U/mL IL-2 with the addition of fresh media every 2 days.</p></sec><sec id="s4-5"><title>Primary human T cell stimulation</title><p>For edited primary human T cells, the cells were transferred to fresh media lacking IL-2 after 9 days of culturing. The T cells were then stimulated with anti-CD3/anti-CD28 antibodies using flat bottom plates coated with anti-CD3 antibody (Tonbo) at a 10 μg/mL concentration, and anti-CD28 antibody (Tonbo) added to the cell culture media at a concentration of 5 µg/mL. In all other primary human T cell stimulation experiments the cells were stimulated with anti-CD3/anti-CD28 antibodies as mentioned above along with 50 U/mL IL-2.</p></sec><sec id="s4-6"><title>4-Thiouridine optimization for PAR-CLIP experiments</title><p>We used Jurkat cells as a model for T cells, as PAR-CLIP experiments require a large number of cells labeled with 4-thiouridine (Sigma) at a non-toxic concentration (<xref ref-type="bibr" rid="bib5">Ascano et al., 2012</xref>). Jurkat cells also have a defined T cell receptor and transcriptome, avoiding the donor-to-donor variability of primary T cells. Jurkat cells were seeded, so that they reached 8 × 10<sup>5</sup> cells ml<sup>–1</sup> seeding density on the day of the experiment. Varying concentrations of 4-thiouridine (s4U) were added to the cells (50 µM, 75 µM, 100 µM, or none as a negative control). The cells were then incubated for different time points: 8, 10, 12, or 16 hr. After each incubation time, cell viability was determined using the CellTiter-Glo assay (Promega), according to the manufacturer’s instructions. Concentrations at which the relative luminescence in the presence of s<sup>4</sup>U (luminescence of the s<sup>4</sup>U treated cells/luminescence of the untreated cells) exceeded 95% were considered non-toxic. Based on these measurements, we used 50 µM of 4-thiouridine for PAR-CLIP experiments.</p></sec><sec id="s4-7"><title>PAR-CLIP</title><p>Two biological replicates were used to perform PAR-CLIP analysis as described in <xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>, with modifications for Jurkat cells. 50 µM of 4-thiouridine was determined as non-toxic to Jurkat cells over the time course of the PAR-CLIP experiments (<xref ref-type="bibr" rid="bib5">Ascano et al., 2012</xref>). A total of 55 million Jurkat cells seeded at 8 × 10<sup>5</sup> cells ml<sup>–1</sup> was treated with 50 µM of 4-thiouridine for 7 hr, then stimulated with 1 X Cell Stimulation Cocktail for 5 hr in media containing 50 µM of 4-thiouridine (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The same number of cells were treated with 50 µM of 4-thiouridine for 12 hr without stimulation as a non-activated control. The cells were then crosslinked on ice with 365 nm UV irradiation at an energy dose of 0.2 J cm<sup>–2</sup>. The cells were pelleted by centrifugation at 100 x g for 15 min at 4 °C, and the pellet was resuspended in three volumes of NP40 lysis buffer (50 mM HEPES-KOH pH 7.5, 150 mM KCl, 2 mM EDTA, 0.5% Nonidet P-40 alternative, 0.5 mM dithiothreitol (DTT), 1 Complete Mini EDTA-free Protease Inhibitor Cocktail tablet (Roche)). The cell suspension was then incubated on ice for 10 min, passed through an 18 G needle five times, and centrifuged at 13,000 x g for 15 min at 4 °C and RNAs were lightly digested by treatment with MNase (Thermo Scientific) at a final concentration of 0.05 U μl<sup>–1</sup> for 20 min at 16 °C. For each PAR-CLIP assay, 1000 μl of Dynabeads (Invitrogen) and 800 μl of anti-EIF3B antibody (Bethyl A301-761A) were used. The remaining steps of the PAR-CLIP analysis were performed exactly as described in <xref ref-type="bibr" rid="bib22">Danan et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref> with the exception of using MNase at 5 U μl<sup>–1</sup> for the on-bead digestion step.</p></sec><sec id="s4-8"><title>Mass spectrometry</title><p>To identify eIF3 subunits that crosslinked with RNAs in the PAR-CLIP experiments, a portion of eIF3 immunoprecipitated using Dynabeads as described above were treated with nonradioactive ATP (NEB) during the T4 polynucleotide kinase labeling step. The nonradioactive samples were then run on the same gel next to the radiolabeled PAR-CLIP samples, Coomassie stained (Pierce) and the bands that matched with the phosphorimager printout were excised from the gel and submitted for identification using one-dimensional LC-MS/MS (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p></sec><sec id="s4-9"><title>PAR-CLIP computational analysis</title><p>PAR-CLIP cDNA libraries were sequenced on an Illumina HiSeq 2,500 platform. To eliminate potential PCR biases during PAR-CLIP library preparation, a random bar code was introduced into the 3’ adapter and all the reads that matched the random barcode were collapsed into single reads. Clusters of overlapping sequence reads mapped against the human genome version hg38 were generated using the PARalyzer software (<xref ref-type="bibr" rid="bib20">Corcoran et al., 2011</xref>) incorporated into the PARpipe pipeline (<ext-link ext-link-type="uri" xlink:href="https://ohlerlab.mdc-berlin.de/software/PARpipe_119/">https://ohlerlab.mdc-berlin.de/software/PARpipe_119/</ext-link>, <xref ref-type="bibr" rid="bib66">Mukherjee et al., 2019</xref>) with the settings below. Binding sites were categorized using the Gencode GRCh38.p12 GTF annotations (gencode.v21.annotation.gtf), <ext-link ext-link-type="uri" xlink:href="https://www.gencodegenes.org/human/">https://www.gencodegenes.org/human/</ext-link>.</p><p>The PARpipe settings used were:</p><list list-type="bullet"><list-item><p>Conversion = T &gt; C</p></list-item><list-item><p>Minimum read count per group = 5</p></list-item><list-item><p>Minimum read count per cluster = 7</p></list-item><list-item><p>Minimum read count for kde = 3</p></list-item><list-item><p>Minimum cluster size = 11</p></list-item><list-item><p>Minimum conversion locations for cluster = 2</p></list-item><list-item><p>Minimum conversion count for cluster = 2</p></list-item><list-item><p>Minimum read count for cluster inclusion = 1</p></list-item><list-item><p>Minimum read length = 20</p></list-item><list-item><p>Maximum number of non conversion mismatches = 1</p></list-item></list></sec><sec id="s4-10"><title>Comparison of eIF3 PAR-CLIP results in Jurkat and HEK293T cells</title><p>To compare RNAs in activated Jurkat cells crosslinked to eIF3 with those crosslinked to eIF3 in HEK293T cells (<xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>), the gene cluster lists (*.gene_cl.csv) from APA_REP1, APA_REP2, APB_REP1, APB_REP2, APD_REP1, and APD_REP2 were used (see <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). The genes were first sorted by total read counts (‘ReadCountSum’) from high to low for each library to obtain the top candidate genes. Then, the same number of top candidate genes from these sorted lists as the number of genes identified in HEK293T cells, for eIF3 subunit EIF3A, EIF3B, and EIF3D crosslinked to RNA (<xref ref-type="bibr" rid="bib54">Lee et al., 2015</xref>), were chosen for comparison. We could not compare RNAs in non-activated Jurkat cells to those in HEK293T cells for the EIF3A/B/C or EIF3D/L samples (NPA_REP1, NPA_REP2, NPD_REP1, NPD_REP2 libraries) due to the low numbers of RNAs that crosslinked to eIF3 in these conditions (157 or 165 RNAs in the EIF3A/B/C samples, and 117 or 126 RNAs in the EIF3D/L samples). In the EIF3B/C samples (NPB_REP1 and NPB_REP2) more RNAs crosslinked to these subunits. However, only 8 RNAs in the NPB_REP1 sample and only 27 RNAs in the NBP_REP2 sample had ReadCountSum values exceeding the threshold used for the APB_REP1 and APB_REP2 libraries from activated cells.</p></sec><sec id="s4-11"><title>PAR-CLIP pathway analysis</title><p>To determine biological pathways enriched in the set of mRNAs that crosslinked to eIF3 in activated Jurkat cells, genes with at least 100 total aligned reads were used, as determined in the PARpipe analysis described above (<xref ref-type="bibr" rid="bib66">Mukherjee et al., 2019</xref>), from the EIF3A/C/B samples. Since PAR-CLIP reads are short, it is not possible to determine with certainty which mRNA transcript isoform cross-linked with eIF3. Therefore the most abundant mRNA transcript isoform for each gene was chosen, as determined by transcriptome profiling using kallisto (protein_coding category) (<xref ref-type="bibr" rid="bib11">Bray et al., 2016</xref>), as described in the Transcriptome Profiling section. Even with this choice, eIF3 crosslinks to mRNAs do not correlate with mRNA abundance (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>). Human genome GRCh38.p13 annotation was used to extract mRNA lengths by 5’-UTR, coding region and 3’-UTR (Ensembl Biomart) (<xref ref-type="bibr" rid="bib21">Cunningham et al., 2019</xref>). These genes were then sorted by the density of PAR-CLIP reads in the mRNA 5’-UTR region, prior to mapping pathways of transcripts that crosslinked to eIF3. Due to the complexity of <italic>TCRA</italic> and <italic>TCRB</italic> transcript annotation, these transcripts were excluded from the normalization calculation, but included in the pathway analysis. The top 500 genes from the resulting EIF3A/C/B PAR-CLIP gene lists were used, sorted as described above, to analyze gene enrichment profiles in the STRING database (<xref ref-type="bibr" rid="bib83">Szklarczyk et al., 2019</xref>). The top tissue-specific categories involve the immune system and T cell function (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). Note that the STRING database categories are not mutually exclusive gene lists, and do not include TCR subunits in its analysis.</p></sec><sec id="s4-12"><title>Metagene analysis</title><p>The PAR-CLIP genes sorted as described above in the ‘PAR-CLIP pathway analysis’ were used and mapped against the most abundant mRNA transcript isoforms to generate cumulative plots of the reads. Reads for the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs were manually extracted from the Bowtie version 1.0.0 Hg38 alignment of the eIF3 PAR-CLIP reads. We did not identify reads mapped to the D segment of <italic>TCRB</italic> (e.g. to <italic>TRBD2</italic>) due to its short length of 16 nucleotides. These reads were combined with the mapped reads in the *.read.csv files generated by Parpipe. The combined reads were then sorted to extract only reads annotated as 5’-UTR, start codon, coding, stop codon, and 3’-UTR. The most abundant transcript isoform, as identified in the Transcriptome Profiling section using kallisto (described below) was used. Reads mapped to the 5’-UTR and start codon were normalized by the length of the 5’-UTR. Reads mapped to the coding region and stop codon were normalized by the length of the coding region. Finally, reads mapped to the 3’-UTR were normalized to the length of the 3’-UTR. Relative positions of the mapped reads along a metagene were computed based on the locations each mapped read fell within its respective feature. Relative positions were from –1 to 0 for the 5’-UTR, 0 to 1 for the coding region, and 1 to 2 for the 3’-UTR. 5’-UTR values were computed by multiplying the relative position by –1, whereas the 3’-UTR values were computed by adding one to the relative position. Coding region relative positions were unchanged.</p><p>The empirical cumulative distribution frequency function from R package ggplot2 (<xref ref-type="bibr" rid="bib93">Wickham and Chang, 2016</xref>) was used to build the metagene plots from the vector of relative positions for the reads which mapped to a given set of reads. We defined mRNAs having a ratio of normalized 5’-UTR reads divided by 3’-UTR reads of 20 or more as ‘5’-UTR enriched’ with respect to eIF3 crosslinking. All others were categorized as ‘pan-mRNAs’, with eIF3 crosslinking across the entire length of the mRNA. The cut-off value 20 is not a sharp boundary between the two categories of mRNA (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>).</p></sec><sec id="s4-13"><title>Transcriptome profiling</title><p>RNA samples were extracted from non-activated Jurkat cells or Jurkat cells activated for 5 hr with I + PMA, using the Direct-zol RNA Miniprep kit (Zymo Research). The libraries were prepared using TruSeq Stranded RNA LT Ribo-Zero Gold kit (Illumina) following the manufacturer’s instructions, with two biological replicates. Cutadapt (version 2.6) (<xref ref-type="bibr" rid="bib60">Martin, 2011</xref>) with a minimum read length of 20, 5’ end with a cutoff of 15 and the 3’ end with a cutoff of 10 in paired-end mode was used to remove adapters. RNA-seq reads were pseudoaligned using kallisto v.0.46.0 run in quant mode with default parameters to estimate transcript abundance (transcripts per million, TPM) (<xref ref-type="bibr" rid="bib11">Bray et al., 2016</xref>). The transcript index for kallisto was made with default parameters and GENCODE Release 32 (GRCh38.p13) FASTA file (<xref ref-type="bibr" rid="bib28">Frankish et al., 2019</xref>).</p></sec><sec id="s4-14"><title>RNA-FISH and immunofluorescence</title><p>Jurkat cells were washed with PBS, fixed with 3.7% (vol./vol.) paraformaldehyde (VWR) for 10 min at room temperature and washed three times with PBS. PBS was discarded and 1 ml 70% ethanol was added. The cells were incubated at 4 °C for 16 hr. The 70% ethanol was aspirated and the cells were washed once with 0.5 ml Stellaris RNA wash buffer A (Biosearch technologies). The cells were then incubated with 100 μl Stellaris hybridization buffer (Biosearch Technologies) containing Stellaris RNA FISH probes (Biosearch Technologies) at a final concentration of 125 nM (<xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>) and with the relevant antibody (<xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>) for 16 hr at 28 °C. The cells were then washed twice with 0.5 ml Stellaris RNA wash buffer A containing secondary antibody conjugated with a fluorophore for 30 min at 37 °C in the dark. The second Stellaris RNA wash buffer A contained DAPI in addition to the secondary antibody. Finally, the cells were washed once with 0.5 mL Stellaris RNA wash buffer B and mounted with mounting solution (Invitrogen). All high-resolution images were taken using confocal ZEISS LSM 880 in Airyscan super-resolution mode, equipped withA Plan-Apochromat 63 x/1.4 Oil objective (Zeiss). To measure colocalization of <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs with each other or with P bodies (using DCP1 antibody, <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>) or stress granules (G3BP1 antibody, <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>) the cells were mounted along with 0.1 µm TetraSpeck microspheres (ThermoFisher) adhered to the slide according to manufacturer’s instructions, to be able to account for the chromatic shift during image acquisition.</p></sec><sec id="s4-15"><title>Colocalization analysis</title><p>To measure colocalization of <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs with each other or with P bodies (using DCP1 antibody) or stress granules (G3BP1 antibody), immunofluorescently labeled cells (see above) were mounted along with 0.1 µm TetraSpeck microspheres (ThermoFisher) adhered to the slide according to manufacturer’s instructions. The microspheres allowed for the correction of lateral and axial chromatic aberrations during image acquisition.</p><p>Z-stacks were acquired with 35 nm x 35 nm x 190 nm voxels on a ZEISS LSM 880 in Airyscan super-resolution mode, equipped with a Plan-Apochromat 63 x/1.4 Oil objective (Zeiss). The images were then deconvolved to a lateral resolution of ≈150 nm and an axial resolution of ≈500 nm (as confirmed by observing the discrete Fourier transform of the z-stacks). After imaging a single cell, beads that were on the slide axial to the cell were imaged to measure the corresponding lateral and axial chromatic aberrations.</p><p>To quantify the relative colocalization, we developed an automated processing and analysis pipeline in ImageJ 1.52p available on github: <ext-link ext-link-type="uri" xlink:href="https://github.com/Llamero/TCR_colocalization_analysis-macro">https://github.com/Llamero/TCR_colocalization_analysis-macro</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:d3a725357f9583e2d915b70ad9a513dd62bddf54;origin=https://github.com/Llamero/TCR_colocalization_analysis-macro;visit=swh:1:snp:e6dc14170cc0d4448cbed1f13435930e2b5db8eb;anchor=swh:1:rev:95714d5f24259dd03aa5c184a15b9d5f1bb17b40">swh:1:rev:95714d5f24259dd03aa5c184a15b9d5f1bb17b40</ext-link>, <xref ref-type="bibr" rid="bib59">Marson, 2021</xref>). Specifically, the chromatic aberrations in the z-stacks were compensated for by registering the channels of the bead z-stack to one another, and then applying the same registration vectors to the corresponding channels in the cell z-stack (<xref ref-type="bibr" rid="bib71">Parslow et al., 2014</xref>). Each channel of a z-stack was then thresholded to remove background in the image, and then the colocalization between each pair of images was measured using the Pearson’s correlation coefficient. Samples in which any pair of channels in the bead z-stack had a correlation of less than 0.45 were removed from final analysis, as this suggested that the images had insufficient dynamic range in at least one of the channels for an accurate deconvolution.</p></sec><sec id="s4-16"><title>Polysome analysis of eIF3-associated mRNAs</title><p>To isolate polysomes from Jurkat cells, the cells were seeded to reach 8 × 10<sup>5</sup> cells ml<sup>–1</sup> on the day of harvest and then stimulated with anti-CD3/anti-CD28 antibodies as described above for 5 hr. To isolate polysomes from primary human T cells, the cells were seeded to reach 1 × 10<sup>6</sup> cells/mL on the day of harvest and then stimulated with anti-CD3 and anti-CD28 antibodies as described above for 1 hr. Both Jurkat and primary human T cells were treated with 100 μg ml<sup>–1</sup> cycloheximide (VWR) 5 min before harvesting. Cells were then collected into a 50 ml falcon tube and rinsed once with ice cold PBS (ThermoFisher) supplemented with 100 μg ml<sup>–1</sup> cycloheximide. The cells were then incubated with 0.5 mM of the crosslinking reagent dithiobis (succinimidyl propionate) (DSP, Thermofisher, Cat. #: PG82081) and 100 μg ml<sup>–1</sup> cycloheximide in PBS at room temperature for 15 min, with rocking. The crosslinking reagent was then removed and the cells were incubated with quenching reagent (PBS, 100 μg ml<sup>–1</sup> cycloheximide and 300 mM Glycine(Sigma)) for 5 min on ice. The cells were then rinsed again with ice cold PBS and flash frozen in liquid nitrogen.</p><p>A total of 4 × 10<sup>8</sup> cells were lysed with 400 μl hypotonic lysis buffer (10 mM Hepes pH 7.9, 1.5 mM MgCl<sub>2</sub>, 10 mM KCl, 0.5 mM DTT, 1% Triton, 100 μg ml<sup>–1</sup> cycloheximide, and one Complete EDTA-free Proteinase Inhibitor Cocktail tablet (Roche)). The cells were incubated for 10 min on ice and then passed through an 18-G needle five times, and centrifuged at 13,000× g for 15 min at 4 °C. The 400 μl supernatant was then transferred to a fresh eppendorf tube and subjected to RNase H digestion by adding the following reagents: 3 mM MgCl<sub>2</sub>, 10 mM DTT, 200 units RNase H (NEB) and 20 μl of SUPERasIN (ThermoFisher), with a total of 4 μM DNA oligos (IDT), as indicated in the figure legends. The mixture was then incubated at 37 °C for 20 min. After incubation 10 μl of the RNase H treated lysate mixture was isolated to test the efficiency of the RNase H digestion using qRT-PCR (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B, D and G</xref>) and the rest of the lysate was layered onto a 12 ml 10%–50% sucrose gradient, made with gradient buffer consisting of: 10% sucrose (w/v) or 50% sucrose (w/v), 100 mM KCl, 20 mM Hepes pH 7.6, 5 mM MgCl<sub>2</sub>, 1 mM DTT and 100 μg ml<sup>–1</sup> cycloheximide. The gradient was centrifuged at 36,000 rpm (222 k x g) for 2 hr at 4 °C in a SW-41 rotor. The gradient was then fractionated using the Brandel gradient fractionator and ISCO UA-6 UV detector and all the polysome fractions ( ~ 5 ml) were collected into a fresh 15 ml falcon tube. From each of the polysome fractions, 100 μl was kept aside to measure the input RNA amounts, and the rest of each polysome fraction was incubated with 100 μl of Dynabeads (Invitrogen) conjugated with 40 μl of anti-EIF3B antibody (Bethyl A301-761A) for 16 hr, rotating at 4 °C. After incubation, the beads were rinsed three times with 1000 μl room temperature NP40 lysis buffer (defined in the PAR-CLIP section), rotating for 5 min for each wash. After the final wash the beads were resuspended in 400 μl of Trizol (Thermofisher), the RNA was extracted and qRT-PCR was performed as described above.</p></sec><sec id="s4-17"><title>Western blot</title><p>Western blot analysis was performed using the antibodies listed in <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>.</p></sec><sec id="s4-18"><title>Total mRNA isolation and quantitative RT-PCR analysis</title><p>Total RNA was isolated from whole cells for qRT-PCR using Quick RNA miniprep plus kit from Zymo Research following the manufacturer’s instructions. Quantitative RT-PCR analysis was performed using the Power SYBR Green RNA-to-Ct 1-Step kit (Applied Biosystems) according to the manufacturer’s instructions, and the QuantStudio 3 Real-Time PCR System (ThermoFisher). Each target mRNA was quantified in three biological replicates, with each biological replicate having three technical replicates.</p></sec><sec id="s4-19"><title>Plasmids</title><p>Nanoluciferase reporters (<xref ref-type="bibr" rid="bib35">Hall et al., 2012</xref>) were constructed using the 5’-UTR of the human beta globin mRNA (<italic>HBB</italic>) and a PEST destabilization domain. The PEST domain reduces protein half-life (<xref ref-type="bibr" rid="bib89">Voon et al., 2005</xref>) and was used to provide better time resolution of nanoluciferase expression after T cell activation. The <italic>TCRA</italic> 3’-UTR and <italic>TCRB</italic> 3’-UTR sequences were amplified from Jurkat genomic DNA. The nanoluciferease sequence fused to a PEST domain was amplified from pNL1.2[<italic>NlucP</italic>] Vector Sequence (Promega) and was cloned into a modified CD813A vector (<ext-link ext-link-type="uri" xlink:href="http://www.integratedsci.com.au/brands/system-biosciences.html">System Biosciences</ext-link>) using the In-Fusion HD Cloning Kit (Takara). The subsequent mutations in the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs were generated using these initial constructs. For <italic>TCRA</italic> Δ<italic>PAR</italic> constructs, nucleotides 102–338 in the 3’-UTR of <italic>TCRA</italic> mRNA were deleted. For <italic>TCRB</italic> Δ<italic>PAR</italic> constructs, nucleotides 16–161 in the 3’-UTR of <italic>TCRB</italic> mRNA were deleted. <italic>TCRA/TCRB</italic> Δ<italic>PAR</italic>, <italic>TCRA/TCRB R*PAR, 3’-LTR</italic> (3’-Long Terminal Repeat), <italic>JUN</italic> 5’-UTR hairpin (<xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>) and HCV IRES domain III (<xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>) sequences were purchased as gblocks from IDT and were cloned into this plasmid backbone. The <italic>WPRE</italic> (Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element) 3’-UTR sequence was amplified from the CD813A-1 (System Biosciences) vector.</p><p>For nanoluciferase reporters designed to be membrane-tethered, we fused the N-terminal sequence of CD3-zeta spanning the transmembrane helix (amino acids 1–60) ordered as a gblocks from IDT to the nanoluciferase sequence above. To prevent interaction of the CD3-zeta-nanoluciferase fusion protein with the TCR, we made mutations in the CD3-zeta-derived transmembrane helix that would disrupt interactions with the TCR, based on the cryo-EM structure of the complex (<xref ref-type="bibr" rid="bib24">Dong et al., 2019</xref>) (PDB entry 6JXR) and consistent with earlier biochemical results (<xref ref-type="bibr" rid="bib13">Call et al., 2002</xref>). The two mutations, L35F and D36V, are predicted to introduce a steric clash and disrupt an intra-membrane salt bridge, respectively, with other subunits in the TCR holo-complex. These CD3-zeta-nanoluciferase chimeras were cloned into the modified CD813A plasmids described above.</p></sec><sec id="s4-20"><title>Generation of primary human T cells stably expressing nanoluciferase reporters</title><p>For lentiviral production, HEK293T cells were plated at a density of 80% in T-75 flasks the night before transfection. The cells were then transfected with plasmids: expressing the nanoluciferase, PsPAX2 and pCMV-VSV-G using the Lipofectamine 2000 reagent (ThermoFisher) following the manufacturer’s instructions. Forty-eight hours after transfection, the viral supernatant was collected, filtered, and concentrated using PEG-it Virus Precipitation Solution (System Biosciences) following the manufacturer’s instructions. The virus pellets were then resuspended in ImmunoCult-XF T Cell Expansion media and stored in –80 °C.</p><p>The primary human T cell transductions were done with multiple viral titers using TransDux MAX Lentivirus Transduction Reagent (System Biosciences) following the manufacturer’s instructions. To test the viral transduction efficiency of the cells, 48 hr after viral transduction the percent of cells expressing GFP was measured by FACS analysis and cells expressing less than 30% GFP were treated with 1 µg ml<sup>–1</sup> puromycin (ThermoFisher) for 4 days or until ~90% of the cells were GFP positive.</p></sec><sec id="s4-21"><title>Luciferase reporter assays</title><p>The stable cell lines expressing the nanoluciferase reporters were stimulated with anti-CD3/anti-CD28 antibodies with 50 U/mL IL-2 and the nanoluciferase activity was assayed after 30 min, 1 hr, 3 hr, and 5 hr after stimulation using Nano-Glo Luciferase Assay System (Promega). For each time point, 200,000 cells were tested in triplicate for each cell line.</p><p>For assays of TCR and CD28 signaling requirements, the stable cell lines were stimulated with anti-CD3 or anti-CD28 antibodies individually in the presence of 50 U/mL IL-2, and assayed as described above. To identify signaling pathways downstream of CD28, cells were incubated with AKT inhibitor AZD5363 at 1 μM (Cayman Chemical), mTOR inhibitor Torin 1 at 250 nM (Cayman Chemical) or DMSO for 3 hr prior to T cell activation with anti-CD3/anti-CD28 antibodies (Tonbo) as indicated above. The cells were assayed as described above, and the extent of AKT and mTOR inhibition were determined by western blot analysis of phosphorylation of their substrates GSK-3β and 4E-BP1, respectively.</p></sec><sec id="s4-22"><title>RNA immunoprecipitation and qPCR</title><p>The EIF3B-RNA immunoprecipitations were carried out following the exact same conditions used for the PAR-CLIP analysis with the following changes. For each immunoprecipitation, cell lysates were prepared in NP40 lysis buffer (defined in the PAR-CLIP section) with 4 million cells. The lysates were then incubated with 50 μl Protein G Dynabeads conjugated with 20 μl of anti-EIF3B antibody (Bethyl A301-761A) for two hours at 4 °C. After incubation, the flow through was removed and the beads were washed three times with 1 ml NP40 lysis buffer for each wash. The beads were then resuspended in 400 μl TRIzol reagent (ThermoFisher) and vortexed for 1 min. The RNA was extracted following the manufacturer’s instructions and qPCR was performed as described above using primers listed in <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>.</p></sec><sec id="s4-23"><title>sgRNA/Cas9 RNP production</title><p>The sgRNA/Cas9 RNPs used to edit Jurkat cells were produced by complexing sgRNA (Synthego) to Cas9 as described (<xref ref-type="bibr" rid="bib80">Schumann et al., 2015</xref>) while RNPs to edit Primary Human T cells were produced by complexing a two-component gRNA (crRNA and tracrRNA, Dharmacon) to Cas9 as described in <xref ref-type="bibr" rid="bib76">Roth et al., 2018</xref>. The targeting sequences for the sgRNAs and crRNA are given in <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>. Recombinant Cas9-NLS was obtained from MacroLab in the California Institute for Quantitative Biosciences.</p></sec><sec id="s4-24"><title>Primary T cell and Jurkat genome editing</title><p>Jurkat cells used for electroporation were collected at passage five or lower and were maintained at a seeding density of 8 × 10<sup>5</sup> cells ml<sup>–1</sup> or lower. Primary T cells were isolated as described above. Prior to electroporation the Primary T cells were stimulated with magnetic anti-CD3/anti-CD28 Dynabeads (ThermoFisher) for 48 hr. After 48 hr, these beads were removed from the cells by placing cells on an EasySep cell separation magnet for 2 min before electroporation. One million Jurkat (not activated) or primary T cells cells (activated with anti-CD3/anti-CD28 Dynabeads for 48 hr) were rinsed with PBS and then resuspended in 20 µl of Lonza electroporation buffer P3. The cells were then mixed with 2.5 μl Cas9 RNPs (50 pmol total) along with 2 μl of a 127-nucleotide non-specific single-stranded DNA oligonucleotide at 2 μg μl<sup>–1</sup> (4 μg ssDNA oligonucleotide total). The cells were then electroporated per well using a Lonza 4D 96-well electroporation system with pulse code DN100 for Jurkat cells and EH115 for primary human T cells. Immediately after electroporation, 80 μl of pre-warmed media (without cytokines) was added to each well, and the cells were allowed to rest for 15 min at 37 °C in a cell culture incubator while remaining in electroporation cuvettes. After 15 min, cells were moved to final culture flasks. Jurkat cells were clonally selected by single cell sorting into U-bottomed 96-well plates and by testing each clone using PCR primers flanking the editing site (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). The clones producing a single PCR band of 1283 bp and 1022 bp were selected as clonal populations for <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR,</italic> respectively.</p><p>Genome edited populations of primary T cells with the <italic>TCRA</italic> Δ<italic>PAR</italic> and <italic>TCRB</italic> Δ<italic>PAR</italic> mutations were determined by measuring the density of the PCR bands described above resulting from the edited cell population compared to the PCR band from non edited cells, using ImageJ. To compare with the <italic>TCRA</italic> Δ<italic>PAR</italic> or <italic>TCRB</italic> Δ<italic>PAR</italic> primary T cell populations, we edited cells from both donors using each gRNA targeting the <italic>TCRA</italic> 3’-UTR and <italic>TCRB</italic> 3’-UTR region separately (single gRNA experiments), a gRNA targeting the coding sequence (CDS) of <italic>TCRA</italic> which knocks out TCR expression with high efficiency (Δ<italic>TCR</italic>) (<xref ref-type="bibr" rid="bib76">Roth et al., 2018</xref>), a scrambled gRNA (SC) which does not target any site in the human genome, and cells mixed with the gRNA/Cas9 RNPs but not nucleofected.</p></sec><sec id="s4-25"><title>Analysis of TCR cluster formation</title><p>WT, <italic>TCRA ΔPAR,</italic> or <italic>TCRB ΔPAR</italic> T cells were activated with anti-CD3/anti-CD28 antibodies for 1, 3, or 5 hr, as described above. Cells were collected and stained with anti-TCRA antibodies, followed by a secondary antibody Alexa Fluor 488 goat anti-mouse IgG (Invitrogen). For the counting of cells containing TCR clusters, immunofluorescent imaging was performed on a Revolve Epi-Fluorescence microscope (Echo), equipped with an A Plan-Apochromat 40 x objective (Olympus). Cells with substantial puncta (arrows in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>) were scored as having TCR cluster formation (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p></sec><sec id="s4-26"><title>Flow cytometry and cell sorting</title><p>Flow cytometric analysis was performed on an Attune NxT Acoustic Focusing Cytometer (ThermoFisher). Surface staining for flow cytometry and cell sorting was performed by pelleting cells and resuspending in 50 μl of FACS buffer (2% FBS in PBS) with antibodies at a 1:100 concentration (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>) for 20 min at 4 °C in the dark. Cells were washed twice in FACS buffer before resuspension and analysis. For the analysis of cell surface TCR levels, the gate for TCR+ cells was set based on analysis of TCR levels in the TCR knockout (Δ<italic>TCR</italic>) T cells. The gates for CD69+ and CD25+ cells were set based on CD69 and CD25 levels in the Δ<italic>TCR</italic> T cells.</p></sec><sec id="s4-27"><title>ELISA</title><p>The cell culture supernatants were collected after each time point of activation with anti-CD3/anti-CD28 antibodies for WT, <italic>TCRA ΔPAR,</italic> or <italic>TCRB ΔPAR</italic> cells. For each timepoint, the same number of cells were used from each strain to be able to compare across strains and time points. The amount of secreted IL-2 in the cell suspensions after activation anti-CD3/anti-CD28 antibodies for WT, <italic>TCRA ΔPAR</italic> or <italic>TCRB ΔPAR</italic> cells were measured by ELISA MAX Deluxe Set Human IL-2 (BioLegend) according to the manufacturer’s instructions.</p></sec><sec id="s4-28"><title>Chimeric antigen receptor (CAR) construct sequences</title><p>The CDS region of the Juno anti-CD19 chimeric antigen receptor (<xref ref-type="bibr" rid="bib44">June et al., 2014</xref>; <xref ref-type="bibr" rid="bib45">Kalos et al., 2011</xref>) or the Kite anti-CD19 chimeric antigen receptor (<xref ref-type="bibr" rid="bib50">Kochenderfer et al., 2010</xref>; <xref ref-type="bibr" rid="bib49">Kochenderfer et al., 2009</xref>) (GenBank entry HM852952.1), both presently used in the clinic, were cloned into CD813A lentiviral vectors (Systems Biosciences) with a common core EF1alpha promoter and 5’-UTR with an inserted intron. The CDS sequence was followed by various 3’-UTRs. Two of the 3’-UTRs are presently used in clinical CAR T cells, the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (<italic>WPRE</italic>) (<xref ref-type="bibr" rid="bib44">June et al., 2014</xref>; <xref ref-type="bibr" rid="bib63">Milone et al., 2009</xref>), or the murine stem cell virus (MSCV) retroviral 3’-long terminal repeat (<italic>3’-LTR</italic>) (<xref ref-type="bibr" rid="bib49">Kochenderfer et al., 2009</xref>). We also cloned the full <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTR sequences including the polyadenylation sites after the anti-CD19 CAR CDS sequence.</p></sec><sec id="s4-29"><title>Production of CAR T cells</title><p>Production of the CAR-expressing lentiviruses was carried out as described above using HEK293T cells. The viruses were then concentrated using PEG-it Virus Precipitation Solution (System Biosciences) following the manufacturer’s instructions. The virus pellets were then resuspended in ImmunoCult-XF T Cell Expansion media and stored in –80 °C. Frozen primary human T cell pellets were thawed and then stimulated at a starting density of approximately 1 million cells per mL of media with ImmunoCult Human CD3/CD28/CD2 T Cell Activator (Stemcell) for 48 hr and then transduced with various CAR viruses using TransDux MAX Lentivirus Transduction Reagent (System Biosciences) as described above. Two days after transduction the percent of cells expressing GFP was measured by FACS analysis and cells expressing less than 30% GFP were treated with 1 µg mL<sup>–1</sup> puromycin (ThermoFisher) for 2 days or until ~90% of the cells are GFP positive. After removal of puromycin the cells were seeded at 1 × 10<sup>6</sup> cells/mL up to 9 days from the day the cells were transduced by adding fresh ImmunoCult-XF T Cell Expansion Medium (StemCell) and fresh IL-2 (500 U/mL or 50 U/mL) every other day. The amount of IL-2 added varied based on the experiment performed as mentioned in the figure legends. After 9 days, the CAR T cells were used for various assays.</p></sec><sec id="s4-30"><title>Production of TCR knockout CAR T cells</title><p>Frozen primary human T cell pellets were thawed and then stimulated at a starting density of approximately 1 million cells per mL of media with anti-human CD3/CD28 Dynabeads (ThermoFisher), at a bead to cell ratio of 1:1, and cultured in ImmunoCult-XF T Cell Expansion media containing IL-2 (500 U ml<sup>−1</sup>;Peprotech), IL-7 (5 ng ml<sup>−1</sup>; ThermoFisher), and IL-15 (5 ng ml<sup>−1</sup>; Life Tech). After 24 hr of stimulation, cells still attached to the Dynabeads were transduced with various CAR lentiviruses using TransDux MAX Lentivirus Transduction Reagent (System Biosciences) as described above. After 48 hr of stimulation (i.e. 24 hr after viral transduction), the beads were removed from the cells by placing cells on an EasySep cell separation magnet for 2 min before electroporation. One million CAR T cells were then electroporated with Cas9 RNP targeting the <italic>TCRA</italic> CDS (<xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>) using the pulse code EH115 as described above. Immediately after electroporation, 80 μL of pre-warmed media was added to each well and incubated at 37 °C for 20 min. Cells were then transferred to a round bottom 96-well plate with 50 U/mL IL-2 at 1 × 10<sup>6</sup> cells /mL in appropriate tissue culture vessels. Three days after the nucleofection, the percent of cells expressing GFP was measured by FACS analysis and cells expressing less than 30% GFP were treated with 1 µg mL<sup>–1</sup> puromycin (ThermoFisher) for 2 days or until ~90% of the cells were GFP positive. After removal of puromycin the cells were seeded at 1 × 10<sup>6</sup> cells/mL up to 9 days from the day the cells were transduced by adding fresh ImmunoCult-XF T Cell Expansion Medium (StemCell) and fresh IL-2 (50 U/mL) every other day. After 9 days the CAR T cells were used for various assays.</p></sec><sec id="s4-31"><title>CAR expression dynamics</title><p>To measure CAR expression dynamics by western blot analysis, CAR T cells were incubated with NALM6 tumor cells at a ratio of 1:2 CAR T cell:NALM6 cells, in ImmunoCult-XF T Cell Expansion Medium (StemCell) and 50 U/mL IL-2. Cells were collected at the indicated time points and processed for western blot analysis as described above. The total protein expression level of the anti-CD19 CAR was detected with an anti-CD3z antibody (Santa Cruz Biotechnology).</p></sec><sec id="s4-32"><title>CAR T-cell cytotoxicity assays</title><p>CAR T-cell cytotoxicity was determined using a FACS based assay. First, NALM6 or Jeko 1 tumor cells were stained with CTV (CellTrace Violet, Thermofisher). Cells were resuspended in 10 mL PBS (5 × 10<sup>6</sup> cells), 5 μl CTV was added, and the cells were incubated for 20 min at 37 °C. After incubation, 30 mL of RPMI media was added and the cells incubated for an additional 5 min at 37 °C. The cells were then gently pelleted, rinsed and resuspended in fresh ImmunoCult-XF T Cell Expansion Medium (StemCell) and 50 U/mL IL-2. Then in a round bottom 96-well plate, 20,000 stained tumor cells were cocultured with CAR T cells at different effector-target ratios in a total volume of 200 μL for 24, 48, and 72 hr. T cells transduced with a membrane-tethered nanoluciferase reporter containing the <italic>TCRA</italic> 3’-UTR (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) were used as a negative control. The CAR T cell killing capacity was measured by Flow Cytometry as diagrammed in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>. Briefly, the 96-well plates were incubated at 4 °C for 30 min to terminate the killing by CAR T cells. Then 2 μL of propidium iodide (1000 x stock, Thermofisher) was added to each column in the plate one by one and the dead and living tumor cells, as well as live T cells, were measured as shown in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>A provisional patent application has been filed on some of the work presented herein</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>is a co-founder of Arsenal Therapeutics</p></fn><fn fn-type="COI-statement" id="conf4"><p>is a compensated co-founder, member of the boards of directors, and a member of the scientific advisory boards of Spotlight Therapeutics and Arsenal Biosciences. Was a compensated member of the scientific advisory board at PACT Pharma and was a compensated advisor to Juno Therapeutics. Owns stock in Arsenal Biosciences, Spotlight Therapeutics, PACT Pharma and Merck. AM has received fees from Vertex, Merck, Amgen, Trizell, Genentech, AlphaSights, Rupert Case Management and Bernstein. Is an investor in and informal advisor to Offline Ventures. The Marson lab has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead, and Anthem</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Methodology, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Methodology, Software, Supervision, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology, Resources</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Funding acquisition, Methodology, Resources, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Funding acquisition, Investigation, Methodology, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Subunits in eIF3 crosslinked to RNA in activated Jurkat cells.</title><p>Lists the eIF3 subunits, percent sequence coverage and number of identified peptides.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74272-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>PARpipe statistics for eIF3 PAR-CLIP samples.</title><p>Samples are indexed in the first tab, including both biological replicates for activated and non-activated Jurkat cells. Statistics are given for each library at the read, cluster and group level.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74272-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>PAR-CLIP mapping to individual genes for each eIF3 PAR-CLIP sample.</title><p>Samples are indexed in the first tab, including both biological replicates for activated and non-activated Jurkat cells. First lists the gene name and number of clusters identified. The statistics also include: Sum, sum of that statistic over all sites for that gene; Med, median of that statistic for all sites for that gene; ReadCount, total reads mapping to the gene; T2C fraction, number of reads with T-to-C conversions / number of reads; ConversionSpecificity, log (number of reads with T-to-C conversions / number of reads with other conversions); UniqueReads, reads collapsed to single copies. Also included: 5'utr/Intron/Exon/3'utr/Start_codon/Stop_codon, number of sites mapping to that annotation category; Junction, number of sites mapping to a junction between categories (coding-intron, coding-3'utr, etc.); GeneType, as described in the gene_type category for this gene in the.gtf file used.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74272-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Transcriptome analysis of non-activated or activated Jurkat cells.</title><p>Each tab lists transcript name and version, gene name, type of transcript, length of transcript, and mean transcripts per million, calculated from two biological replicates.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74272-supp4-v2.xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Pathway enrichment analysis.</title><p>Lists for both biological replicates of the EIF3A/C/B PAR-CLIP libraries are included (genes with ≥ 100 reads), along with associated transcript names, lengths in nts of the 5’-UTR, coding region, and 3’-UTR, and reads normalized to the lengths of the transcript regions. Tabs also include the top tissue-specific pathway enrichment categories determined using the STRING Database. These list: the Gene Ontology (GO) number, GO description, observed gene count, background gene count, false discovery rate, and matching proteins in the network by Ensembl protein ID, and by gene name.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74272-supp5-v2.xlsx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Reagent information for experiments.</title><p>Lists include antibodies used, PCR primers, qPCR primers, gRNA targeting sequences, and FISH probes, and DNA oligos for RNase H experiments.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74272-supp6-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-74272-transrepform1-v2.docx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Original western blots for main figures and figure supplements.</title><p>Boxed regions are the regions shown in the figures.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74272-supp7-v2.zip"/></supplementary-material><supplementary-material id="sdata2"><label>Source data 2.</label><caption><title>Spreadsheets with numerical data used in figures and figure supplements.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74272-supp8-v2.zip"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Sequencing data has been deposited in GEO (GSE191306). Code used to analyze the microscopy images is available on github at <ext-link ext-link-type="uri" xlink:href="https://github.com/Llamero/TCR_colocalization_analysis-macro">https://github.com/Llamero/TCR_colocalization_analysis-macro</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:rev:95714d5f24259dd03aa5c184a15b9d5f1bb17b40">https://archive.softwareheritage.org/swh:1:rev:95714d5f24259dd03aa5c184a15b9d5f1bb17b40</ext-link>).</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>De Silva</surname><given-names>D</given-names></name><name><surname>Cate</surname><given-names>JH</given-names></name><name><surname>Chin</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Genome-wide mapping of eIF3-RNA interactions in Jurkat cells using PAR-CLIP</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE191306">GSE191306</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank M Hafner for advice on PAR-CLIP methodology and data analysis, A Weiss for experimental suggestions and advice, H Nolla and A Valeros at the UC Berkeley flow cytometry facility for helping out with the FACS analysis and single cell sorting, F Ives and H L Aaron at the UC Berkeley Imaging center for help with microscopy, J Lui and J Bohlen for advice on planning experiments and for suggestions on the manuscript, N Aleksashin and AM González-Sánchez for advice on the manuscript, and M Mignardi for advice on FISH experiments. <xref ref-type="fig" rid="fig6">Figures 6E</xref> and <xref ref-type="fig" rid="fig7">7</xref> were created using Biorender.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>AB</given-names></name><name><surname>Ford</surname><given-names>ML</given-names></name><name><surname>Larsen</surname><given-names>CP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway</article-title><source>Journal of Immunology</source><volume>197</volume><fpage>2045</fpage><lpage>2050</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601135</pub-id><pub-id pub-id-type="pmid">27591335</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahern</surname><given-names>T</given-names></name><name><surname>Sampson</surname><given-names>J</given-names></name><name><surname>Kay</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="1974">1974</year><article-title>Initiation of protein synthesis during lymphocyte stimulation</article-title><source>Nature</source><volume>248</volume><fpage>519</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1038/248519a0</pub-id><pub-id pub-id-type="pmid">4824348</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>KA</given-names></name><name><surname>Sajti</surname><given-names>E</given-names></name><name><surname>Collier</surname><given-names>JG</given-names></name><name><surname>Gosselin</surname><given-names>D</given-names></name><name><surname>Troutman</surname><given-names>TD</given-names></name><name><surname>Stone</surname><given-names>EL</given-names></name><name><surname>Hedrick</surname><given-names>SM</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Affinity and dose of TCR engagement yield proportional enhancer and gene activity in CD4+ T cells</article-title><source>eLife</source><volume>5</volume><elocation-id>e10134</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.10134</pub-id><pub-id pub-id-type="pmid">27376549</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreotti</surname><given-names>AH</given-names></name><name><surname>Joseph</surname><given-names>RE</given-names></name><name><surname>Conley</surname><given-names>JM</given-names></name><name><surname>Iwasa</surname><given-names>J</given-names></name><name><surname>Berg</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Multidomain Control Over TEC Kinase Activation State Tunes the T Cell Response</article-title><source>Annual Review of Immunology</source><volume>36</volume><fpage>549</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-042617-053344</pub-id><pub-id pub-id-type="pmid">29677469</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascano</surname><given-names>M</given-names></name><name><surname>Hafner</surname><given-names>M</given-names></name><name><surname>Cekan</surname><given-names>P</given-names></name><name><surname>Gerstberger</surname><given-names>S</given-names></name><name><surname>Tuschl</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Identification of RNA-protein interaction networks using PAR-CLIP</article-title><source>Wiley Interdisciplinary Reviews. RNA</source><volume>3</volume><fpage>159</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1002/wrna.1103</pub-id><pub-id pub-id-type="pmid">22213601</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au-Yeung</surname><given-names>BB</given-names></name><name><surname>Zikherman</surname><given-names>J</given-names></name><name><surname>Mueller</surname><given-names>JL</given-names></name><name><surname>Ashouri</surname><given-names>JF</given-names></name><name><surname>Matloubian</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>DA</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A sharp T-cell antigen receptor signaling threshold for T-cell proliferation</article-title><source>PNAS</source><volume>111</volume><fpage>E3679</fpage><lpage>E3688</lpage><pub-id pub-id-type="doi">10.1073/pnas.1413726111</pub-id><pub-id pub-id-type="pmid">25136127</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au-Yeung</surname><given-names>BB</given-names></name><name><surname>Smith</surname><given-names>GA</given-names></name><name><surname>Mueller</surname><given-names>JL</given-names></name><name><surname>Heyn</surname><given-names>CS</given-names></name><name><surname>Jaszczak</surname><given-names>RG</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Zikherman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>IL-2 Modulates the TCR Signaling Threshold for CD8 but Not CD4 T Cell Proliferation on a Single-Cell Level</article-title><source>Journal of Immunology</source><volume>198</volume><fpage>2445</fpage><lpage>2456</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601453</pub-id><pub-id pub-id-type="pmid">28159902</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyersdorf</surname><given-names>N</given-names></name><name><surname>Hanke</surname><given-names>T</given-names></name><name><surname>Kerkau</surname><given-names>T</given-names></name><name><surname>Hünig</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases</article-title><source>Annals of the Rheumatic Diseases</source><volume>64 Suppl 4</volume><fpage>iv91</fpage><lpage>iv95</lpage><pub-id pub-id-type="doi">10.1136/ard.2005.042564</pub-id><pub-id pub-id-type="pmid">16239397</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohlen</surname><given-names>J</given-names></name><name><surname>Fenzl</surname><given-names>K</given-names></name><name><surname>Kramer</surname><given-names>G</given-names></name><name><surname>Bukau</surname><given-names>B</given-names></name><name><surname>Teleman</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Selective 40S Footprinting Reveals Cap-Tethered Ribosome Scanning in Human Cells</article-title><source>Molecular Cell</source><volume>79</volume><fpage>561</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.06.005</pub-id><pub-id pub-id-type="pmid">32589966</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boomer</surname><given-names>JS</given-names></name><name><surname>Green</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>An enigmatic tail of CD28 signaling</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>2</volume><elocation-id>a002436</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a002436</pub-id><pub-id pub-id-type="pmid">20534709</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>NL</given-names></name><name><surname>Pimentel</surname><given-names>H</given-names></name><name><surname>Melsted</surname><given-names>P</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Near-optimal probabilistic RNA-seq quantification</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>525</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/nbt.3519</pub-id><pub-id pub-id-type="pmid">27043002</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckler</surname><given-names>JL</given-names></name><name><surname>Walsh</surname><given-names>PT</given-names></name><name><surname>Porrett</surname><given-names>PM</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Turka</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cutting Edge: T Cell Requirement for CD28 Costimulation Is Due to Negative Regulation of TCR Signals by PTEN</article-title><source>The Journal of Immunology</source><volume>177</volume><fpage>4262</fpage><lpage>4266</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.7.4262</pub-id><pub-id pub-id-type="pmid">16982858</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Call</surname><given-names>ME</given-names></name><name><surname>Pyrdol</surname><given-names>J</given-names></name><name><surname>Wiedmann</surname><given-names>M</given-names></name><name><surname>Wucherpfennig</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The Organizing Principle in the Formation of the T Cell Receptor-CD3 Complex</article-title><source>Cell</source><volume>111</volume><fpage>967</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)01194-7</pub-id><pub-id pub-id-type="pmid">12507424</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Call</surname><given-names>ME</given-names></name><name><surname>Wucherpfennig</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>THE T CELL RECEPTOR: Critical Role of the Membrane Environment in Receptor Assembly and Function</article-title><source>Annual Review of Immunology</source><volume>23</volume><fpage>101</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115625</pub-id><pub-id pub-id-type="pmid">15771567</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Flies</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular mechanisms of T cell co-stimulation and co-inhibition</article-title><source>Nature Reviews Immunology</source><volume>13</volume><fpage>227</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/nri3405</pub-id><pub-id pub-id-type="pmid">23470321</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>AR</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Woo</surname><given-names>YH</given-names></name><name><surname>Cheon</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Yoon</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Co-treatment of LY294002 or MK-2206 with AZD5363 Attenuates AZD5363-induced Increase in the Level of Phosphorylated AKT</article-title><source>Anticancer Research</source><volume>36</volume><fpage>5849</fpage><lpage>5858</lpage><pub-id pub-id-type="doi">10.21873/anticanres.11170</pub-id><pub-id pub-id-type="pmid">27793908</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>AK</given-names></name><name><surname>Kahn</surname><given-names>LE</given-names></name><name><surname>Bourne</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Circular polysomes predominate on the rough endoplasmic reticulum of somatotropes and mammotropes in the rat anterior pituitary</article-title><source>The American Journal of Anatomy</source><volume>178</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1002/aja.1001780102</pub-id><pub-id pub-id-type="pmid">3825959</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>AK</given-names></name><name><surname>Bourne</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Shape of large bound polysomes in cultured fibroblasts and thyroid epithelial cells</article-title><source>The Anatomical Record</source><volume>255</volume><fpage>116</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0185(19990601)255:2&lt;116::AID-AR2&gt;3.0.CO;2-O</pub-id><pub-id pub-id-type="pmid">10359513</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cochran</surname><given-names>JR</given-names></name><name><surname>Aivazian</surname><given-names>D</given-names></name><name><surname>Cameron</surname><given-names>TO</given-names></name><name><surname>Stern</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Receptor clustering and transmembrane signaling in T cells</article-title><source>Trends in Biochemical Sciences</source><volume>26</volume><fpage>304</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/s0968-0004(01)01815-1</pub-id><pub-id pub-id-type="pmid">11343923</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corcoran</surname><given-names>DL</given-names></name><name><surname>Georgiev</surname><given-names>S</given-names></name><name><surname>Mukherjee</surname><given-names>N</given-names></name><name><surname>Gottwein</surname><given-names>E</given-names></name><name><surname>Skalsky</surname><given-names>RL</given-names></name><name><surname>Keene</surname><given-names>JD</given-names></name><name><surname>Ohler</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>PARalyzer: definition of RNA binding sites from PAR-CLIP short-read sequence data</article-title><source>Genome Biology</source><volume>12</volume><elocation-id>R79</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2011-12-8-r79</pub-id><pub-id pub-id-type="pmid">21851591</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>F</given-names></name><name><surname>Achuthan</surname><given-names>P</given-names></name><name><surname>Akanni</surname><given-names>W</given-names></name><name><surname>Allen</surname><given-names>J</given-names></name><name><surname>Amode</surname><given-names>MR</given-names></name><name><surname>Armean</surname><given-names>IM</given-names></name><name><surname>Bennett</surname><given-names>R</given-names></name><name><surname>Bhai</surname><given-names>J</given-names></name><name><surname>Billis</surname><given-names>K</given-names></name><name><surname>Boddu</surname><given-names>S</given-names></name><name><surname>Cummins</surname><given-names>C</given-names></name><name><surname>Davidson</surname><given-names>C</given-names></name><name><surname>Dodiya</surname><given-names>KJ</given-names></name><name><surname>Gall</surname><given-names>A</given-names></name><name><surname>Girón</surname><given-names>CG</given-names></name><name><surname>Gil</surname><given-names>L</given-names></name><name><surname>Grego</surname><given-names>T</given-names></name><name><surname>Haggerty</surname><given-names>L</given-names></name><name><surname>Haskell</surname><given-names>E</given-names></name><name><surname>Hourlier</surname><given-names>T</given-names></name><name><surname>Izuogu</surname><given-names>OG</given-names></name><name><surname>Janacek</surname><given-names>SH</given-names></name><name><surname>Juettemann</surname><given-names>T</given-names></name><name><surname>Kay</surname><given-names>M</given-names></name><name><surname>Laird</surname><given-names>MR</given-names></name><name><surname>Lavidas</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Loveland</surname><given-names>JE</given-names></name><name><surname>Marugán</surname><given-names>JC</given-names></name><name><surname>Maurel</surname><given-names>T</given-names></name><name><surname>McMahon</surname><given-names>AC</given-names></name><name><surname>Moore</surname><given-names>B</given-names></name><name><surname>Morales</surname><given-names>J</given-names></name><name><surname>Mudge</surname><given-names>JM</given-names></name><name><surname>Nuhn</surname><given-names>M</given-names></name><name><surname>Ogeh</surname><given-names>D</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Parton</surname><given-names>A</given-names></name><name><surname>Patricio</surname><given-names>M</given-names></name><name><surname>Abdul Salam</surname><given-names>AI</given-names></name><name><surname>Schmitt</surname><given-names>BM</given-names></name><name><surname>Schuilenburg</surname><given-names>H</given-names></name><name><surname>Sheppard</surname><given-names>D</given-names></name><name><surname>Sparrow</surname><given-names>H</given-names></name><name><surname>Stapleton</surname><given-names>E</given-names></name><name><surname>Szuba</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>K</given-names></name><name><surname>Threadgold</surname><given-names>G</given-names></name><name><surname>Thormann</surname><given-names>A</given-names></name><name><surname>Vullo</surname><given-names>A</given-names></name><name><surname>Walts</surname><given-names>B</given-names></name><name><surname>Winterbottom</surname><given-names>A</given-names></name><name><surname>Zadissa</surname><given-names>A</given-names></name><name><surname>Chakiachvili</surname><given-names>M</given-names></name><name><surname>Frankish</surname><given-names>A</given-names></name><name><surname>Hunt</surname><given-names>SE</given-names></name><name><surname>Kostadima</surname><given-names>M</given-names></name><name><surname>Langridge</surname><given-names>N</given-names></name><name><surname>Martin</surname><given-names>FJ</given-names></name><name><surname>Muffato</surname><given-names>M</given-names></name><name><surname>Perry</surname><given-names>E</given-names></name><name><surname>Ruffier</surname><given-names>M</given-names></name><name><surname>Staines</surname><given-names>DM</given-names></name><name><surname>Trevanion</surname><given-names>SJ</given-names></name><name><surname>Aken</surname><given-names>BL</given-names></name><name><surname>Yates</surname><given-names>AD</given-names></name><name><surname>Zerbino</surname><given-names>DR</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ensembl 2019</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D745</fpage><lpage>D751</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1113</pub-id><pub-id pub-id-type="pmid">30407521</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danan</surname><given-names>C</given-names></name><name><surname>Manickavel</surname><given-names>S</given-names></name><name><surname>Hafner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>PAR-CLIP: A Method for Transcriptome-Wide Identification of RNA Binding Protein Interaction Sites</article-title><source>Methods in Molecular Biology</source><volume>1358</volume><fpage>153</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-3067-8_10</pub-id><pub-id pub-id-type="pmid">26463383</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Parra</surname><given-names>C</given-names></name><name><surname>Ernlund</surname><given-names>A</given-names></name><name><surname>Alard</surname><given-names>A</given-names></name><name><surname>Ruggles</surname><given-names>K</given-names></name><name><surname>Ueberheide</surname><given-names>B</given-names></name><name><surname>Schneider</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A widespread alternate form of cap-dependent mRNA translation initiation</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>3068</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05539-0</pub-id><pub-id pub-id-type="pmid">30076308</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural basis of assembly of the human T cell receptor-CD3 complex</article-title><source>Nature</source><volume>573</volume><fpage>546</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1537-0</pub-id><pub-id pub-id-type="pmid">31461748</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>R</given-names></name><name><surname>Libby</surname><given-names>KA</given-names></name><name><surname>Blaeschke</surname><given-names>F</given-names></name><name><surname>Fuchs</surname><given-names>W</given-names></name><name><surname>Marson</surname><given-names>A</given-names></name><name><surname>Vale</surname><given-names>RD</given-names></name><name><surname>Su</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Rewired signaling network in T cells expressing the chimeric antigen receptor (CAR)</article-title><source>The EMBO Journal</source><volume>39</volume><elocation-id>e104730</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2020104730</pub-id><pub-id pub-id-type="pmid">32643825</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esensten</surname><given-names>JH</given-names></name><name><surname>Helou</surname><given-names>YA</given-names></name><name><surname>Chopra</surname><given-names>G</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CD28 Costimulation: From Mechanism to Therapy</article-title><source>Immunity</source><volume>44</volume><fpage>973</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.04.020</pub-id><pub-id pub-id-type="pmid">27192564</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyquem</surname><given-names>J</given-names></name><name><surname>Mansilla-Soto</surname><given-names>J</given-names></name><name><surname>Giavridis</surname><given-names>T</given-names></name><name><surname>van der Stegen</surname><given-names>SJC</given-names></name><name><surname>Hamieh</surname><given-names>M</given-names></name><name><surname>Cunanan</surname><given-names>KM</given-names></name><name><surname>Odak</surname><given-names>A</given-names></name><name><surname>Gönen</surname><given-names>M</given-names></name><name><surname>Sadelain</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection</article-title><source>Nature</source><volume>543</volume><fpage>113</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1038/nature21405</pub-id><pub-id pub-id-type="pmid">28225754</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frankish</surname><given-names>A</given-names></name><name><surname>Diekhans</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>AM</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Jungreis</surname><given-names>I</given-names></name><name><surname>Loveland</surname><given-names>J</given-names></name><name><surname>Mudge</surname><given-names>JM</given-names></name><name><surname>Sisu</surname><given-names>C</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Armstrong</surname><given-names>J</given-names></name><name><surname>Barnes</surname><given-names>I</given-names></name><name><surname>Berry</surname><given-names>A</given-names></name><name><surname>Bignell</surname><given-names>A</given-names></name><name><surname>Carbonell Sala</surname><given-names>S</given-names></name><name><surname>Chrast</surname><given-names>J</given-names></name><name><surname>Cunningham</surname><given-names>F</given-names></name><name><surname>Di Domenico</surname><given-names>T</given-names></name><name><surname>Donaldson</surname><given-names>S</given-names></name><name><surname>Fiddes</surname><given-names>IT</given-names></name><name><surname>García Girón</surname><given-names>C</given-names></name><name><surname>Gonzalez</surname><given-names>JM</given-names></name><name><surname>Grego</surname><given-names>T</given-names></name><name><surname>Hardy</surname><given-names>M</given-names></name><name><surname>Hourlier</surname><given-names>T</given-names></name><name><surname>Hunt</surname><given-names>T</given-names></name><name><surname>Izuogu</surname><given-names>OG</given-names></name><name><surname>Lagarde</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>FJ</given-names></name><name><surname>Martínez</surname><given-names>L</given-names></name><name><surname>Mohanan</surname><given-names>S</given-names></name><name><surname>Muir</surname><given-names>P</given-names></name><name><surname>Navarro</surname><given-names>FCP</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Pei</surname><given-names>B</given-names></name><name><surname>Pozo</surname><given-names>F</given-names></name><name><surname>Ruffier</surname><given-names>M</given-names></name><name><surname>Schmitt</surname><given-names>BM</given-names></name><name><surname>Stapleton</surname><given-names>E</given-names></name><name><surname>Suner</surname><given-names>MM</given-names></name><name><surname>Sycheva</surname><given-names>I</given-names></name><name><surname>Uszczynska-Ratajczak</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Yates</surname><given-names>A</given-names></name><name><surname>Zerbino</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Aken</surname><given-names>B</given-names></name><name><surname>Choudhary</surname><given-names>JS</given-names></name><name><surname>Gerstein</surname><given-names>M</given-names></name><name><surname>Guigó</surname><given-names>R</given-names></name><name><surname>Hubbard</surname><given-names>TJP</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Paten</surname><given-names>B</given-names></name><name><surname>Reymond</surname><given-names>A</given-names></name><name><surname>Tress</surname><given-names>ML</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>GENCODE reference annotation for the human and mouse genomes</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D766</fpage><lpage>D773</lpage><pub-id pub-id-type="doi">10.1093/nar/gky955</pub-id><pub-id pub-id-type="pmid">30357393</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>KM</given-names></name><name><surname>Garrett</surname><given-names>TE</given-names></name><name><surname>Evans</surname><given-names>JW</given-names></name><name><surname>Horton</surname><given-names>HM</given-names></name><name><surname>Latimer</surname><given-names>HJ</given-names></name><name><surname>Seidel</surname><given-names>SL</given-names></name><name><surname>Horvath</surname><given-names>CJ</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells</article-title><source>Human Gene Therapy</source><volume>29</volume><fpage>585</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1089/hum.2018.001</pub-id><pub-id pub-id-type="pmid">29641319</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>MP</given-names></name><name><surname>Conley</surname><given-names>JM</given-names></name><name><surname>Vangala</surname><given-names>P</given-names></name><name><surname>Garber</surname><given-names>M</given-names></name><name><surname>Reboldi</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hierarchy of signaling thresholds downstream of the T cell receptor and the Tec kinase ITK</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2025825118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2025825118</pub-id><pub-id pub-id-type="pmid">34452995</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Globerson Levin</surname><given-names>A</given-names></name><name><surname>Rivière</surname><given-names>I</given-names></name><name><surname>Eshhar</surname><given-names>Z</given-names></name><name><surname>Sadelain</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CAR T cells: Building on the CD19 paradigm</article-title><source>European Journal of Immunology</source><volume>51</volume><fpage>2151</fpage><lpage>2163</lpage><pub-id pub-id-type="doi">10.1002/eji.202049064</pub-id><pub-id pub-id-type="pmid">34196410</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>JM</given-names></name><name><surname>Noel</surname><given-names>PJ</given-names></name><name><surname>Sperling</surname><given-names>AI</given-names></name><name><surname>Walunas</surname><given-names>TL</given-names></name><name><surname>Gray</surname><given-names>GS</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Absence of B7-dependent responses in CD28-deficient mice</article-title><source>Immunity</source><volume>1</volume><fpage>501</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1016/1074-7613(94)90092-2</pub-id><pub-id pub-id-type="pmid">7534617</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>JM</given-names></name><name><surname>Karpitskiy</surname><given-names>V</given-names></name><name><surname>Kimzey</surname><given-names>SL</given-names></name><name><surname>Shaw</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Coordinate regulation of T cell activation by CD2 and CD28</article-title><source>Journal of Immunology</source><volume>164</volume><fpage>3591</fpage><lpage>3595</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.164.7.3591</pub-id><pub-id pub-id-type="pmid">10725714</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hafner</surname><given-names>M</given-names></name><name><surname>Landthaler</surname><given-names>M</given-names></name><name><surname>Burger</surname><given-names>L</given-names></name><name><surname>Khorshid</surname><given-names>M</given-names></name><name><surname>Hausser</surname><given-names>J</given-names></name><name><surname>Berninger</surname><given-names>P</given-names></name><name><surname>Rothballer</surname><given-names>A</given-names></name><name><surname>Ascano</surname><given-names>M</given-names></name><name><surname>Jungkamp</surname><given-names>AC</given-names></name><name><surname>Munschauer</surname><given-names>M</given-names></name><name><surname>Ulrich</surname><given-names>A</given-names></name><name><surname>Wardle</surname><given-names>GS</given-names></name><name><surname>Dewell</surname><given-names>S</given-names></name><name><surname>Zavolan</surname><given-names>M</given-names></name><name><surname>Tuschl</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP</article-title><source>Cell</source><volume>141</volume><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.03.009</pub-id><pub-id pub-id-type="pmid">20371350</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>MP</given-names></name><name><surname>Unch</surname><given-names>J</given-names></name><name><surname>Binkowski</surname><given-names>BF</given-names></name><name><surname>Valley</surname><given-names>MP</given-names></name><name><surname>Butler</surname><given-names>BL</given-names></name><name><surname>Wood</surname><given-names>MG</given-names></name><name><surname>Otto</surname><given-names>P</given-names></name><name><surname>Zimmerman</surname><given-names>K</given-names></name><name><surname>Vidugiris</surname><given-names>G</given-names></name><name><surname>Machleidt</surname><given-names>T</given-names></name><name><surname>Robers</surname><given-names>MB</given-names></name><name><surname>Benink</surname><given-names>HA</given-names></name><name><surname>Eggers</surname><given-names>CT</given-names></name><name><surname>Slater</surname><given-names>MR</given-names></name><name><surname>Meisenheimer</surname><given-names>PL</given-names></name><name><surname>Klaubert</surname><given-names>DH</given-names></name><name><surname>Fan</surname><given-names>F</given-names></name><name><surname>Encell</surname><given-names>LP</given-names></name><name><surname>Wood</surname><given-names>KV</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate</article-title><source>ACS Chemical Biology</source><volume>7</volume><fpage>1848</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1021/cb3002478</pub-id><pub-id pub-id-type="pmid">22894855</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallumi</surname><given-names>E</given-names></name><name><surname>Shalah</surname><given-names>R</given-names></name><name><surname>Lo</surname><given-names>WL</given-names></name><name><surname>Corso</surname><given-names>J</given-names></name><name><surname>Oz</surname><given-names>I</given-names></name><name><surname>Beach</surname><given-names>D</given-names></name><name><surname>Wittman</surname><given-names>S</given-names></name><name><surname>Isenberg</surname><given-names>A</given-names></name><name><surname>Sela</surname><given-names>M</given-names></name><name><surname>Urlaub</surname><given-names>H</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Yablonski</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Itk Promotes the Integration of TCR and CD28 Costimulation through Its Direct Substrates SLP-76 and Gads</article-title><source>Journal of Immunology</source><volume>206</volume><fpage>2322</fpage><lpage>2337</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2001053</pub-id><pub-id pub-id-type="pmid">33931484</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>FA</given-names></name><name><surname>McArthur</surname><given-names>JG</given-names></name><name><surname>Gross</surname><given-names>JA</given-names></name><name><surname>Raulet</surname><given-names>DH</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones</article-title><source>Nature</source><volume>356</volume><fpage>607</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1038/356607a0</pub-id><pub-id pub-id-type="pmid">1313950</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>FA</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help</article-title><source>The Journal of Experimental Medicine</source><volume>177</volume><fpage>1791</fpage><lpage>1796</lpage><pub-id pub-id-type="doi">10.1084/jem.177.6.1791</pub-id><pub-id pub-id-type="pmid">7684435</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández</surname><given-names>G</given-names></name><name><surname>García</surname><given-names>A</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Lasko</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Unorthodox Mechanisms to Initiate Translation Open Novel Paths for Gene Expression</article-title><source>Journal of Molecular Biology</source><volume>432</volume><elocation-id>166702</elocation-id><pub-id pub-id-type="doi">10.1016/j.jmb.2020.10.035</pub-id><pub-id pub-id-type="pmid">33166539</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>E</given-names></name><name><surname>Cheung</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Taylor</surname><given-names>MJ</given-names></name><name><surname>Wallweber</surname><given-names>HA</given-names></name><name><surname>Sasmal</surname><given-names>DK</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name><name><surname>Vale</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition</article-title><source>Science</source><volume>355</volume><fpage>1428</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1126/science.aaf1292</pub-id><pub-id pub-id-type="pmid">28280247</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huppa</surname><given-names>JB</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>T-cell-antigen recognition and the immunological synapse</article-title><source>Nature Reviews. Immunology</source><volume>3</volume><fpage>973</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1038/nri1245</pub-id><pub-id pub-id-type="pmid">14647479</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iezzi</surname><given-names>G</given-names></name><name><surname>Karjalainen</surname><given-names>K</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The duration of antigenic stimulation determines the fate of naive and effector T cells</article-title><source>Immunity</source><volume>8</volume><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(00)80461-6</pub-id><pub-id pub-id-type="pmid">9462514</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Nie</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations</article-title><source>Human Vaccines &amp; Immunotherapeutics</source><volume>15</volume><fpage>1111</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1080/21645515.2019.1571892</pub-id><pub-id pub-id-type="pmid">30888929</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Porter</surname><given-names>DL</given-names></name><name><surname>Kalos</surname><given-names>MD</given-names></name><name><surname>Milone</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2014">2014</year><source>Compositions for Treatment of Cancer</source><publisher-name>US Patent 8911993</publisher-name></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Porter</surname><given-names>DL</given-names></name><name><surname>Katz</surname><given-names>S</given-names></name><name><surname>Grupp</surname><given-names>SA</given-names></name><name><surname>Bagg</surname><given-names>A</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia</article-title><source>Science Translational Medicine</source><volume>3</volume><elocation-id>95ra73</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3002842</pub-id><pub-id pub-id-type="pmid">21832238</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamphorst</surname><given-names>AO</given-names></name><name><surname>Wieland</surname><given-names>A</given-names></name><name><surname>Nasti</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Barber</surname><given-names>DL</given-names></name><name><surname>Konieczny</surname><given-names>BT</given-names></name><name><surname>Daugherty</surname><given-names>CZ</given-names></name><name><surname>Koenig</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Sica</surname><given-names>GL</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Blazar</surname><given-names>BR</given-names></name><name><surname>Turka</surname><given-names>LA</given-names></name><name><surname>Owonikoko</surname><given-names>TK</given-names></name><name><surname>Pillai</surname><given-names>RN</given-names></name><name><surname>Ramalingam</surname><given-names>SS</given-names></name><name><surname>Araki</surname><given-names>K</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent</article-title><source>Science</source><volume>355</volume><fpage>1423</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.1126/science.aaf0683</pub-id><pub-id pub-id-type="pmid">28280249</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kieft</surname><given-names>JS</given-names></name><name><surname>Zhou</surname><given-names>K</given-names></name><name><surname>Jubin</surname><given-names>R</given-names></name><name><surname>Doudna</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Mechanism of ribosome recruitment by hepatitis C IRES RNA</article-title><source>RNA</source><volume>7</volume><fpage>194</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1017/s1355838201001790</pub-id><pub-id pub-id-type="pmid">11233977</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleijn</surname><given-names>M</given-names></name><name><surname>Proud</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The regulation of protein synthesis and translation factors by CD3 and CD28 in human primary T lymphocytes</article-title><source>BMC Biochemistry</source><volume>3</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2091-3-11</pub-id><pub-id pub-id-type="pmid">12028592</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochenderfer</surname><given-names>JN</given-names></name><name><surname>Feldman</surname><given-names>SA</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Black</surname><given-names>MA</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Wilson</surname><given-names>WH</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor</article-title><source>Journal of Immunotherapy</source><volume>32</volume><fpage>689</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e3181ac6138</pub-id><pub-id pub-id-type="pmid">19561539</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochenderfer</surname><given-names>JN</given-names></name><name><surname>Wilson</surname><given-names>WH</given-names></name><name><surname>Janik</surname><given-names>JE</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>M</given-names></name><name><surname>Feldman</surname><given-names>SA</given-names></name><name><surname>Maric</surname><given-names>I</given-names></name><name><surname>Raffeld</surname><given-names>M</given-names></name><name><surname>Nathan</surname><given-names>DAN</given-names></name><name><surname>Lanier</surname><given-names>BJ</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19</article-title><source>Blood</source><volume>116</volume><fpage>4099</fpage><lpage>4102</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-04-281931</pub-id><pub-id pub-id-type="pmid">20668228</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochenderfer</surname><given-names>JN</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Carpenter</surname><given-names>RO</given-names></name><name><surname>Kassim</surname><given-names>SH</given-names></name><name><surname>Rose</surname><given-names>JJ</given-names></name><name><surname>Telford</surname><given-names>WG</given-names></name><name><surname>Hakim</surname><given-names>FT</given-names></name><name><surname>Halverson</surname><given-names>DC</given-names></name><name><surname>Fowler</surname><given-names>DH</given-names></name><name><surname>Hardy</surname><given-names>NM</given-names></name><name><surname>Mato</surname><given-names>AR</given-names></name><name><surname>Hickstein</surname><given-names>DD</given-names></name><name><surname>Gea-Banacloche</surname><given-names>JC</given-names></name><name><surname>Pavletic</surname><given-names>SZ</given-names></name><name><surname>Sportes</surname><given-names>C</given-names></name><name><surname>Maric</surname><given-names>I</given-names></name><name><surname>Feldman</surname><given-names>SA</given-names></name><name><surname>Hansen</surname><given-names>BG</given-names></name><name><surname>Wilder</surname><given-names>JS</given-names></name><name><surname>Blacklock-Schuver</surname><given-names>B</given-names></name><name><surname>Jena</surname><given-names>B</given-names></name><name><surname>Bishop</surname><given-names>MR</given-names></name><name><surname>Gress</surname><given-names>RE</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation</article-title><source>Blood</source><volume>122</volume><fpage>4129</fpage><lpage>4139</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-08-519413</pub-id><pub-id pub-id-type="pmid">24055823</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koning</surname><given-names>F</given-names></name><name><surname>Lew</surname><given-names>AM</given-names></name><name><surname>Maloy</surname><given-names>WL</given-names></name><name><surname>Valas</surname><given-names>R</given-names></name><name><surname>Coligan</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>The biosynthesis and assembly of T cell receptor alpha- and beta-chains with the CD3 complex</article-title><source>Journal of Immunology</source><volume>140</volume><fpage>3126</fpage><lpage>3134</lpage><pub-id pub-id-type="pmid">2966207</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamper</surname><given-names>AM</given-names></name><name><surname>Fleming</surname><given-names>RH</given-names></name><name><surname>Ladd</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>ASY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A phosphorylation-regulated eIF3d translation switch mediates cellular adaptation to metabolic stress</article-title><source>Science</source><volume>370</volume><fpage>853</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1126/science.abb0993</pub-id><pub-id pub-id-type="pmid">33184215</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>ASY</given-names></name><name><surname>Kranzusch</surname><given-names>PJ</given-names></name><name><surname>Cate</surname><given-names>JHD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>eIF3 targets cell-proliferation messenger RNAs for translational activation or repression</article-title><source>Nature</source><volume>522</volume><fpage>111</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1038/nature14267</pub-id><pub-id pub-id-type="pmid">25849773</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AS</given-names></name><name><surname>Kranzusch</surname><given-names>PJ</given-names></name><name><surname>Doudna</surname><given-names>JA</given-names></name><name><surname>Cate</surname><given-names>JHD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>eIF3d is an mRNA cap-binding protein that is required for specialized translation initiation</article-title><source>Nature</source><volume>536</volume><fpage>96</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1038/nature18954</pub-id><pub-id pub-id-type="pmid">27462815</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Polte</surname><given-names>C</given-names></name><name><surname>Duan</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Xing</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>G</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Ignatova</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wolf</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>eIF3 Associates with 80S Ribosomes to Promote Translation Elongation, Mitochondrial Homeostasis, and Muscle Health</article-title><source>Molecular Cell</source><volume>79</volume><fpage>575</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.06.003</pub-id><pub-id pub-id-type="pmid">32589965</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manfrini</surname><given-names>N</given-names></name><name><surname>Ricciardi</surname><given-names>S</given-names></name><name><surname>Miluzio</surname><given-names>A</given-names></name><name><surname>Fedeli</surname><given-names>M</given-names></name><name><surname>Scagliola</surname><given-names>A</given-names></name><name><surname>Gallo</surname><given-names>S</given-names></name><name><surname>Brina</surname><given-names>D</given-names></name><name><surname>Adler</surname><given-names>T</given-names></name><name><surname>Busch</surname><given-names>DH</given-names></name><name><surname>Gailus-Durner</surname><given-names>V</given-names></name><name><surname>Fuchs</surname><given-names>H</given-names></name><name><surname>Hrabě de Angelis</surname><given-names>M</given-names></name><name><surname>Biffo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>High levels of eukaryotic Initiation Factor 6 (eIF6) are required for immune system homeostasis and for steering the glycolytic flux of TCR-stimulated CD4+ T cells in both mice and humans</article-title><source>Developmental and Comparative Immunology</source><volume>77</volume><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.dci.2017.07.022</pub-id><pub-id pub-id-type="pmid">28743432</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Green</surname><given-names>JM</given-names></name><name><surname>Safer</surname><given-names>B</given-names></name><name><surname>Lindsten</surname><given-names>T</given-names></name><name><surname>Frederickson</surname><given-names>RM</given-names></name><name><surname>Miyamoto</surname><given-names>S</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Regulation of translation initiation factor gene expression during human T cell activation</article-title><source>The Journal of Biological Chemistry</source><volume>267</volume><fpage>20444</fpage><lpage>20450</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(19)88722-7</pub-id><pub-id pub-id-type="pmid">1400363</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Marson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>TCR_colocalization_analysis-macro Public</data-title><version designator="swh:1:rev:95714d5f24259dd03aa5c184a15b9d5f1bb17b40">swh:1:rev:95714d5f24259dd03aa5c184a15b9d5f1bb17b40</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:d3a725357f9583e2d915b70ad9a513dd62bddf54;origin=https://github.com/Llamero/TCR_colocalization_analysis-macro;visit=swh:1:snp:e6dc14170cc0d4448cbed1f13435930e2b5db8eb;anchor=swh:1:rev:95714d5f24259dd03aa5c184a15b9d5f1bb17b40">https://archive.softwareheritage.org/swh:1:dir:d3a725357f9583e2d915b70ad9a513dd62bddf54;origin=https://github.com/Llamero/TCR_colocalization_analysis-macro;visit=swh:1:snp:e6dc14170cc0d4448cbed1f13435930e2b5db8eb;anchor=swh:1:rev:95714d5f24259dd03aa5c184a15b9d5f1bb17b40</ext-link></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cutadapt removes adapter sequences from high-throughput sequencing reads</article-title><source>EMBnet.Journal</source><volume>17</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.14806/ej.17.1.200</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>KD</given-names></name><name><surname>Patil</surname><given-names>DP</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zinoviev</surname><given-names>A</given-names></name><name><surname>Skabkin</surname><given-names>MA</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Pestova</surname><given-names>TV</given-names></name><name><surname>Qian</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>5’ UTR m(6)A Promotes Cap-Independent Translation</article-title><source>Cell</source><volume>163</volume><fpage>999</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.10.012</pub-id><pub-id pub-id-type="pmid">26593424</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>F</given-names></name><name><surname>Attal-Bonnefoy</surname><given-names>G</given-names></name><name><surname>Mangino</surname><given-names>G</given-names></name><name><surname>Mise-Omata</surname><given-names>S</given-names></name><name><surname>Acuto</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>CD28 as a molecular amplifier extending TCR ligation and signaling capabilities</article-title><source>Immunity</source><volume>15</volume><fpage>935</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(01)00244-8</pub-id><pub-id pub-id-type="pmid">11754815</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milone</surname><given-names>MC</given-names></name><name><surname>Fish</surname><given-names>JD</given-names></name><name><surname>Carpenito</surname><given-names>C</given-names></name><name><surname>Carroll</surname><given-names>RG</given-names></name><name><surname>Binder</surname><given-names>GK</given-names></name><name><surname>Teachey</surname><given-names>D</given-names></name><name><surname>Samanta</surname><given-names>M</given-names></name><name><surname>Lakhal</surname><given-names>M</given-names></name><name><surname>Gloss</surname><given-names>B</given-names></name><name><surname>Danet-Desnoyers</surname><given-names>G</given-names></name><name><surname>Campana</surname><given-names>D</given-names></name><name><surname>Riley</surname><given-names>JL</given-names></name><name><surname>Grupp</surname><given-names>SA</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo</article-title><source>Molecular Therapy</source><volume>17</volume><fpage>1453</fpage><lpage>1464</lpage><pub-id pub-id-type="doi">10.1038/mt.2009.83</pub-id><pub-id pub-id-type="pmid">19384291</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Hershey</surname><given-names>JWB</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Changes in ribosomal binding activity of eIF3 correlate with increased translation rates during activation of T lymphocytes</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>28251</fpage><lpage>28264</lpage><pub-id pub-id-type="doi">10.1074/jbc.M414129200</pub-id><pub-id pub-id-type="pmid">15946946</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mondino</surname><given-names>A</given-names></name><name><surname>Mueller</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>mTOR at the crossroads of T cell proliferation and tolerance</article-title><source>Seminars in Immunology</source><volume>19</volume><fpage>162</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2007.02.008</pub-id><pub-id pub-id-type="pmid">17383196</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>N</given-names></name><name><surname>Wessels</surname><given-names>HH</given-names></name><name><surname>Lebedeva</surname><given-names>S</given-names></name><name><surname>Sajek</surname><given-names>M</given-names></name><name><surname>Ghanbari</surname><given-names>M</given-names></name><name><surname>Garzia</surname><given-names>A</given-names></name><name><surname>Munteanu</surname><given-names>A</given-names></name><name><surname>Yusuf</surname><given-names>D</given-names></name><name><surname>Farazi</surname><given-names>T</given-names></name><name><surname>Hoell</surname><given-names>JI</given-names></name><name><surname>Akat</surname><given-names>KM</given-names></name><name><surname>Akalin</surname><given-names>A</given-names></name><name><surname>Tuschl</surname><given-names>T</given-names></name><name><surname>Ohler</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Deciphering human ribonucleoprotein regulatory networks</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>570</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1185</pub-id><pub-id pub-id-type="pmid">30517751</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>DR</given-names></name><name><surname>Wheeler</surname><given-names>B</given-names></name><name><surname>Roose</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>mTOR and other effector kinase signals that impact T cell function and activity</article-title><source>Immunological Reviews</source><volume>291</volume><fpage>134</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1111/imr.12796</pub-id><pub-id pub-id-type="pmid">31402496</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noguchi</surname><given-names>S</given-names></name><name><surname>Arakawa</surname><given-names>T</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><name><surname>Furuno</surname><given-names>M</given-names></name><name><surname>Hasegawa</surname><given-names>A</given-names></name><name><surname>Hori</surname><given-names>F</given-names></name><name><surname>Ishikawa-Kato</surname><given-names>S</given-names></name><name><surname>Kaida</surname><given-names>K</given-names></name><name><surname>Kaiho</surname><given-names>A</given-names></name><name><surname>Kanamori-Katayama</surname><given-names>M</given-names></name><name><surname>Kawashima</surname><given-names>T</given-names></name><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Kubosaki</surname><given-names>A</given-names></name><name><surname>Manabe</surname><given-names>RI</given-names></name><name><surname>Murata</surname><given-names>M</given-names></name><name><surname>Nagao-Sato</surname><given-names>S</given-names></name><name><surname>Nakazato</surname><given-names>K</given-names></name><name><surname>Ninomiya</surname><given-names>N</given-names></name><name><surname>Nishiyori-Sueki</surname><given-names>H</given-names></name><name><surname>Noma</surname><given-names>S</given-names></name><name><surname>Saijyo</surname><given-names>E</given-names></name><name><surname>Saka</surname><given-names>A</given-names></name><name><surname>Sakai</surname><given-names>M</given-names></name><name><surname>Simon</surname><given-names>C</given-names></name><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Tagami</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name><name><surname>Arner</surname><given-names>P</given-names></name><name><surname>Axton</surname><given-names>RA</given-names></name><name><surname>Babina</surname><given-names>M</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><name><surname>Barnett</surname><given-names>TC</given-names></name><name><surname>Beckhouse</surname><given-names>AG</given-names></name><name><surname>Blumenthal</surname><given-names>A</given-names></name><name><surname>Bodega</surname><given-names>B</given-names></name><name><surname>Bonetti</surname><given-names>A</given-names></name><name><surname>Briggs</surname><given-names>J</given-names></name><name><surname>Brombacher</surname><given-names>F</given-names></name><name><surname>Carlisle</surname><given-names>AJ</given-names></name><name><surname>Clevers</surname><given-names>HC</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Detmar</surname><given-names>M</given-names></name><name><surname>Dohi</surname><given-names>T</given-names></name><name><surname>Edge</surname><given-names>ASB</given-names></name><name><surname>Edinger</surname><given-names>M</given-names></name><name><surname>Ehrlund</surname><given-names>A</given-names></name><name><surname>Ekwall</surname><given-names>K</given-names></name><name><surname>Endoh</surname><given-names>M</given-names></name><name><surname>Enomoto</surname><given-names>H</given-names></name><name><surname>Eslami</surname><given-names>A</given-names></name><name><surname>Fagiolini</surname><given-names>M</given-names></name><name><surname>Fairbairn</surname><given-names>L</given-names></name><name><surname>Farach-Carson</surname><given-names>MC</given-names></name><name><surname>Faulkner</surname><given-names>GJ</given-names></name><name><surname>Ferrai</surname><given-names>C</given-names></name><name><surname>Fisher</surname><given-names>ME</given-names></name><name><surname>Forrester</surname><given-names>LM</given-names></name><name><surname>Fujita</surname><given-names>R</given-names></name><name><surname>Furusawa</surname><given-names>JI</given-names></name><name><surname>Geijtenbeek</surname><given-names>TB</given-names></name><name><surname>Gingeras</surname><given-names>T</given-names></name><name><surname>Goldowitz</surname><given-names>D</given-names></name><name><surname>Guhl</surname><given-names>S</given-names></name><name><surname>Guler</surname><given-names>R</given-names></name><name><surname>Gustincich</surname><given-names>S</given-names></name><name><surname>Ha</surname><given-names>TJ</given-names></name><name><surname>Hamaguchi</surname><given-names>M</given-names></name><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Hasegawa</surname><given-names>Y</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Hitchens</surname><given-names>KJ</given-names></name><name><surname>Hume</surname><given-names>DA</given-names></name><name><surname>Ikawa</surname><given-names>T</given-names></name><name><surname>Ishizu</surname><given-names>Y</given-names></name><name><surname>Kai</surname><given-names>C</given-names></name><name><surname>Kawamoto</surname><given-names>H</given-names></name><name><surname>Kawamura</surname><given-names>YI</given-names></name><name><surname>Kempfle</surname><given-names>JS</given-names></name><name><surname>Kenna</surname><given-names>TJ</given-names></name><name><surname>Kere</surname><given-names>J</given-names></name><name><surname>Khachigian</surname><given-names>LM</given-names></name><name><surname>Kitamura</surname><given-names>T</given-names></name><name><surname>Klein</surname><given-names>S</given-names></name><name><surname>Klinken</surname><given-names>SP</given-names></name><name><surname>Knox</surname><given-names>AJ</given-names></name><name><surname>Kojima</surname><given-names>S</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Koyasu</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Lennartsson</surname><given-names>A</given-names></name><name><surname>Mackay-Sim</surname><given-names>A</given-names></name><name><surname>Mejhert</surname><given-names>N</given-names></name><name><surname>Mizuno</surname><given-names>Y</given-names></name><name><surname>Morikawa</surname><given-names>H</given-names></name><name><surname>Morimoto</surname><given-names>M</given-names></name><name><surname>Moro</surname><given-names>K</given-names></name><name><surname>Morris</surname><given-names>KJ</given-names></name><name><surname>Motohashi</surname><given-names>H</given-names></name><name><surname>Mummery</surname><given-names>CL</given-names></name><name><surname>Nakachi</surname><given-names>Y</given-names></name><name><surname>Nakahara</surname><given-names>F</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Nozaki</surname><given-names>T</given-names></name><name><surname>Ogishima</surname><given-names>S</given-names></name><name><surname>Ohkura</surname><given-names>N</given-names></name><name><surname>Ohno</surname><given-names>H</given-names></name><name><surname>Ohshima</surname><given-names>M</given-names></name><name><surname>Okada-Hatakeyama</surname><given-names>M</given-names></name><name><surname>Okazaki</surname><given-names>Y</given-names></name><name><surname>Orlando</surname><given-names>V</given-names></name><name><surname>Ovchinnikov</surname><given-names>DA</given-names></name><name><surname>Passier</surname><given-names>R</given-names></name><name><surname>Patrikakis</surname><given-names>M</given-names></name><name><surname>Pombo</surname><given-names>A</given-names></name><name><surname>Pradhan-Bhatt</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>XY</given-names></name><name><surname>Rehli</surname><given-names>M</given-names></name><name><surname>Rizzu</surname><given-names>P</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Sajantila</surname><given-names>A</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Satoh</surname><given-names>H</given-names></name><name><surname>Savvi</surname><given-names>S</given-names></name><name><surname>Saxena</surname><given-names>A</given-names></name><name><surname>Schmidl</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Schulze-Tanzil</surname><given-names>GG</given-names></name><name><surname>Schwegmann</surname><given-names>A</given-names></name><name><surname>Sheng</surname><given-names>G</given-names></name><name><surname>Shin</surname><given-names>JW</given-names></name><name><surname>Sugiyama</surname><given-names>D</given-names></name><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Summers</surname><given-names>KM</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Takai</surname><given-names>J</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Tatsukawa</surname><given-names>H</given-names></name><name><surname>Tomoiu</surname><given-names>A</given-names></name><name><surname>Toyoda</surname><given-names>H</given-names></name><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>van den Berg</surname><given-names>LM</given-names></name><name><surname>Verardo</surname><given-names>R</given-names></name><name><surname>Vijayan</surname><given-names>D</given-names></name><name><surname>Wells</surname><given-names>CA</given-names></name><name><surname>Winteringham</surname><given-names>LN</given-names></name><name><surname>Wolvetang</surname><given-names>E</given-names></name><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Yanagi-Mizuochi</surname><given-names>C</given-names></name><name><surname>Yoneda</surname><given-names>M</given-names></name><name><surname>Yonekura</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>PG</given-names></name><name><surname>Zucchelli</surname><given-names>S</given-names></name><name><surname>Abugessaisa</surname><given-names>I</given-names></name><name><surname>Arner</surname><given-names>E</given-names></name><name><surname>Harshbarger</surname><given-names>J</given-names></name><name><surname>Kondo</surname><given-names>A</given-names></name><name><surname>Lassmann</surname><given-names>T</given-names></name><name><surname>Lizio</surname><given-names>M</given-names></name><name><surname>Sahin</surname><given-names>S</given-names></name><name><surname>Sengstag</surname><given-names>T</given-names></name><name><surname>Severin</surname><given-names>J</given-names></name><name><surname>Shimoji</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Kawai</surname><given-names>J</given-names></name><name><surname>Kondo</surname><given-names>N</given-names></name><name><surname>Itoh</surname><given-names>M</given-names></name><name><surname>Daub</surname><given-names>CO</given-names></name><name><surname>Kasukawa</surname><given-names>T</given-names></name><name><surname>Kawaji</surname><given-names>H</given-names></name><name><surname>Carninci</surname><given-names>P</given-names></name><name><surname>Forrest</surname><given-names>ARR</given-names></name><name><surname>Hayashizaki</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>FANTOM5 CAGE profiles of human and mouse samples</article-title><source>Scientific Data</source><volume>4</volume><elocation-id>170112</elocation-id><pub-id pub-id-type="doi">10.1038/sdata.2017.112</pub-id><pub-id pub-id-type="pmid">28850106</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohashi</surname><given-names>PS</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name><name><surname>Van den Elsen</surname><given-names>P</given-names></name><name><surname>Yanagi</surname><given-names>Y</given-names></name><name><surname>Yoshikai</surname><given-names>Y</given-names></name><name><surname>Calman</surname><given-names>AF</given-names></name><name><surname>Terhorst</surname><given-names>C</given-names></name><name><surname>Stobo</surname><given-names>JD</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer</article-title><source>Nature</source><volume>316</volume><fpage>606</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1038/316606a0</pub-id><pub-id pub-id-type="pmid">4033759</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Omer</surname><given-names>A</given-names></name><name><surname>Peres</surname><given-names>A</given-names></name><name><surname>Rodriguez</surname><given-names>OL</given-names></name><name><surname>Watson</surname><given-names>CT</given-names></name><name><surname>Lees</surname><given-names>W</given-names></name><name><surname>Polak</surname><given-names>P</given-names></name><name><surname>Collins</surname><given-names>AM</given-names></name><name><surname>Yaari</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>T Cell Receptor Beta (TRB) Germline Variability Is Revealed by Inference From Repertoire Data</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.05.17.444409</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parslow</surname><given-names>A</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name><name><surname>Bryson-Richardson</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Sample drift correction following 4D confocal time-lapse imaging</article-title><source>Journal of Visualized Experiments</source><volume>10</volume><elocation-id>51086</elocation-id><pub-id pub-id-type="doi">10.3791/51086</pub-id><pub-id pub-id-type="pmid">24747942</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>J</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Organizing Principles of Eukaryotic Ribosome Recruitment</article-title><source>Annual Review of Biochemistry</source><volume>88</volume><fpage>307</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-013118-111042</pub-id><pub-id pub-id-type="pmid">31220979</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>JS</given-names></name><name><surname>Johnstone</surname><given-names>TG</given-names></name><name><surname>Baturevych</surname><given-names>A</given-names></name><name><surname>Hause</surname><given-names>RJ</given-names></name><name><surname>Ragan</surname><given-names>SP</given-names></name><name><surname>Clouser</surname><given-names>CR</given-names></name><name><surname>Jones</surname><given-names>JC</given-names></name><name><surname>Ponce</surname><given-names>R</given-names></name><name><surname>Krejsa</surname><given-names>CM</given-names></name><name><surname>Salmon</surname><given-names>RA</given-names></name><name><surname>Ports</surname><given-names>MO</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib</article-title><source>Journal of Immunotherapy</source><volume>43</volume><fpage>107</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1097/CJI.0000000000000307</pub-id><pub-id pub-id-type="pmid">31899702</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricciardi</surname><given-names>S</given-names></name><name><surname>Manfrini</surname><given-names>N</given-names></name><name><surname>Alfieri</surname><given-names>R</given-names></name><name><surname>Calamita</surname><given-names>P</given-names></name><name><surname>Crosti</surname><given-names>MC</given-names></name><name><surname>Gallo</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>R</given-names></name><name><surname>Pagani</surname><given-names>M</given-names></name><name><surname>Abrignani</surname><given-names>S</given-names></name><name><surname>Biffo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Translational Machinery of Human CD4+ T Cells Is Poised for Activation and Controls the Switch from Quiescence to Metabolic Remodeling</article-title><source>Cell Metabolism</source><volume>28</volume><fpage>895</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.08.009</pub-id><pub-id pub-id-type="pmid">30197303</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>AC</given-names></name><name><surname>Lun</surname><given-names>ATL</given-names></name><name><surname>Lau</surname><given-names>WWY</given-names></name><name><surname>Göttgens</surname><given-names>B</given-names></name><name><surname>Marioni</surname><given-names>JC</given-names></name><name><surname>Griffiths</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>T cell cytolytic capacity is independent of initial stimulation strength</article-title><source>Nature Immunology</source><volume>19</volume><fpage>849</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0160-9</pub-id><pub-id pub-id-type="pmid">30013148</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>TL</given-names></name><name><surname>Puig-Saus</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name><name><surname>Shifrut</surname><given-names>E</given-names></name><name><surname>Carnevale</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>PJ</given-names></name><name><surname>Hiatt</surname><given-names>J</given-names></name><name><surname>Saco</surname><given-names>J</given-names></name><name><surname>Krystofinski</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tobin</surname><given-names>V</given-names></name><name><surname>Nguyen</surname><given-names>DN</given-names></name><name><surname>Lee</surname><given-names>MR</given-names></name><name><surname>Putnam</surname><given-names>AL</given-names></name><name><surname>Ferris</surname><given-names>AL</given-names></name><name><surname>Chen</surname><given-names>JW</given-names></name><name><surname>Schickel</surname><given-names>JN</given-names></name><name><surname>Pellerin</surname><given-names>L</given-names></name><name><surname>Carmody</surname><given-names>D</given-names></name><name><surname>Alkorta-Aranburu</surname><given-names>G</given-names></name><name><surname>Del Gaudio</surname><given-names>D</given-names></name><name><surname>Matsumoto</surname><given-names>H</given-names></name><name><surname>Morell</surname><given-names>M</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Cho</surname><given-names>M</given-names></name><name><surname>Quadros</surname><given-names>RM</given-names></name><name><surname>Gurumurthy</surname><given-names>CB</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Haugwitz</surname><given-names>M</given-names></name><name><surname>Hughes</surname><given-names>SH</given-names></name><name><surname>Weissman</surname><given-names>JS</given-names></name><name><surname>Schumann</surname><given-names>K</given-names></name><name><surname>Esensten</surname><given-names>JH</given-names></name><name><surname>May</surname><given-names>AP</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><name><surname>Kupfer</surname><given-names>GM</given-names></name><name><surname>Greeley</surname><given-names>SAW</given-names></name><name><surname>Bacchetta</surname><given-names>R</given-names></name><name><surname>Meffre</surname><given-names>E</given-names></name><name><surname>Roncarolo</surname><given-names>MG</given-names></name><name><surname>Romberg</surname><given-names>N</given-names></name><name><surname>Herold</surname><given-names>KC</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Leonetti</surname><given-names>MD</given-names></name><name><surname>Marson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Reprogramming human T cell function and specificity with non-viral genome targeting</article-title><source>Nature</source><volume>559</volume><fpage>405</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0326-5</pub-id><pub-id pub-id-type="pmid">29995861</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudd</surname><given-names>CE</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Schneider</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>CD28 and CTLA-4 coreceptor expression and signal transduction</article-title><source>Immunological Reviews</source><volume>229</volume><fpage>12</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2009.00770.x</pub-id><pub-id pub-id-type="pmid">19426212</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scaviner</surname><given-names>D</given-names></name><name><surname>Lefranc</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The human T cell receptor alpha variable (TRAV) genes</article-title><source>Experimental and Clinical Immunogenetics</source><volume>17</volume><fpage>83</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1159/000019128</pub-id><pub-id pub-id-type="pmid">10810225</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrum</surname><given-names>AG</given-names></name><name><surname>Palmer</surname><given-names>E</given-names></name><name><surname>Turka</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Distinct temporal programming of naive CD4+ T cells for cell division versus TCR-dependent death susceptibility by antigen-presenting macrophages</article-title><source>European Journal of Immunology</source><volume>35</volume><fpage>449</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1002/eji.200425635</pub-id><pub-id pub-id-type="pmid">15682456</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumann</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Boyer</surname><given-names>E</given-names></name><name><surname>Simeonov</surname><given-names>DR</given-names></name><name><surname>Subramaniam</surname><given-names>M</given-names></name><name><surname>Gate</surname><given-names>RE</given-names></name><name><surname>Haliburton</surname><given-names>GE</given-names></name><name><surname>Ye</surname><given-names>CJ</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name><name><surname>Doudna</surname><given-names>JA</given-names></name><name><surname>Marson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Generation of knock-in primary human T cells using Cas9 ribonucleoproteins</article-title><source>PNAS</source><volume>112</volume><fpage>10437</fpage><lpage>10442</lpage><pub-id pub-id-type="doi">10.1073/pnas.1512503112</pub-id><pub-id pub-id-type="pmid">26216948</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahinian</surname><given-names>A</given-names></name><name><surname>Pfeffer</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>KP</given-names></name><name><surname>Kündig</surname><given-names>TM</given-names></name><name><surname>Kishihara</surname><given-names>K</given-names></name><name><surname>Wakeham</surname><given-names>A</given-names></name><name><surname>Kawai</surname><given-names>K</given-names></name><name><surname>Ohashi</surname><given-names>PS</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Differential T cell costimulatory requirements in CD28-deficient mice</article-title><source>Science</source><volume>261</volume><fpage>609</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1126/science.7688139</pub-id><pub-id pub-id-type="pmid">7688139</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siefken</surname><given-names>R</given-names></name><name><surname>Klein-Hessling</surname><given-names>S</given-names></name><name><surname>Serfling</surname><given-names>E</given-names></name><name><surname>Kurrle</surname><given-names>R</given-names></name><name><surname>Schwinzer</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A CD28-associated signaling pathway leading to cytokine gene transcription and T cell proliferation without TCR engagement</article-title><source>Journal of Immunology</source><volume>161</volume><fpage>1645</fpage><lpage>1651</lpage><pub-id pub-id-type="pmid">9712026</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Gable</surname><given-names>AL</given-names></name><name><surname>Lyon</surname><given-names>D</given-names></name><name><surname>Junge</surname><given-names>A</given-names></name><name><surname>Wyder</surname><given-names>S</given-names></name><name><surname>Huerta-Cepas</surname><given-names>J</given-names></name><name><surname>Simonovic</surname><given-names>M</given-names></name><name><surname>Doncheva</surname><given-names>NT</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>LJ</given-names></name><name><surname>Mering</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D607</fpage><lpage>D613</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id><pub-id pub-id-type="pmid">30476243</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Shaw</surname><given-names>TI</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Blanco</surname><given-names>DB</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Rankin</surname><given-names>S</given-names></name><name><surname>Guy</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Integrative Proteomics and Phosphoproteomics Profiling Reveals Dynamic Signaling Networks and Bioenergetics Pathways Underlying T Cell Activation</article-title><source>Immunity</source><volume>46</volume><fpage>488</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.02.010</pub-id><pub-id pub-id-type="pmid">28285833</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tauber</surname><given-names>D</given-names></name><name><surname>Tauber</surname><given-names>G</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanisms and Regulation of RNA Condensation in RNP Granule Formation</article-title><source>Trends in Biochemical Sciences</source><volume>45</volume><fpage>764</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2020.05.002</pub-id><pub-id pub-id-type="pmid">32475683</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoreen</surname><given-names>CC</given-names></name><name><surname>Kang</surname><given-names>SA</given-names></name><name><surname>Chang</surname><given-names>JW</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Reichling</surname><given-names>LJ</given-names></name><name><surname>Sim</surname><given-names>T</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>8023</fpage><lpage>8032</lpage><pub-id pub-id-type="doi">10.1074/jbc.M900301200</pub-id><pub-id pub-id-type="pmid">19150980</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuosto</surname><given-names>L</given-names></name><name><surname>Acuto</surname><given-names>O</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>CD28 affects the earliest signaling events generated by TCR engagement</article-title><source>European Journal of Immunology</source><volume>28</volume><fpage>2131</fpage><lpage>2142</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1521-4141(199807)28:07&lt;2131::AID-IMMU2131&gt;3.0.CO;2-Q</pub-id><pub-id pub-id-type="pmid">9692882</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Stipdonk</surname><given-names>MJ</given-names></name><name><surname>Lemmens</surname><given-names>EE</given-names></name><name><surname>Schoenberger</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation</article-title><source>Nature Immunology</source><volume>2</volume><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1038/87730</pub-id><pub-id pub-id-type="pmid">11323696</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voon</surname><given-names>DC</given-names></name><name><surname>Subrata</surname><given-names>LS</given-names></name><name><surname>Baltic</surname><given-names>S</given-names></name><name><surname>Leu</surname><given-names>MP</given-names></name><name><surname>Whiteway</surname><given-names>JM</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Knight</surname><given-names>SA</given-names></name><name><surname>Christiansen</surname><given-names>FT</given-names></name><name><surname>Daly</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Use of mRNA- and protein-destabilizing elements to develop a highly responsive reporter system</article-title><source>Nucleic Acids Research</source><volume>33</volume><elocation-id>e27</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gni030</pub-id><pub-id pub-id-type="pmid">15716309</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>S</given-names></name><name><surname>Herrmannová</surname><given-names>A</given-names></name><name><surname>Hronová</surname><given-names>V</given-names></name><name><surname>Gunišová</surname><given-names>S</given-names></name><name><surname>Sen</surname><given-names>ND</given-names></name><name><surname>Hannan</surname><given-names>RD</given-names></name><name><surname>Hinnebusch</surname><given-names>AG</given-names></name><name><surname>Shirokikh</surname><given-names>NE</given-names></name><name><surname>Preiss</surname><given-names>T</given-names></name><name><surname>Valášek</surname><given-names>LS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Selective Translation Complex Profiling Reveals Staged Initiation and Co-translational Assembly of Initiation Factor Complexes</article-title><source>Molecular Cell</source><volume>79</volume><fpage>546</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.06.004</pub-id><pub-id pub-id-type="pmid">32589964</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Munoz</surname><given-names>J</given-names></name><name><surname>Goy</surname><given-names>A</given-names></name><name><surname>Locke</surname><given-names>FL</given-names></name><name><surname>Jacobson</surname><given-names>CA</given-names></name><name><surname>Hill</surname><given-names>BT</given-names></name><name><surname>Timmerman</surname><given-names>JM</given-names></name><name><surname>Holmes</surname><given-names>H</given-names></name><name><surname>Jaglowski</surname><given-names>S</given-names></name><name><surname>Flinn</surname><given-names>IW</given-names></name><name><surname>McSweeney</surname><given-names>PA</given-names></name><name><surname>Miklos</surname><given-names>DB</given-names></name><name><surname>Pagel</surname><given-names>JM</given-names></name><name><surname>Kersten</surname><given-names>MJ</given-names></name><name><surname>Milpied</surname><given-names>N</given-names></name><name><surname>Fung</surname><given-names>H</given-names></name><name><surname>Topp</surname><given-names>MS</given-names></name><name><surname>Houot</surname><given-names>R</given-names></name><name><surname>Beitinjaneh</surname><given-names>A</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Rossi</surname><given-names>JM</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name><name><surname>Rao</surname><given-names>AV</given-names></name><name><surname>Reagan</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma</article-title><source>The New England Journal of Medicine</source><volume>382</volume><fpage>1331</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1914347</pub-id><pub-id pub-id-type="pmid">32242358</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Kuramitsu</surname><given-names>S</given-names></name><name><surname>Posey</surname><given-names>AD</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>2486</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02486</pub-id><pub-id pub-id-type="pmid">30416506</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>ggplot2: Create elegant data visualisations using the grammar of graphics</data-title><publisher-name>R Package Version 2</publisher-name></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>T</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Zoppi</surname><given-names>G</given-names></name><name><surname>Vogel</surname><given-names>IA</given-names></name><name><surname>Akhmedov</surname><given-names>M</given-names></name><name><surname>Bleck</surname><given-names>CKE</given-names></name><name><surname>Beltraminelli</surname><given-names>T</given-names></name><name><surname>Rieckmann</surname><given-names>JC</given-names></name><name><surname>Ramirez</surname><given-names>NJ</given-names></name><name><surname>Benevento</surname><given-names>M</given-names></name><name><surname>Notarbartolo</surname><given-names>S</given-names></name><name><surname>Bumann</surname><given-names>D</given-names></name><name><surname>Meissner</surname><given-names>F</given-names></name><name><surname>Grimbacher</surname><given-names>B</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Kwee</surname><given-names>I</given-names></name><name><surname>Geiger</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dynamics in protein translation sustaining T cell preparedness</article-title><source>Nature Immunology</source><volume>21</volume><fpage>927</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-0714-5</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>YH</given-names></name><name><surname>Huang</surname><given-names>YF</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Chou</surname><given-names>CY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment</article-title><source>Frontiers in Pharmacology</source><volume>11</volume><elocation-id>206</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2020.00206</pub-id><pub-id pub-id-type="pmid">32194423</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>ZZ</given-names></name><name><surname>Mathews</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Prediction of Secondary Structures Conserved in Multiple RNA Sequences</article-title><source>Methods in Molecular Biology</source><volume>1490</volume><fpage>35</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-6433-8_3</pub-id><pub-id pub-id-type="pmid">27665591</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74272.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Malissen</surname><given-names>Bernard</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université</institution><country>France</country></aff></contrib></contrib-group></front-stub><body><p>The work addresses the role of translation initiation in the early induction of specific genes during T cell activation. It primarily uses the Jurkat T cell line and demonstrates that the translation initiation factor eIF3 interacts with the 3'-untranslated regions of the TCRA and TCRB mRNAs. This interaction resulted in a rapid burst in TCRA and TCRB translation through a mechanism dependent on CD28. Adding the TCRA or TCRB 3' UTR to an anti-CD19 chimeric antigen receptor (CAR) improves the ability of the corresponding CAR-T cells to kill tumor cells in vitro.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74272.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Malissen</surname><given-names>Bernard</given-names></name><role>Reviewing Editor</role><aff><institution>Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université</institution><country>France</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your work entitled &quot;Robust T cell activation requires an eIF3-driven burst in T cell receptor translation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by Dr B. Malissen as the Reviewing Editor and Tadatsugu Taniguchi as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor and their views concur.</p><p>The work primarily uses the Jurkat T cell line and demonstrates that eIF3 binds to TCRA and TCRB RNAs. The 3' UTR of TCRA and TCRB was responsible for eIF3 binding and this interaction resulted in a rapid burst in TCRA and TCRB translation through a mechanism dependent on CD28. Adding the TCRA or TCRB 3' UTR to a CAR-T construct improved its ability to kill tumor cells. Although the work has potential for publication in <italic>eLife</italic>, it requires essential additional data to support the central claims of the paper. Each reviewer raised substantive concerns (see below) that need to be resolved experimentally. To quote a few, you should document in Jurkat and in primary T cells whether the rapid burst in TCRA and TCRB translation results in TCR up regulation on the cell surface. This would be important for the functional implications of your findings and considering that (1) CD247 is generally considered as the limiting factor in TCR surface expression, and (2) primary T-cells display a phenomenal sensitivity towards antigen, as the presence of typically only a few antigens on the APC is sufficient to trigger the full T-cell response. Along the same line the readout of T-cell activation shown in Figure 5 and 6 are rather weak. For instance, in Figure 6, gating for CD25 and CD69 is hard to see in the raw flow cytometry plots. Can this be adjusted with the biexponential axis? How were these gates set? In Figure 5, providing primary where possible will support results represented purely as graphs. Among the mechanistic issues, one particularly puzzling issue concerns the observation that the CD28-dependent burst in translation requires membrane tethering whereas the CD3-dependent increase does not. Please note that during the Reviewer discussion, it has been noted that the Western blots displayed in Figure 6D showed strikingly similar bands for donors 1 and 2 in several of the rows probed for CAR-TCR or HSP90. Even the slopes and shapes of these band seem similar. Accordingly, Reviewers have suggested to include the original blots in the revision.</p><p><italic>Reviewer #1:</italic></p><p>Da Silva et al. demonstrate via biochemical and functional assays and bioinformatics that the 3'UTR of both TCRalpha and β are targeted as part of translationally active polysomes by the eukaryotic initiation factor 3 (elf3) in a fashion that depends on the activation of the costimulatory CD28 signaling pathway. They also show by means of mutagenesis of the 3'UTRs that translation of the resulting TCR mRNAs is increased under conditions where elf3 is allowed to bind. By means of nanoluciferase-based reporter assays they also provide evidence that 3'UTR-targeting by elf3 depends on membrane-proximal CD28 signaling. Furthermore, they were able to link activation-driven burst of TCR-translation levels to elf3-3'UTR binding. They present a convincing case that elf3-3'UTR binding in response to TCR-mediated stimulation promotes TCR-clustering, upregulation of CD25 and CD69 (in CD8<sup>+</sup> T-cells) as well as IL-2 (and to some extent IFNγ) secretion. Lastly, they show that CD19-CARs equipped with either a TCRa- or a TCRb-3'UTR are earlier and more robustly translated upon CAR-T-cell activation with a B-cell lines. This behavior coincides with a somewhat increased CAR-T-cell-mediated killing activity especially at lower CAR-T-cell:target cell ratios or when CAR-T-cells are confronted with a target cell line expressing lower levels of CD19. Overall the study highlights the importance of the 3'UTR for TCR and CAR translation in a setting of CD28-signaling with implications for (CAR-)T-cell functionality.</p><p>Strengths</p><p>Apart from the overall subject being highly relevant for a better understanding of T-cell physiology, T-cell antigen recognition and the design and implementation of improved CAR-T-cell-based immunotherapies, the study excels with the quality of experimentation and the quantitative nature, its readability and clear conclusions that are in my view nuanced enough to avoid overinterpretation of the findings. To my best knowledge methodologies and the execution of the experiments are all described with necessary clarity and precision leaving little to no room for ambiguities, so that others in the field will be able to reproduce the data.</p><p>I find both the reasoning underlying the flow of experimentation and the conclusions drawn from individual observations convincing and compelling. Leads from bioinformatics are verified by detailed biochemistry with clean and clear-cut results, which are then followed up with (i) functional studies concerning mRNA-stability, -elf3 binding and -translation and (ii) studies pertaining to T-cell physiology, all of which provide insights of high relevance.</p><p>The highly quantitative nature of all readouts applied (which all include meaningful negative controls) leaves little to no doubts with regard to the conclusions drawn.</p><p>Weaknesses</p><p>I find only few weaknesses which pertain to the (i) proposed mechanism by which CD28-downstream signaling affects elf3-binding to the 3'UTRs and (ii) the readout of TCR-surface expression and also T-cell activation, the latter lacking definition with regards to TCR-/CAR-proximity. Keeping the scope of the study on in mind, I am of the opinion that these subjects warrant in large part a more detailed discussion and in some cases a few more experiments which could be done with reasonable effort.</p><p>(i) Worthy of discussion: To me it is not clear how the CD28/PI3K pathway affects elf3-3'UTR binding. To what extent the binding elf3 to other parts of the mRNA effected by this pathway? Is this a general effect of one that is specific to selected 3'UTRs. How could this be addressed in future experiments? It has been reported that the PD1-PD-L1 interaction as it often occurs in the tumor microenvironment or in another setting of T-cell exhaustion affects predominantly CD28 signaling. Is the PD1-mediated inhibition of the T-cell response directly linked to a loss in elf3-3'UTR binding?</p><p>(ii) The authors show a boost in TCR and CAR translation that depends on the 3'UTR being able to bind elf3. How is TCR- and CAR- surface expression affected in the course of activation? How is activation-induced TCR- and CAR- downregulation affected? Primary T-cells feature a phenomenal sensitivity towards antigen, as the presence of typically only a few antigens on the APC is sufficient to trigger the full T-cell response. The situation with CARs is different in that they require 100x – 1000x more antigen for stimulation. How is (CAR-)T-cell sensitivity affected by elf3-3'UTR binding? Time-lapsed flow cytometry experiments using IP26/recombinant CD19 (both commercially available) for detection and a simple titration experiment (involving plate-bound OKT3 or CD19 for stimulation) would clarify these sets of questions.</p><p>I am fond of this manuscript. because it provides an important aspect of TCR- and CAR-related physiology that appears highly relevant for T-cell-related immune protection and pathologies as well as T-cell based immunotherapies. On the one hand, it becomes clear now, that attention will need to be paid when exchanging TCRs via CRISPR-Cas9-based approaches. On the other hand, CARs featuring a TCRa or TCRb 3'UTR may give rise to better overall performance (to be tested in more detail in vitro and in vivo).</p><p>As I have outlined in previous sections of my review I regard the quality of the presented work as high. I also agree with the flow of experimentation and the conclusions drawn. What is missing in my view is a more detailed investigation (within the scope of this manuscript.) or discussion of the underlying mechanisms (see suggestions in the previous section). I recommend accepting the manuscript. with minor revisions.</p><p>Suggested points:</p><p>(i) Discuss and assess in more detail how CD28-downstream signaling (PI3K activity) may affect elf3-3'UTR binding.</p><p>Are Tec-kinases, which are known to boost TCR-downstream signaling, involved? An experiment involving pharmacological Tec-inhibition would be insightful (applying 3'UTR mutants).</p><p>(ii) TCR-/CAR-surface expression: how is it affected by the nature of the TCRa,b 3'UTR before, during and after activation? A simple flow cytometry experiment would tell. For T-cells OKT3 could be used for stimulation and IP26 for surface detection. For CD19-CAR-T-cells, B-cell lines could be used for stimulation and recombinant CD19 for CAR-detection.</p><p>(iii) One last aspect that would boost in my opinion the significance of the findings is antigen sensitivity, which could be addressed with little (to reasonable) effort by subjecting (CAR-) T-cells to antigen (OKT3, CD19) immobilized in a titrated fashion onto plates. Readout of activation could be as simple as measuring cytokine secretion in the tissue culture supernatant.</p><p><italic>Reviewer #2:</italic></p><p>The authors explore the role of eIF3 in T cells using a wide variety of experimental techniques. Experiments are very well-explained in the text and documented in the methods. They begin by using PAR-CLIP in the Jurkat T cell line and find that eIF3 binds to TCRA and TCRB, among other RNAs. They also identify a new pattern of eIF3 binding to the coding sequences of many genes, some of which are validated in primary human cells. Looking at the 3' UTR of TCRA and TCRB, the authors show that eIF3 binding to the 3' UTRs is responsible for activation-induced translational bursting, through a mechanism dependent on CD28. Finally, the authors add the TCRA or TCRB 3' UTR to a CAR-T construct and test its impact on CAR expression and cancer cell killing. Some findings in the study are better-supported than others. The finding of eIF3 controlling translational bursting of TCRA and TCRB by binding the 3' UTR is convincing. However, the discovery of pan-mRNA binding behaviour of eIF3 could use more support from primary cells, and the data from CAR-T cell experiments is subtle and low in replicates. For these reasons it is hard to interpret the data.</p><p>1) The use of a cell line in PAR-CLIP discovery experiments detracts from the generalizability of results, particularly the new finding of coding sequence binding. While the validation of several transcripts in primary human cells is appreciated, it is hard to know how common this phenomenon is. It is also unfortunate that TCRA and TCRB could not be validated in primary cells.</p><p>2) When looking at transcript localization in Jurkat cells by FISH, all the mRNA transcripts measured were in distinct puncta. Is this common for all transcripts? It would be important to see a transcript that behaves differently in order to conclude that the puncta are significant.</p><p>3) CAR T cell data is one representative of 2 donors, and the killing enhancement seen with TCRA or TCRB 3' UTR addition is mild. More biological replicates would be needed to convincingly show this with statistical testing.</p><p>Recommendations for the authors</p><p>1) It is possible to expand primary cells to 55 million, and this would enable the PAR-CLIP to be carried out on primary cells.</p><p>2) The authors conclude that eIF3 binding is specific to selected transcripts based on the fact that eIF3 cross-linking isn't correlated with mRNA abundance. Are these selected transcripts simply those that are newly transcribed? This would also explain why the eIF3-bound transcripts are highly enriched for immune processes.</p><p>3) The comparison of PAR-CLIP results between HEK293T and Jurkat cells relies on ranking and thresholding. It would be preferable to do a more formal statistical comparison.</p><p>i) In several places in the Methods there seem to be conflicting descriptions of Jurkat cells being used at 8 x 105 versus 8 x 106 / mL.</p><p>4) Gating for CD25 and CD69 is hard to see in the raw flow cytometry plots. Can this be adjusted with the biexponential axis? How were these gates set? Many percentages on gates in Figure 5 —figure supplement 2a are missing.</p><p>5) The live cell gate in Figure 6 —figure supplement 1b is non-conventional, at least to this reviewer. Can this be explained?</p><p><italic>Reviewer #3:</italic></p><p>De Silva et al. 2021 present exciting results regarding the role of the eIF3 complex in T cell activation. The authors use PAR-CLIP to identify the binding patterns of eIF3 in Jurkat cells and find that regions within the 3´ UTRs of TCRA and TCRB mRNAs are sufficient to increase their translation and drive T cell activation. Moreover, expression of the TCRA and TCRB 3´UTRs in CAR T cells improves their ability to kill tumor cells, demonstrating the therapeutic potential of their findings.</p><p>– Figure 1: Venn diagrams should include data from non-activated Jurkat cells. The overlap between different data sets (eg. EIF3A/C/B vs. EIF3D/L) should also be represented using a Venn diagram and included in this figure to convince the reader that the IPs against the different subunits are representative of what the entire complex is binding to. GO terms for overlapping mRNAs should be moved to the main figure and discussed in more detail in the text.</p><p>– All sequencing tracks presented in the manuscript should include a scale in order for the reader to better assess the data.</p><p>– When discussing the PAR-CLIP data, the authors state that &quot;eIF3 crosslinking does not correlate with mRNA abundance.&quot; Was RNA-seq performed in parallel? These data should be discussed in more detail and the relevant analyses should be included in the main figures.</p><p>– The authors specify that the sites that were modified within the 3´UTRs of TCRA and TCRB were identified through PAR-CLIP. However, the size of the deleted sequence is only mentioned in the context of their CRISPR/Cas9 deletion mutants (Figure 5 supplement 1A). Was the same region targeted in their reporters? Is there evidence that TCRA and TCRB mRNAs that contain these deletions in their 3´UTRs are adequately exported out of the nucleus?</p><p>– The data presented in figure 2 nicely demonstrate that eIF3 is bound to the coding regions of certain mRNAs during their translation. However, it does not provide evidence that the binding of eIF3 occurs &quot;via&quot; the coding sequence as the authors claim in the Discussion section of the manuscript.</p><p>– The lack of colocalization with stress granules and P bodies alone does not provide convincing evidence that the TCRA and TCRB are in &quot;translational hot spots.&quot; Figure 1F should be moved to the supplements as supporting information for the sucrose gradients presented in figure 2.</p><p>– In figure 3E, the authors demonstrate that the 3´UTRs of TCRA and TCRB are required for the interaction between these RNAs and eIF3. What is the proposed mechanism for interactions between eIF3 and the 3´UTR that appear to drive the extensive interaction of eIF3 with the mRNA and the observed translational increase?</p><p>– How does eIF3 spread across the CDS? What is the relevance of the interactions between eIF3 and the CDS?</p><p>– The authors should discuss why the CD28-dependent burst in translation requires membrane tethering but the CD3-dependent increase does not. This section emerged from nowhere and greater explanation would be helpful both for the technical details and for the potential physiological importance of the membrane tethering dependency.</p><p>– De Silva et al. demonstrate that expressing the 3´UTRs of TCRA and TCRB in CAR T cells leads to a faster increase in CAR protein expression. However, their data indicate that the increase in translation is transient (Figure 6D and Figure 6 supplement 1A). Therefore, the authors should comment on whether this decreased lag time in protein expression might also accelerate CAR T cell exhaustion.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Robust T cell activation requires an eIF3-driven burst in T cell receptor translation&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Tadatsugu Taniguchi (Senior Editor) and a Reviewing Editor.</p><p>The manuscript has been improved but there is a small remaining concern that one of the Reviewer would like to see addressed, as outlined below:</p><p>&quot;The concern with the killing assay is that the 24 and 48h time points at which the remaining CTV-labeled target cells were measured do not take cell proliferation of T cells or targets into account. Thus, the increased differences at 48h compared to 24h could be skewed by differential cell proliferation. A control would be needed to account for this.&quot;</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74272.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>The work primarily uses the Jurkat T cell line and demonstrates that eIF3 binds to TCRA and TCRB RNAs. The 3' UTR of TCRA and TCRB was responsible for eIF3 binding and this interaction resulted in a rapid burst in TCRA and TCRB translation through a mechanism dependent on CD28. Adding the TCRA or TCRB 3' UTR to a CAR-T construct improved its ability to kill tumor cells. Although the work has potential for publication in eLife, it requires essential additional data to support the central claims of the paper.</p></disp-quote><p>We thank the reviewers for their generally positive view of the results we present in the manuscript. We address their concerns as described in more detail below. We also include additional experiments, also as described below.</p><disp-quote content-type="editor-comment"><p>Each reviewer raised substantive concerns (see below) that need to be resolved experimentally. To quote a few, you should document in Jurkat and in primary T cells whether the rapid burst in TCRA and TCRB translation results in TCR up regulation on the cell surface. This would be important for the functional implications of your findings and considering that (1) CD247 is generally considered as the limiting factor in TCR surface expression, and (2) primary T-cells display a phenomenal sensitivity towards antigen, as the presence of typically only a few antigens on the APC is sufficient to trigger the full T-cell response.</p></disp-quote><p>These are interesting points which we now address in more detail in the Discussion. Although we did not look at surface expression of the TCR directly, we did look at TCR clustering after activation with anti-CD3/anti-CD28 antibodies (Figure 5C and Figure 5—figure supplement 1C), which requires TCR surface expression as a prerequisite. We saw clear delays in TCR clustering due to the mutations in the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs. We also looked at TCR levels on the cell surface by FACS after activation by PMA/Ionomycin in Figure 5—figure supplement 1D-1E, again observing a decrease in cell surface TCR due to the mutations in the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs. We used PMA/Ionomycin because we could not examine TCR levels on the cell surface by FACS after anti-CD3/anti-CD28 activation, for the technical reason that the anti-CD3 antibody we used for activation in all of our assays (clone UCHT1) interfered with binding of the fluorescent antibody we used for TCR detection in FACS experiments.</p><disp-quote content-type="editor-comment"><p>Along the same line the readout of T-cell activation shown in Figure 5 and 6 are rather weak. For instance, in Figure 6, gating for CD25 and CD69 is hard to see in the raw flow cytometry plots. Can this be adjusted with the biexponential axis? How were these gates set? In Figure 5, providing primary where possible will support results represented purely as graphs.</p></disp-quote><p>We thank the reviewers for pointing out these issues of clarity with respect to Figure 5 (we assume the mention of Figure 6 was actually for Figure 5 based on the context). We have divided the Figure 5 figure supplements into separate figures, so that the flow cytometry plots can be included without loss of resolution. We also include a more detailed description of how the gates were set in the Materials and methods and figure legends. In brief, we used the TCR KO cells (Δ<italic>TCR)</italic> to set the CD69+ and CD25+ gating, as we were able to obtain knockout editing efficiency of 95% or higher in those cells.</p><disp-quote content-type="editor-comment"><p>Among the mechanistic issues, one particularly puzzling issue concerns the observation that the CD28-dependent burst in translation requires membrane tethering whereas the CD3-dependent increase does not.</p></disp-quote><p>We agree this is one of the more interesting observations we made. We think unraveling mechanisms underlying the CD28-dependent and membrane-proximal signaling requirement will be an exciting line of experiments to pursue in a follow-up study. We expanded the Discussion section of this observation to highlight this surprising finding, as described in more detail below.</p><disp-quote content-type="editor-comment"><p>Please note that during the Reviewer discussion, it has been noted that the Western blots displayed in Figure 6D showed strikingly similar bands for donors 1 and 2 in several of the rows probed for CAR-TCR or HSP90. Even the slopes and shapes of these band seem similar. Accordingly, Reviewers have suggested to include the original blots in the revision.</p></disp-quote><p>We thank the reviewers for checking these gels. We had included the original blots in the Source Data File 1 zip file. We applied only two adjustments to these gel images for presentation in Figure 6. First, we adjusted the background by setting a “floor” pixel count, and then used linear adjustments to set the maximal values. Second, we rotated the blots so that the various sections are as close to horizontal as possible.</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>Da Silva et al. demonstrate via biochemical and functional assays and bioinformatics that the 3'UTR of both TCRalpha and β are targeted as part of translationally active polysomes by the eukaryotic initiation factor 3 (elf3) in a fashion that depends on the activation of the costimulatory CD28 signaling pathway. They also show by means of mutagenesis of the 3'UTRs that translation of the resulting TCR mRNAs is increased under conditions where elf3 is allowed to bind. By means of nanoluciferase-based reporter assays they also provide evidence that 3'UTR-targeting by elf3 depends on membrane-proximal CD28 signaling. Furthermore, they were able to link activation-driven burst of TCR-translation levels to elf3-3'UTR binding. They present a convincing case that elf3-3'UTR binding in response to TCR-mediated stimulation promotes TCR-clustering, upregulation of CD25 and CD69 (in CD8<sup>+</sup> T-cells) as well as IL-2 (and to some extent IFNγ) secretion. Lastly, they show that CD19-CARs equipped with either a TCRa- or a TCRb-3'UTR are earlier and more robustly translated upon CAR-T-cell activation with a B-cell lines. This behavior coincides with a somewhat increased CAR-T-cell-mediated killing activity especially at lower CAR-T-cell:target cell ratios or when CAR-T-cells are confronted with a target cell line expressing lower levels of CD19. Overall the study highlights the importance of the 3'UTR for TCR and CAR translation in a setting of CD28-signaling with implications for (CAR-)T-cell functionality.</p></disp-quote><p>We thank the reviewer for their overall positive comments on the manuscript. We do note that we see upregulation of CD25 and CD69 in both CD8<sup>+</sup> and CD4<sup>+</sup> T cells (Figure 5—figure supplement 2A-2B), although this may not have been clear in how we wrote the figure legend. We have divided those figure supplements into separate files, based on feedback from the reviewers as described above.</p><disp-quote content-type="editor-comment"><p>Strengths</p><p>Apart from the overall subject being highly relevant for a better understanding of T-cell physiology, T-cell antigen recognition and the design and implementation of improved CAR-T-cell-based immunotherapies, the study excels with the quality of experimentation and the quantitative nature, its readability and clear conclusions that are in my view nuanced enough to avoid overinterpretation of the findings. To my best knowledge methodologies and the execution of the experiments are all described with necessary clarity and precision leaving little to no room for ambiguities, so that others in the field will be able to reproduce the data.</p><p>I find both the reasoning underlying the flow of experimentation and the conclusions drawn from individual observations convincing and compelling. Leads from bioinformatics are verified by detailed biochemistry with clean and clear-cut results, which are then followed up with (i) functional studies concerning mRNA-stability, -elf3 binding and -translation and (ii) studies pertaining to T-cell physiology, all of which provide insights of high relevance.</p><p>The highly quantitative nature of all readouts applied (which all include meaningful negative controls) leaves little to no doubts with regard to the conclusions drawn.</p></disp-quote><p>We are gratified the reviewer was satisfied with the rigor of our experiments, and their interest in our results.</p><disp-quote content-type="editor-comment"><p>Weaknesses</p><p>I find only few weaknesses which pertain to the (i) proposed mechanism by which CD28-downstream signaling affects elf3-binding to the 3'UTRs and (ii) the readout of TCR-surface expression and also T-cell activation, the latter lacking definition with regards to TCR-/CAR-proximity. Keeping the scope of the study on in mind, I am of the opinion that these subjects warrant in large part a more detailed discussion and in some cases a few more experiments which could be done with reasonable effort.</p><p>(i) Worthy of discussion: To me it is not clear how the CD28/PI3K pathway affects elf3-3'UTR binding. To what extent the binding elf3 to other parts of the mRNA effected by this pathway? Is this a general effect of one that is specific to selected 3'UTRs. How could this be addressed in future experiments? It has been reported that the PD1-PD-L1 interaction as it often occurs in the tumor microenvironment or in another setting of T-cell exhaustion affects predominantly CD28 signaling. Is the PD1-mediated inhibition of the T-cell response directly linked to a loss in elf3-3'UTR binding?</p></disp-quote><p>These are all great questions that we are interested in answering in future studies. In particular, we agree with the reviewer that it will be interesting to determine if there is a connection between PD1-mediated inhibition and eIF3-3’-UTR binding. One key point we didn’t make clearly is that, since both the TCRA and TCRB subunits are integral membrane proteins, the CD28- and membrane-dependent regulation may primarily affect the immune-related membrane proteins or secreted proteins that we identified in the PAR-CLIP data (i.e. B2M, CD28, CD3D, HLA-E, LAT in Supplementary File 5 and TAP1 and TAP2 in Supplementary File 3). This could be addressed using the tethered vs. non-tethered Nanoluciferase reporters, with 3’-UTRs of other mRNAs we identified in the PAR-CLIP experiment. We have expanded the Discussion to address these questions based on our present knowledge.</p><disp-quote content-type="editor-comment"><p>(ii) The authors show a boost in TCR and CAR translation that depends on the 3'UTR being able to bind elf3. How is TCR- and CAR- surface expression affected in the course of activation? How is activation-induced TCR- and CAR- downregulation affected? Primary T-cells feature a phenomenal sensitivity towards antigen, as the presence of typically only a few antigens on the APC is sufficient to trigger the full T-cell response. The situation with CARs is different in that they require 100x – 1000x more antigen for stimulation. How is (CAR-)T-cell sensitivity affected by elf3-3'UTR binding? Time-lapsed flow cytometry experiments using IP26/recombinant CD19 (both commercially available) for detection and a simple titration experiment (involving plate-bound OKT3 or CD19 for stimulation) would clarify these sets of questions.</p></disp-quote><p>These are all excellent questions for future studies. At present we have only used B tumor cells expressing CD19 for stimulation. We think there are likely to be challenges using plate-bound antibodies to address CAR vs. TCR sensitivity due to the fact that CARs likely do not recapitulate immune synapses. For example, it has been shown that CD19 CARs do not cluster on the T cell surface in immune synapses similarly to TCRs (see <sup>1</sup>). We have expanded the Discussion to address the difference between CAR and TCR sensitivity, which is likely to be a more general problem beyond the CD19 CARs we used here in proof-of-principle experiments. We will explore other options, including possibly using live cell microscopy in the future to tackle these longstanding problems.</p><disp-quote content-type="editor-comment"><p>I am fond of this manuscript. because it provides an important aspect of TCR- and CAR-related physiology that appears highly relevant for T-cell-related immune protection and pathologies as well as T-cell based immunotherapies. On the one hand, it becomes clear now, that attention will need to be paid when exchanging TCRs via CRISPR-Cas9-based approaches. On the other hand, CARs featuring a TCRa or TCRb 3'UTR may give rise to better overall performance (to be tested in more detail in vitro and in vivo).</p><p>As I have outlined in previous sections of my review I regard the quality of the presented work as high. I also agree with the flow of experimentation and the conclusions drawn. What is missing in my view is a more detailed investigation (within the scope of this manuscript.) or discussion of the underlying mechanisms (see suggestions in the previous section).</p></disp-quote><p>Again, we thank the reviewer for their overall enthusiasm for the manuscript, and interest in the underlying mechanisms. We have expanded the Discussion to address these, and will explore these questions in future studies.</p><disp-quote content-type="editor-comment"><p>Suggested points:</p><p>(i) Discuss and assess in more detail how CD28-downstream signaling (PI3K activity) may affect elf3-3'UTR binding.</p><p>Are Tec-kinases, which are known to boost TCR-downstream signaling, involved? An experiment involving pharmacological Tec-inhibition would be insightful (applying 3'UTR mutants).</p></disp-quote><p>We thank the reviewer for pointing out this connection to Tec-kinases. This together with the PD1 experiment described above will be important to address in future experiments. We have added these ideas to the Discussion.</p><disp-quote content-type="editor-comment"><p>(ii) TCR-/CAR-surface expression: how is it affected by the nature of the TCRa,b 3'UTR before, during and after activation? A simple flow cytometry experiment would tell. For T-cells OKT3 could be used for stimulation and IP26 for surface detection. For CD19-CAR-T-cells, B-cell lines could be used for stimulation and recombinant CD19 for CAR-detection.</p></disp-quote><p>As noted above, we did look at TCR clustering as a function of time, which is dependent on TCR surface expression (Figure 5C). We also looked at TCR surface expression after PMA/Ionomycin activation (Figure 5—figure supplement 1C). We also think the fact that CARs do not form clusters like TCRs in the immune synapse needs to be addressed in the actual CAR design itself. This is a general problem with CARs that is beyond the scope of this manuscript. See <sup>1</sup>. We thank the reviewer for pointing out that OKT3 and IP26 can be used in combination for stimulation and detection of TCR surface expression by flow cytometry. We used anti-CD3 antibody UCHT1, which interfered with IP26 staining in our hands.</p><disp-quote content-type="editor-comment"><p>(iii) One last aspect that would boost in my opinion the significance of the findings is antigen sensitivity, which could be addressed with little (to reasonable) effort by subjecting (CAR-) T-cells to antigen (OKT3, CD19) immobilized in a titrated fashion onto plates. Readout of activation could be as simple as measuring cytokine secretion in the tissue culture supernatant.</p></disp-quote><p>We agree the distinction between CAR affinity and TCR affinity for antigen is an important parameter to consider. However, as noted above due to the differences in how CARs vs. TCRs cluster in the immune synapse, we think these experiments will require a long-term effort that deserves more attention in a follow-up manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>The authors explore the role of eIF3 in T cells using a wide variety of experimental techniques. Experiments are very well-explained in the text and documented in the methods. They begin by using PAR-CLIP in the Jurkat T cell line and find that eIF3 binds to TCRA and TCRB, among other RNAs. They also identify a new pattern of eIF3 binding to the coding sequences of many genes, some of which are validated in primary human cells. Looking at the 3' UTR of TCRA and TCRB, the authors show that eIF3 binding to the 3' UTRs is responsible for activation-induced translational bursting, through a mechanism dependent on CD28. Finally, the authors add the TCRA or TCRB 3' UTR to a CAR-T construct and test its impact on CAR expression and cancer cell killing. Some findings in the study are better-supported than others. The finding of eIF3 controlling translational bursting of TCRA and TCRB by binding the 3' UTR is convincing. However, the discovery of pan-mRNA binding behaviour of eIF3 could use more support from primary cells, and the data from CAR-T cell experiments is subtle and low in replicates. For these reasons it is hard to interpret the data.</p></disp-quote><p>We thank the reviewer for their interest in our results. In terms of pan-mRNA binding of eIF3 in primary T cells, we were limited by the technical approach of the RNase H experiment. In primary T cells, the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs have variable 5’-UTRs and coding regions near the 5’-end of the CDS, precluding the design of DNA oligos for targeting RNase H cleavage, and qPCR of the mRNA in this region. We did see the same pattern of eIF3 binding to <italic>DUSP2</italic> mRNA in the RNase H experiments in primary T cells, as observed in Jurkat cells (Figure 2F-2H).</p><p>We have now included additional killing assays with the CAR T cells to increase confidence in the cytotoxicity results. Briefly, we propagated CAR T cells in low or high IL2 concentrations (50 U/mL or 500 u/mL, respectively) prior to performing the killing assays, and observed improved killing in the case of CAR mRNAs containing the <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTRs in both sets of conditions. We also carried out a killing assay using a different CD19 CAR used in the clinic (Kite Pharma) using T cells from one donor. Finally, we made CAR T cells in which we knocked out TCR expression, and also observed improved killing with the <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTRs with these cells. Overall, we now report killing assays using 6 donors, with a range of CD19 CAR T designs and conditions. This highlights the robust nature of our results in vitro. We have added these additional killing assays in new figure supplements to Figure 6.</p><disp-quote content-type="editor-comment"><p>1) The use of a cell line in PAR-CLIP discovery experiments detracts from the generalizability of results, particularly the new finding of coding sequence binding. While the validation of several transcripts in primary human cells is appreciated, it is hard to know how common this phenomenon is. It is also unfortunate that TCRA and TCRB could not be validated in primary cells.</p></disp-quote><p>We respectfully disagree with this view of the role of the PAR-CLIP experiment. We view the PAR-CLIP experiment primarily as a “hypothesis generator” rather than as a final result. We absolutely agree that validation of the results, using primary cells where possible, is the best approach to interpreting the PAR-CLIP data. We endeavored to take this approach here, and also agree there is still plenty to be explored based on the results from the PAR-CLIP experiment.</p><disp-quote content-type="editor-comment"><p>2) When looking at transcript localization in Jurkat cells by FISH, all the mRNA transcripts measured were in distinct puncta. Is this common for all transcripts? It would be important to see a transcript that behaves differently in order to conclude that the puncta are significant.</p></disp-quote><p>This is an interesting point. We have now compared <italic>GAPDH</italic> mRNA distribution in Jurkat cells activated for 5 hours to <italic>TCRA</italic> mRNA distribution in confocal z-stacks collected in parallel. We used the distance analysis package DiAna in ImageJ (see <sup>2</sup>) to identify puncta. Surprisingly (to us), we see <italic>GAPDH</italic> mRNA also forming puncta indistinguishable in size distribution compared to <italic>TCRA</italic> mRNA puncta. The number of <italic>GAPDH</italic> mRNA puncta identified using the DiAna segmentation algorithm also matches approximately the number of <italic>GAPDH</italic> mRNAs we expect to find based on transcription profiling (see Supplementary file 4), and comparisons to the absolute number of mRNAs seen in activated B cells (See <sup>3</sup>). The number of <italic>TCRA</italic> transcripts is lower than <italic>GAPDH</italic>, based on our transcription profiling results (annotated for the constant region <italic>TRAC</italic> in Supplementary file 4). Thus, the “puncta” we originally assumed to be clusters of mRNAs are more likely than not to be individual mRNAs. We have therefore changed the wording in the main text to emphasize that the <italic>TCRA</italic> and <italic>TCRB</italic> mRNAs do not colocalize with P bodies or stress granules, and eliminated any mention of puncta. Combined with the observation that the mRNAs exhibit the pan-mRNA crosslinking pattern with eIF3, this still supports the model that the mRNAs are being actively translated.</p><disp-quote content-type="editor-comment"><p>3) CAR T cell data is one representative of 2 donors, and the killing enhancement seen with TCRA or TCRB 3' UTR addition is mild. More biological replicates would be needed to convincingly show this with statistical testing.</p></disp-quote><p>As noted above, we have included additional biological replicates to address these concerns. Overall, we now report killing assays using 6 donors, with a range of CD19 CAR T designs and conditions. We think this is a good sign that the effects of the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs are robust to varying experimental conditions.</p><disp-quote content-type="editor-comment"><p>Recommendations for the authors</p><p>1) It is possible to expand primary cells to 55 million, and this would enable the PAR-CLIP to be carried out on primary cells.</p></disp-quote><p>This is something we can consider for the future. We note that the use of 4-thio-U can be toxic to cells (See <sup>4</sup>). We spent considerable time optimizing concentrations of 4-thio-U for Jurkat cells that limited toxicity before carrying out the PAR-CLIP experiment. See the Materials and methods section, “4-thiouridine optimization for PAR-CLIP experiments”. We would need to control for likely different responses in primary T cells. We also note that we may have missed the appropriate time to crosslink the cells had we not used Jurkat cells to begin with, followed by validation in primary cells. This is a bit of serendipity that we acknowledge.</p><disp-quote content-type="editor-comment"><p>2) The authors conclude that eIF3 binding is specific to selected transcripts based on the fact that eIF3 cross-linking isn't correlated with mRNA abundance. Are these selected transcripts simply those that are newly transcribed? This would also explain why the eIF3-bound transcripts are highly enriched for immune processes.</p></disp-quote><p>This is an interesting idea. We did carry out transcription profiling and have deposited those data along with the PAR-CLIP data in the Gene Expression Omnibus database. They are also quantified in Supplementary file 4. We also compared the transcription profiles to PAR-CLIP results in Figure 1—figure supplement 1F. Unfortunately, we don’t have a time series to compare to, which could be done in the future. We have looked at Nanoluciferase reporter mRNA levels in Figure 3C and Figure 3H. We do see mRNA levels go up, but the translation levels don’t correlate directly with mRNA levels. The “peak” of the translation burst reaches 5x-10x (Figure 3B and Figure 3G) when mRNA levels are only up about 2x-3x. For these reporter mRNAs, even when translation drops off, mRNA levels stabilize or continue to increase.</p><disp-quote content-type="editor-comment"><p>3) The comparison of PAR-CLIP results between HEK293T and Jurkat cells relies on ranking and thresholding. It would be preferable to do a more formal statistical comparison.</p></disp-quote><p>This is an interesting point. The PAR-CLIP experiments in Jurkat cells were done in a different way than those in HEK293T cells, complicating the direct comparison. First, the sequencing depth in the Jurkat cells was much higher, improving the signal to noise in the experiment relative to the HEK293T cells (See Supplementary files 2 and 3). This is why we used ranking and thresholding by crosslink reads per transcript in the Jurkat experiment. We also used a larger proportion of anti-EIF3B-bound beads to affinity purify the crosslinked eIF3 RNPs from Jurkat cells, again to improve the signal to noise of the experiment. We also used a different RNase (MNase in our case) compared to the HEK293T experiment, based on extensive optimization. Finally, the Venn diagram is only a proxy for eIF3-mRNA interactions, as the pattern of crosslinking differs (i.e. the presence of pan-mRNAs in Jurkat cells). We therefore think the present comparison is the best compromise, given the multiple differences in the experiments. Since the Venn diagrams may be a distraction from the key points we make in the paper, we have moved the Venn diagrams to the figure supplement and moved the GO term figure to the main figure, as suggested below.</p><disp-quote content-type="editor-comment"><p>i) In several places in the Methods there seem to be conflicting descriptions of Jurkat cells being used at 8 x 105 versus 8 x 106 / mL.</p></disp-quote><p>Thanks for catching this discrepancy. We have updated the Methods to indicate the correct number of cells (8x 10^5/mL).</p><disp-quote content-type="editor-comment"><p>4) Gating for CD25 and CD69 is hard to see in the raw flow cytometry plots. Can this be adjusted with the biexponential axis? How were these gates set? Many percentages on gates in Figure 5 —figure supplement 2a are missing.</p></disp-quote><p>As noted for Reviewer #1, we have split off the flow images into separate figure supplements so that the resolution is not lost. Now that these are separate figures, we have added percentages that we originally left off for clarity. We also converted the axes to biexponential axes and clearly mentioned in the Materials and methods that we have used TCR KO cells (Δ<italic>TCR)</italic> to set the CD69+ and CD25+ gating, as we were able to obtain knockout editing efficiency of 95% or higher in those cells.</p><disp-quote content-type="editor-comment"><p>5) The live cell gate in Figure 6 —figure supplement 1b is non-conventional, at least to this reviewer. Can this be explained?</p></disp-quote><p>Thanks for this question. We assume the confusion is that there is an empty channel in the 2-D plot, meaning that there is no signal used from the vertical axis used to select live cells.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>De Silva et al. 2021 present exciting results regarding the role of the eIF3 complex in T cell activation. The authors use PAR-CLIP to identify the binding patterns of eIF3 in Jurkat cells and find that regions within the 3´ UTRs of TCRA and TCRB mRNAs are sufficient to increase their translation and drive T cell activation. Moreover, expression of the TCRA and TCRB 3´UTRs in CAR T cells improves their ability to kill tumor cells, demonstrating the therapeutic potential of their findings.</p></disp-quote><p>We thank the reviewer for their enthusiasm for our results.</p><disp-quote content-type="editor-comment"><p>– Figure 1: Venn diagrams should include data from non-activated Jurkat cells. The overlap between different data sets (eg. EIF3A/C/B vs. EIF3D/L) should also be represented using a Venn diagram and included in this figure to convince the reader that the IPs against the different subunits are representative of what the entire complex is binding to. GO terms for overlapping mRNAs should be moved to the main figure and discussed in more detail in the text.</p></disp-quote><p>This is a good point we now emphasize more strongly. We had noted in the main text that eIF3 crosslinked to about 75x fewer mRNAs in non-activated cells compared to activated cells. In non-activated Jurkat cells, there were very few mRNAs enriched in the PAR-CLIP experiment, to the point we can’t make Venn diagrams using the same cutoffs as for activated cells. We now note this in the Materials and methods, and the data are included in Supplementary files 2 and 3. This distinction is also captured in Figure 1—figure supplement 1C-1D. In terms of the IP, we used a single well-validated anti-EIF3B antibody (Lee et al., 2015) to pull down the entire eIF3 complex. See Figure 1—figure supplement 1B. Given complications with making these Venn diagrams as noted for Reviewer #2, we think the ones we included are sufficient, without overly interfering with the flow of the paper. As noted above, since the Venn diagrams may be a distraction from the key points we make in the paper, we have moved the Venn diagrams to the figure supplement and moved the GO term figure to the main figure, as suggested. We also discuss some of these mRNAs in the context of CD28 signaling, as noted above.</p><disp-quote content-type="editor-comment"><p>– All sequencing tracks presented in the manuscript should include a scale in order for the reader to better assess the data.</p></disp-quote><p>We apologize, we accidently dropped these from the present version of Figure 1E. We have added these back to Figure 1E, as requested. These are also present in Figure 1—figure supplement 1H.</p><disp-quote content-type="editor-comment"><p>– When discussing the PAR-CLIP data, the authors state that &quot;eIF3 crosslinking does not correlate with mRNA abundance.&quot; Was RNA-seq performed in parallel? These data should be discussed in more detail and the relevant analyses should be included in the main figures.</p></disp-quote><p>We did compare mRNA abundance to the PAR-CLIP data in Figure 1—figure supplement 1F. We now note this more clearly in the Results and Materials and methods. The data are included in Supplementary file 4. We prefer to keep the panel in the supplemental figure, which in <italic>eLife</italic> formatting is kept in-line with the text along with the main figure.</p><disp-quote content-type="editor-comment"><p>– The authors specify that the sites that were modified within the 3´UTRs of TCRA and TCRB were identified through PAR-CLIP. However, the size of the deleted sequence is only mentioned in the context of their CRISPR/Cas9 deletion mutants (Figure 5 supplement 1A). Was the same region targeted in their reporters? Is there evidence that TCRA and TCRB mRNAs that contain these deletions in their 3´UTRs are adequately exported out of the nucleus?</p></disp-quote><p>Thanks for pointing out this ambiguity. We did indeed remove (or reverse) the same sites in the 3’-UTRs in the reporter experiments. We did not analyze mRNA export, but it is unlikely that defects in mRNA export can explain our observations. The mRNAs with a deletion or reversal of the 3’-UTR PAR-CLIP sites are still translated (Figure 3B). Thus, if mRNA export were the only problem with these mRNAs, we would still have seen a translational burst from the mutant mRNAs. We don’t observe a burst from these mRNAs despite the fact they are translated, arguing for a direct effect of the 3’-UTR deletions/reversed sequences on translation. Additionally, we don’t see appreciable differences in mRNA levels in Figure 3C with the deletions or reversed sequences compared to WT. In fact, in the cases of <italic>TCRA ΔPAR</italic> and <italic>TCRA</italic> R*<italic>PAR</italic> mRNA levels were actually higher than WT.</p><disp-quote content-type="editor-comment"><p>– The data presented in figure 2 nicely demonstrate that eIF3 is bound to the coding regions of certain mRNAs during their translation. However, it does not provide evidence that the binding of eIF3 occurs &quot;via&quot; the coding sequence as the authors claim in the Discussion section of the manuscript.</p></disp-quote><p>We agree this is perhaps an ambiguous wording, and doesn’t capture our findings with respect to the 3’-UTR. We have changed the wording to indicate that eIF3 binding “includes the mRNA coding sequence.”</p><disp-quote content-type="editor-comment"><p>– The lack of colocalization with stress granules and P bodies alone does not provide convincing evidence that the TCRA and TCRB are in &quot;translational hot spots.&quot; Figure 1F should be moved to the supplements as supporting information for the sucrose gradients presented in figure 2.</p></disp-quote><p>We have qualified the wording to soften the interpretation: “These results suggest… and are possibly…” We think the figure panel fits better in Figure 1, given this new wording.</p><disp-quote content-type="editor-comment"><p>– In figure 3E, the authors demonstrate that the 3´UTRs of TCRA and TCRB are required for the interaction between these RNAs and eIF3. What is the proposed mechanism for interactions between eIF3 and the 3´UTR that appear to drive the extensive interaction of eIF3 with the mRNA and the observed translational increase?</p></disp-quote><p>This is an excellent question that we hope to address in future work. One set of experiments that we now reference in the Discussion is negative stain EM data on the ER membrane by A. Kent Christensen <italic>et al.</italic>, in which the 5’ and 3’ ends of mRNAs are in close proximity in polysome “circles” or “hairpins”. (See <sup>5,6</sup>).</p><disp-quote content-type="editor-comment"><p>– How does eIF3 spread across the CDS? What is the relevance of the interactions between eIF3 and the CDS?</p></disp-quote><p>This is a very good question. We noted recent evidence in the Discussion that eIF3 remains on translating ribosomes at least in the initial portion of the CDS. This could be a similar phenomenon to our observations. Future experiments will be needed to sort this out.</p><disp-quote content-type="editor-comment"><p>– The authors should discuss why the CD28-dependent burst in translation requires membrane tethering but the CD3-dependent increase does not. This section emerged from nowhere and greater explanation would be helpful both for the technical details and for the potential physiological importance of the membrane tethering dependency.</p></disp-quote><p>We thank the reviewer for these questions, and we have expanded our rationale for pursuing this line of experiment, in the Results and Discussion sections.</p><disp-quote content-type="editor-comment"><p>– De Silva et al. demonstrate that expressing the 3´UTRs of TCRA and TCRB in CAR T cells leads to a faster increase in CAR protein expression. However, their data indicate that the increase in translation is transient (Figure 6D and Figure 6 supplement 1A). Therefore, the authors should comment on whether this decreased lag time in protein expression might also accelerate CAR T cell exhaustion.</p></disp-quote><p>This is a good question, and we have commented in the Discussion that future experiments will be needed to explore the effect of CAR expression on T cell exhaustion.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been improved but there is a small remaining concern that one of the Reviewer would like to see addressed, as outlined below:</p><p>&quot;The concern with the killing assay is that the 24 and 48h time points at which the remaining CTV-labeled target cells were measured do not take cell proliferation of T cells or targets into account. Thus, the increased differences at 48h compared to 24h could be skewed by differential cell proliferation. A control would be needed to account for this.&quot;</p></disp-quote><p>We thank the reviewer for raising this question. The reviewer is right that we did not consider CAR T cell propagation in our analysis, which could have confounded are results to some extent. Importantly, we started all experiments with the same number of cells at the designated ratios at the beginning of the assay. We also note that due to the staining of the NALM6 and Jeko 1 cells with CTV, we were able to separate the B tumor cells from the CAR T cells in all conditions over time, which we now diagram in Figure 6—figure supplement 1B. This revised panel shows the separation at 24 hrs. We also see similar separation at 48 hrs and 72 hrs. This indicates that the B tumor cells are not replicating appreciably in these conditions, and even for cells that replicate (seen at 48 hrs and 72 hrs as a drop in CTV signal for a subset of cells), we can cleanly separate B tumor cells from CAR T cells in our analysis. See <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74272-sa2-fig1-v2.tif"/></fig><p>We have updated the cytotoxicity bar graphs according to this updated sorting strategy in two ways. First, we report the percent of NALM6 or Jeko 1 cells killed using the ratio of dead B tumor cells to total B tumor cells, as derived from the CTV staining. This analysis eliminates any confounding cell counting effects due to the presence of CAR T cells. Second, we have now added bar graphs showing the relative number of live CAR T cells in each condition. The values are normalized to the number of WPRE CAR T cells in the 1:1 effector:target conditions at each time point. We used this normalization since we are interested in CAR T cell propagation rather than the control cells. Notably, we almost invariably see that CAR T cells expressing the anti-CD19 CAR using the <italic>TCRA</italic> or <italic>TCRB</italic> 3’-UTR elements propagate better than CAR T cells using the <italic>WPRE</italic> or <italic>3’-LTR</italic> elements. This suggests that using the <italic>TCRA</italic> and <italic>TCRB</italic> 3’-UTRs to express the anti-CD19 CAR improves the health of these CAR T cells relative to the <italic>WPRE</italic> and <italic>3’-LTR</italic> variants. We see this as an exciting observation worth analyzing in future experiments, for example to understand the impact of these 3’-UTRs on CAR T cell exhaustion.</p><p>The updated figures and associated legends are Figure 6F-6G, Figure 6—figure supplement 1B-1D, Figure 6—figure supplements 3-4, Figure 6—figure supplement 5C-5D, and Figure 6—figure supplement 6B-6C.</p></body></sub-article></article>